galantamine profile

Galantamine is an alkaloid derived from the bulbs of the snowdrop (Galanthus nivalis) and the summer snowflake (Leucojum aestivum). It is a cholinesterase inhibitor, meaning it blocks the breakdown of acetylcholine, a neurotransmitter important for memory and learning. Galantamine is used clinically to treat mild to moderate Alzheimer's disease. It has also been investigated for its potential to treat other conditions, such as Parkinson's disease, cognitive decline in healthy aging, and myasthenia gravis. Galantamine's synthesis can be achieved through different methods, including chemical synthesis and extraction from natural sources. Researchers study galantamine because of its potential to enhance cognitive function and its potential to treat neurodegenerative diseases. It is believed to work by increasing the levels of acetylcholine in the brain, which is essential for communication between nerve cells.'

Galantamine: A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

galanthamine : A benzazepine alkaloid isolated from certain species of daffodils. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Related Flora

Flora	Rank	Flora Definition	Family	Family Definition
Galanthus	genus	A plant genus in the family Amaryllidaceae. Galanthus nivalis L. is the source of GALANTHAMINE.[MeSH]	Amaryllidaceae	A family of herbaceous plants with bulbs or rhizomes in the order Asparagales.[MeSH]
Galanthus	genus	A plant genus in the family Amaryllidaceae. Galanthus nivalis L. is the source of GALANTHAMINE.[MeSH]	Amaryllidaceae	A family of herbaceous plants with bulbs or rhizomes in the order Asparagales.[MeSH]

ID Source	ID
PubMed CID	3449
CHEMBL ID	1623394
CHEBI ID	91735
SCHEMBL ID	220427
MeSH ID	M0008951
PubMed CID	9651
CHEMBL ID	659
CHEBI ID	42944
SCHEMBL ID	2577
SCHEMBL ID	3293474
MeSH ID	M0008951

Synonym
BRD-A49148672-004-01-6
6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4as-(4a.alpha.,6.beta.,8ar*))-
OPREA1_098077
OPREA1_097473
galantamin
6h-benzofuro[3a,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, [4as-(4a.alpha.,6.beta.,8ar*)]-
mls000766281 ,
nsc100058 ,
smr000528869
NCI60_000004
FT-0668943
FT-0667895
AKOS000635322
HMS2269H23
STL146336
AKOS021856294
SCHEMBL220427
BBL028838
Q-201144
galanthamine,(3.alpha.-
epigalanthamin
galanthamine #
CHEMBL1623394
HMS3561F13
CHEBI:91735
FT-0668941
epigalanthamine
galantamine; hsdb 7361
BCP28966
Q27163546
lsm-1597
FT-0668942
BRD-A49148672-001-07-9
9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-ol
(1s,12s,14r)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0^{1,12.0^{6,17]heptadeca-6(17),7,9,15-tetraen-14-ol
DTXSID70859345
cerapp_13557
ent- galanthamine
BIDD:GT0517
AC-20240
AB00053614-09
BRD-K49481516-004-03-5
BRD-K49481516-004-04-3
DIVK1C_000590
KBIO1_000590
SDCCGMLS-0066737.P001
SPECTRUM_001271
SPECTRUM5_001673
PRESTWICK3_000588
nsc 100058
6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4as,6r,8as)-
(4as,6r,8as)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol
galantaminum [inn-latin]
galantamina [inn-spanish]
galanthaminum
hsdb 7361
brn 0093736
BPBIO1_000480
SMP1_000131
6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-
gnt ,
(-)-galanthamine
6h-benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4as,6r,8as)-
galantamine (usan/inn)
IDI1_000590
D04292
BSPBIO_003416
PRESTWICK2_000588
PROBES2_000395
PROBES1_000055
galantamine
lycoremin
357-70-0
galanthamine
jilkon
nsc-100058
lycoremine
C08526
inchi=1/c17h21no3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19h,7-10h2,1-2h3/t12-,14-,17-/m0/s1
asutzqlvashgkv-jdfrzjqesa-
CHEBI:42944 ,
1QTI
chembl659 ,
galanthamine, 12
1DX6
DB00674
(1s,12s,14r)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0^{1,12}.0^{6,17}]heptadeca-6,8,10(17),15-tetraen-14-ol
bdbm10404
NCGC00024731-02
KBIO3_002636
KBIO2_004319
KBIO2_006887
KBIOSS_001751
KBIOGR_001417
KBIO2_001751
PRESTWICK1_000588
SPECTRUM3_001738
SPBIO_002655
NINDS_000590
PRESTWICK0_000588
SPECTRUM4_000839
BSPBIO_000436
HMS2089H03
(-)-galantamine
4-27-00-02184 (beilstein handbook reference)
0d3q044kca ,
galantamine [usan:inn:ban]
unii-0d3q044kca
galantamina
galantaminum
nsc759861
nsc-759861
pharmakon1600-01501202
dtxsid2045606 ,
S3866
AKOS015965330
AM62710
NCGC00017256-05
HY-76299
CS-1217
galantamine [hsdb]
(4as,6r,8as)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6h-benzofuro[3a,3,2-ef][2]benzazepin-6-ol
galantamine [who-dd]
galantamine [vandf]
galantamine [inn]
galantamine [mi]
galantamine [usan]
6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4as,6r,8as)
(4as,6r,8as)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6h-benzofurol[3a,3,2,-ef][2]benzazepin-6-ol
gtpl6693
(1s,12s,14r)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-ol
CCG-212961
SCHEMBL2577
ASUTZQLVASHGKV-JDFRZJQESA-N
SCHEMBL3293474
AC-34328
AB00053614_10
6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4a.alpha.,6.beta.,8ar*)-
galanthamine, (+/-)-
(+/-)-galantamine
6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4aalpha,6beta,8ar*)-
unii-1t835z585r
galantamine, (+/-)-
(+/-)-galanthamine
23173-12-8
6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4ar,6s,8ar)-rel-
1t835z585r ,
bodamine
SR-05000001783-4
SBI-0051689.P002
NCGC00017256-11
(4as,6r,8as)-3-methoxy-11-methyl-4a,5,9,10,11,12-hexahydro-6h-benzo[2,3]benzofuro[4,3-cd]azepin-6-ol
(4as,6r,8as)-3-methoxy-11-methyl-5,6,9,10,11,12-hexahydro-4ah-benzo[2,3]benzofuro[4,3-cd]azepin-6-ol
Q412690
mfcd00867189
1008759-59-8
BRD-K49481516-004-09-2
HMS3885C10
NCGC00017256-17
AS-56354
EN300-708805
(1s,12s,14r)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0^{1,12}.0^{6,17}]heptadeca-6(17),7,9,15-tetraen-14-ol
galantaminum (inn-latin)
galantamina (inn-spanish)
(4as,6r,8as)-3-methoxy-11-methyl-5,6,9,10,11,12-hexahydro-4ah-(1)benzofuro(3a,3,2-ef)(2)benzazepin-6-ol
n06da04

Excerpt	Reference	Relevance
" There were no serious adverse events (AEs) or premature withdrawals from the study because of AEs."	( Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers. Iyer, GR; Truyen, L; Verhaeghe, T; Zhao, Q, 2002)	0.31
" Safety and tolerability were monitored throughout the trial by recording adverse events, laboratory tests, and cardiovascular parameters."	( Galantamine pharmacokinetics, safety, and tolerability profiles are similar in healthy Caucasian and Japanese subjects. Brett, M; Huang, F; Hust, R; Raoult, A; Van Osselaer, N; Van Peer, A; Verhaeghe, T; Zhao, Q, 2002)	0.31
" Galantamine and risperidone were both safe and well tolerated administered either alone or together."	( Pharmacokinetic and safety assessments of galantamine and risperidone after the two drugs are administered alone and together. Huang, F; Janssens, L; Lasseter, KC; Lau, H; Verhaeghe, T; Zhao, Q, 2002)	0.31
" Incidence of adverse events in patients > 80 years was similar to that in the overall study population."	( Galantamine demonstrates efficacy and safety in elderly patients with Alzheimer disease. Bullock, R; Gauthier, S; Kurz, A; Marcusson, J; Schwalen, S, )	0.13
" The most frequently reported adverse events, characteristic of older dementia patients, included depression, agitation, and insomnia."	( Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease. Damaraju, CR; Erkinjuntti, T; Kurz, AF; Lilienfeld, S; Small, GW, 2003)	0.32
" Motor scores, as measured by the UPDRS motor subscale, showed mild improvement, which demonstrates that galantamine has no adverse effect on parkinsonian symptoms."	( Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis. Bednarczyk, EM; Edwards, KR; Farlow, M; Hershey, L; Johnson, S; Lichter, D; Wray, L, 2004)	0.32
"6 %)treatment was withdrawn because of mostly gastrointestinal adverse events."	( Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study. Bardelli, F; Bencini, F; Biagini, CA; Caleri, V; Cantini, C; Cavallini, MC; Marini, M; Masotti, G; Mecacci, R; Mossello, E; Razzi, E; Sarcone, E; Tilli, S; Tonon, E, 2004)	0.32
" Adverse events (AEs) were coded to WHO preferred terms, including AEs begun in previous trials."	( Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial. Damaraju, CV; Pirttilä, T; Truyen, L; Wilcock, G, 2004)	0.32
"To provide a systematic review of the best quality evidence of the effects of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in people with mild to moderately-severe AD."	( A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. Clegg, A; Green, C; Kirby, J; Loveman, E; Payne, E; Picot, J; Takeda, A, 2006)	0.33
" Adverse events were generally related to the gastrointestinal system, with a tendency for these to be more common in the treatment arms."	( A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. Clegg, A; Green, C; Kirby, J; Loveman, E; Payne, E; Picot, J; Takeda, A, 2006)	0.33
" All the adverse events (AE) reported were recorded."	( [Observational study on safety, tolerability and effectiveness of galantamine in patients with mild to moderately severe Alzheimer's disease]. Amer, G; Barquero, M; Blesa, R; Ezpeleta, D; Galdós, L; García Ribas, G; Marey López, J; Marsall, C; Olascoaga, J, )	0.13
"Galantamine is a safe and well-tolerated treatment, and provides cognitive, functional, and behavioral benefits in patients with mild to moderately severe AD."	( [Observational study on safety, tolerability and effectiveness of galantamine in patients with mild to moderately severe Alzheimer's disease]. Amer, G; Barquero, M; Blesa, R; Ezpeleta, D; Galdós, L; García Ribas, G; Marey López, J; Marsall, C; Olascoaga, J, )	0.13
"Cardiovascular disorders are the most frequently reported adverse effects of drugs used to treat Alzheimer's disease."	( Anti-Alzheimer drugs: life-threatening adverse effects. , 2007)	0.34
" Adverse events were generally mild and transient."	( Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study. Edwards, K; Farlow, M; Hake, A; Hershey, L; Johnson, S; Lichter, D; Pasquier, F; Royall, D, 2007)	0.34
"Galantamine appears to be an effective and safe therapy for patients with DLB."	( Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study. Edwards, K; Farlow, M; Hake, A; Hershey, L; Johnson, S; Lichter, D; Pasquier, F; Royall, D, 2007)	0.34
" Trial methods, clinical characteristics, outcomes, and adverse events were extracted and checked."	( Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Kavirajan, H; Schneider, LS, 2007)	0.34
" Compared with placebo, more dropouts and adverse events (anorexia, nausea, vomiting, diarrhoea, and insomnia) occurred with the cholinesterase inhibitors, but not with memantine."	( Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Kavirajan, H; Schneider, LS, 2007)	0.34
" The most frequently reported adverse event was nausea (galantamine, 29%; placebo, 10%)."	( Safety and efficacy of galantamine in subjects with mild cognitive impairment. Brashear, HR; Feldman, H; Gauthier, S; Mayorga, AJ; Nye, JS; Scinto, L; Truyen, L; Wang, D; Wilcock, GK; Winblad, B, 2008)	0.35
" Adverse events (drooling, postural hypotension, nausea, dysuria) were observed in 7 (30%) of galantamine treated patients."	( [Efficacy and safety of galantamine (reminyl) in the treatment of dementia in patients with Parkinson's disease (open-label controlled trial)]. Emelin, AIu; Litvinenko, IV; Mogil'naia, VI; Odinak, MM, 2007)	0.34
" Galantamine appears to be safe and tolerable in patients with epilepsy."	( The safety and tolerability of galantamine in patients with epilepsy and memory difficulties. Andrews, S; Faught, E; Griffith, HR; LeBron Paige, A; Martin, R; Ware, J; Welty, T, 2008)	0.35
" Across trials, the incidence of adverse events was generally lowest for donepezil and highest for rivastigmine."	( Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Gartlehner, G; Hansen, RA; Jonas, DE; Moore, CG; Morgan, LC; Webb, AP, 2008)	0.35
" Adverse events, vital signs, laboratory parameters, and electrocardiograms were monitored."	( Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial. Bernabei, R; Bullock, R; Burns, A; Came, E; Cruz Jentoft, AJ; Frölich, L; Hammond, GL; Hock, C; Raivio, M; Schwalen, S; Triau, E; Van Baelen, B; van Oene, JC; Vandewoude, M; Wimo, A, 2009)	0.35
" 183 of 207 patients (88%) who received galantamine and 177 of 200 (89%) who received placebo had adverse events, which were mostly mild to moderate."	( Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial. Bernabei, R; Bullock, R; Burns, A; Came, E; Cruz Jentoft, AJ; Frölich, L; Hammond, GL; Hock, C; Raivio, M; Schwalen, S; Triau, E; Van Baelen, B; van Oene, JC; Vandewoude, M; Wimo, A, 2009)	0.35
" The most common adverse events were nausea, dizziness, and weight loss which more often occurred during the dose-escalation phase."	( Safety and tolerability of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients. Chankrachang, S; Nidhinandana, S; Phanthumchinda, K; Poungvarin, N; Praditsuwan, R; Senanarong, V; Thavichachart, N, 2009)	0.35
"Galantamine, a centrally acting cholinesterase (ChE) inhibitor and a nicotinic allosteric potentiating ligand used to treat Alzheimer's disease, is an effective and safe antidote against poisoning with nerve agents, including soman."	( Effectiveness of donepezil, rivastigmine, and (+/-)huperzine A in counteracting the acute toxicity of organophosphorus nerve agents: comparison with galantamine. Adler, M; Akkerman, M; Albuquerque, EX; Aracava, Y; Pereira, EF, 2009)	0.35
" Fewer donepezil-treated subjects withdrew due to adverse events (AEs) compared with rivastigmine and galantamine-treated subjects."	( Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence. Kelly, S; Lockhart, IA; Mitchell, SA, 2009)	0.35
" Their known adverse effects include bradycardia."	( Bradycardia due to cholinesterase inhibitors: identify adverse effects and take them into account. , 2011)	0.37
"Diisopropylfluorophosphate exerts its toxic effect by irreversibly inhibiting acetylcholinesterase."	( Galantamine as a preventive of diisopropylphosphorofluoridate toxicity effects in rat brain. Pregelj, P; Saghafi, MM; Živin, M, 2013)	0.39
" Compared with placebo, more dropouts and adverse events occurred with the cholinesterase inhibitors, but not with memantine."	( Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Jiang, T; Meng, XF; Tan, CC; Tan, L; Tan, MS; Wang, C; Wang, HF; Yu, JT; Zhu, XC, 2014)	0.4
" The outcome measurements were as follows: the changes of Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog), Mini-Mental State Examination (MMSE), Activities of Daily Living (ADL), Neuropsychiatric Inventory (NPI), Clinicians' Interview-Based Impression of Change with Caregiver's Input (CIBIC+), adverse effects and dropouts."	( Efficacy and safety of galantamine treatment for patients with Alzheimer's disease: a meta-analysis of randomized controlled trials. Jiang, D; Li, M; Wang, Y; Yang, X, 2015)	0.42
"This survey analyzes two national pharmacovigilance databases in order to determine the major adverse reactions observed with the use of cholinesterase inhibitors in dementia."	( Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada. Abagyan, R; Ali, TB; Chen, WY; Reilly, BM; Schleret, TR, 2015)	0.42
" Withdrawals due to adverse events and number of patients experiencing nausea, vomiting, diarrhoea and dizziness were examined as safety profiles."	( The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis. Kobayashi, H; Nakagawa, R; Ohnishi, T; Yoshizawa, K, 2016)	0.43
" Acetylcholinesterase inhibitors (AChEIs) aim to provide symptomatic benefit for cognitive decline, however these drugs are not without adverse events (AEs)."	( Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation. Bradley, J; Chan, P; Herrmann, N; Lanctôt, K; Mohammad, D, 2017)	0.46
"The purpose of this study was to perform a comparative analysis of the number of reported pneumonia cases in individuals prescribed rivastigmine relative to the number of reported cases by patients using other therapeutics including over-the-counter drugs and other AD therapeutics, as reported to the FDA Adverse Event Reporting System (FAERS) database."	( The Association Between Use of Rivastigmine and Pneumonia: Systematic Analysis of FDA Adverse Event Reporting System. Bu, K; Cheng, F; Morris, R; Umeukeje, G, 2021)	0.62
"Patients prescribed rivastigmine were more likely to report pneumonia as an adverse event than many drugs except galantamine."	( The Association Between Use of Rivastigmine and Pneumonia: Systematic Analysis of FDA Adverse Event Reporting System. Bu, K; Cheng, F; Morris, R; Umeukeje, G, 2021)	0.62
"We aimed to perform an updated umbrella review to identify an efficacious and safe treatment for AD patients."	( The Efficacy and Safety of Alzheimer's Disease Therapies: An Updated Umbrella Review. Ai, Y; Cheng, Y; Fan, F; Liu, H; Liu, Q; Shi, X, 2022)	0.72
" We examined the cognitive functions, behavioral symptoms, global clinical assessment, and Activities of Daily Living as efficacy endpoints, and the incidence of adverse events as safety profiles."	( The Efficacy and Safety of Alzheimer's Disease Therapies: An Updated Umbrella Review. Ai, Y; Cheng, Y; Fan, F; Liu, H; Liu, Q; Shi, X, 2022)	0.72
"We included trials assessing cognition with the Mini-Mental State Examination (MMSE), and adverse events."	( Comparative safety and efficacy of cognitive enhancers for Alzheimer's dementia: a systematic review with individual patient data network meta-analysis. Ashoor, HM; Clarke, M; Hemmelgarn, BR; Holroyd-Leduc, J; Mavridis, D; Rios, P; Seitidis, G; Stewart, L; Straus, SE; Tricco, AC; Tudur-Smith, C; Veroniki, AA, 2022)	0.72
" This study evaluated the risk of serious adverse events (SAEs) associated with individual ChEIs in older adults with dementia and also examined sex-based and dose-based effects on this risk."	( Risk of Serious Adverse Events Associated With Individual Cholinesterase Inhibitors Use in Older Adults With Dementia: A Population-Based Cohort Study. Aparasu, RR; Chatterjee, S; Chen, H; Johnson, ML; Masurkar, PP; Sherer, JT, 2022)	0.72
"Dysphagia has been reported as an adverse event for patients receiving rivastigmine for Alzheimer's disease (AD) treatment."	( Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System. Bu, K; Cheng, F; Han, W; Morris, R; Patel, D; Umeukeje, G; Zhu, T, 2022)	0.72
"The purpose of this study was to determine the association between dysphagia and the usage of rivastigmine by using the pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS)."	( Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System. Bu, K; Cheng, F; Han, W; Morris, R; Patel, D; Umeukeje, G; Zhu, T, 2022)	0.72
"When compared to patients prescribed donepezil, galantamine, or memantine, individuals prescribed rivastigmine were almost twice as likely to report dysphagia as an adverse event."	( Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System. Bu, K; Cheng, F; Han, W; Morris, R; Patel, D; Umeukeje, G; Zhu, T, 2022)	0.72
"Patients prescribed rivastigmine were at greater risk of reporting dysphagia as an adverse event than patients prescribed many other medicines."	( Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System. Bu, K; Cheng, F; Han, W; Morris, R; Patel, D; Umeukeje, G; Zhu, T, 2022)	0.72
"While these drugs are known to induce classic cholinergic adverse events such as diarrhea, their potential to cause psychiatric adverse events has yet to be thoroughly examined."	( Psychiatric Adverse Events of Acetylcholinesterase Inhibitors in Alzheimer's Disease and Parkinson's Dementia: Systematic Review and Meta-Analysis. Algharably, EEA; Bermpohl, F; Bittner, N; Brandl, EJ; Funk, CSM; Kreutz, R; Riemer, TG; Schmidt, A, 2023)	0.91
"We sought to determine the risk of psychiatric adverse events associated with the use of AChEIs through a systematic review and meta-analysis of double-blind randomized controlled trials involving patients with Alzheimer's dementia and Parkinson's dementia."	( Psychiatric Adverse Events of Acetylcholinesterase Inhibitors in Alzheimer's Disease and Parkinson's Dementia: Systematic Review and Meta-Analysis. Algharably, EEA; Bermpohl, F; Bittner, N; Brandl, EJ; Funk, CSM; Kreutz, R; Riemer, TG; Schmidt, A, 2023)	0.91
" Anorexia was the most commonly reported psychiatric adverse event, followed by agitation, insomnia, and depression."	( Psychiatric Adverse Events of Acetylcholinesterase Inhibitors in Alzheimer's Disease and Parkinson's Dementia: Systematic Review and Meta-Analysis. Algharably, EEA; Bermpohl, F; Bittner, N; Brandl, EJ; Funk, CSM; Kreutz, R; Riemer, TG; Schmidt, A, 2023)	0.91
" Lowering the dose may resolve some psychiatric adverse events, as may switching to galantamine in the case of insomnia."	( Psychiatric Adverse Events of Acetylcholinesterase Inhibitors in Alzheimer's Disease and Parkinson's Dementia: Systematic Review and Meta-Analysis. Algharably, EEA; Bermpohl, F; Bittner, N; Brandl, EJ; Funk, CSM; Kreutz, R; Riemer, TG; Schmidt, A, 2023)	0.91

Excerpt	Reference	Relevance
" A biexponential decline of concentrations in plasma, with a terminal half-life of 43."	( Galanthamine: pharmacokinetics, tissue distribution and cholinesterase inhibition in brain of mice. Bickel, U; Fischer, JP; Kewitz, H; Thomsen, T; Weber, W, 1991)	0.28
" The plasma AUC, Cmax, tmax and ka suggest that the subcutaneous and oral Nivalin formulations are bioequivalent."	( Pharmacokinetics of galanthamine hydrobromide after single subcutaneous and oral dosage in humans. Jovovich, V; Mihailova, D; Tencheva, J; Yamboliev, I; Zhivkova, Z, 1989)	0.28
" Galanthamine has an elimination half-life of 40-50 min, a volume of distribution over 2 liters/kg, a plasma clearance of about 2 liters/h X kg and an oral bioavailability of about 65%."	( Pharmacokinetics of galanthamine hydrobromide (Nivalin) following single intravenous and oral administration in rats. Mihailova, D; Yamboliev, I, 1986)	0.27
"The pharmacokinetic of some centrally acting cholinesterase inhibitors that have been used to improve memory in patients with dementia of Alzheimer's type, was compared."	( Pharmacokinetic studies of cholinesterase inhibitors. Johansson, M; Nordberg, A, 1993)	0.29
" Specifically, certain metabolic parameters (ie, half-life and route of metabolism/elimination) can affect a drug's tolerability and become important when a switch from one agent to another is contemplated."	( Pharmacokinetic profiles of current therapies for Alzheimer's disease: implications for switching to galantamine. Farlow, MR, 2001)	0.31
" The pharmacokinetic parameters of galantamine were similar in subjects with mild hepatic impairment compared with healthy controls."	( Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers. Iyer, GR; Truyen, L; Verhaeghe, T; Zhao, Q, 2002)	0.31
" The mean plasma concentration-time profiles of galantamine were very similar after single doses of galantamine (4 and 8 mg), and there was an approximate dose proportionality of galantamine pharmacokinetic parameters in both Caucasian and Japanese ethnic groups."	( Galantamine pharmacokinetics, safety, and tolerability profiles are similar in healthy Caucasian and Japanese subjects. Brett, M; Huang, F; Hust, R; Raoult, A; Van Osselaer, N; Van Peer, A; Verhaeghe, T; Zhao, Q, 2002)	0.31
"To explore the steady-state pharmacokinetic profile after coadministration of galantamine and risperidone, an open-label, randomized, single-center, two-way crossover drug-drug interaction study was conducted in 16 healthy elderly subjects, ages 60 years and older."	( Pharmacokinetic and safety assessments of galantamine and risperidone after the two drugs are administered alone and together. Huang, F; Janssens, L; Lasseter, KC; Lau, H; Verhaeghe, T; Zhao, Q, 2002)	0.31
" Data from 15 clinical studies (1089 individuals, 7480 concentration measurements in total) were used to examine the effect of body size, demographic characteristics, and concomitant disease status on galantamine pharmacokinetic parameters."	( Galantamine population pharmacokinetics in patients with Alzheimer's disease: modeling and simulations. Aerssens, J; Armstrong, M; Piotrovsky, V; Van Osselaer, N; Van Peer, A, 2003)	0.32
" Elimination half-life of galantamine was relatively large in rat and dog and smaller in mouse and rabbit."	( Pharmacokinetics of galantamine, a cholinesterase inhibitor, in several animal species. Bode, W; Lavrijsen, K; Meuldermans, W; Monbaliu, J; Verhaeghe, T; Willems, B, 2003)	0.32
" Population pharmacokinetic modelling with galantamine has shown that the variables affecting clearance are age, sex, and bodyweight."	( Clinical pharmacokinetics of galantamine. Farlow, MR, 2003)	0.32
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."	( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004)	0.32
" The pharmacokinetic profile and parameters of galantamine at steady state were similar after administration of a 16-mg dose of galantamine once daily alone and after administration with a 10-mg dose of memantine twice daily."	( Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects. Gold, M; Nye, JS; Padmanabhan, M; Ramael, S; Raoufinia, A; Verhaeghe, T; Walschap, Y; Yao, C; Zhao, Q, 2005)	0.33
"To demonstrate using pharmacokinetic (PK) modeling and simulation, that the PK that the PK parameters for drug exposure with galantamine parameters for drug exposure with galantamine immediate-release (IR) tablet and galantamine extended-release (ER) capsule are comparable in patients with Alzheimer's disease (AD) during in patients with Alzheimer's disease (AD) during the switch from twice-daily IR tablet at steady state to the new once-daily ER capsule, and to support a recommendation that patients receiving the IR tablet at steady state can be successfully switched to the ER capsule at the same daily dosage with no titration period."	( Pharmacokinetic simulation for switching from galantamine immediate-release to extended-release formulation. Brashear, HR; Hing, JP; Kimko, H; Piotrovsky, V; Zhao, Q, 2005)	0.33
" After steady state was achieved with ER galantamine, values for peak concentration and trough concentration were slightly lower (5% and 18%, respectively) than those seen at steady state for IR galantamine; this finding is considered to have no clinical implications."	( Pharmacokinetic simulation for switching from galantamine immediate-release to extended-release formulation. Brashear, HR; Hing, JP; Kimko, H; Piotrovsky, V; Zhao, Q, 2005)	0.33
" Pharmacokinetic parameters of GAL at steady state were determined after morning intake on Day 7 of each treatment week."	( Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteers. Brashear, HR; Janssens, L; Truyen, L; Verhaeghe, T; Zhao, Q, 2005)	0.33
" The treatment ratios and 90% confidence intervals for all above mentioned pharmacokinetic parameters demonstrated bioequivalence (with the range of 80-125%), indicating that food had no effect on GAL-ER bioavailability."	( Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteers. Brashear, HR; Janssens, L; Truyen, L; Verhaeghe, T; Zhao, Q, 2005)	0.33
" From plasma concentrations, AUC(0-->t) (the area under the plasma concentration-time curve from time 0 to the last sampling time, 32 hr), AUC(0-->infinity) (the area under the plasma concentration-time curve from time 0 to infinity), t((1/2)) (elimination of half-life of the terminal log linear phase), C(max) (maximum plasma drug concentration) and T(max) (time to reach C(max)) were evaluated through noncompartmental pharmacokinetic analysis."	( Pharmacokinetics and bioequivalence studies of galantamine hydrobromide dispersible tablet in healthy male Chinese volunteers. Fang, XL; Han, LM; Li, XN; Sha, XY; Wang, QS; Zhang, LJ; Zhang, ZW, 2007)	0.34
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
" The elimination half-life of galantamine is about 7-8 hours."	( A review of clinical pharmacokinetics and pharmacodynamics of galantamine, a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, in healthy subjects and patients. Fu, Y; Huang, F, 2010)	0.36
" Intravenous and oral 6-h blood sampling profiles in old (30 months old) and young (7 months old) rats revealed pharmacokinetic changes similar to those in humans with an approximately 40% increase in C(max) of galantamine and prolonged t(1/2) (1."	( Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats. Aw, CC; Browne, ER; Chen, CP; Goh, CW; Lee, JH, 2011)	0.37
" Hence, the effects of intranasal administration of GH loaded flexible liposomes have been investigated for the first time on the efficiency of acetylcholinesterase inhibition, as well as the pharmacokinetic behavior of GH in rat brain."	( Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes. Hao, B; Kong, P; Li, W; Wang, X; Zhao, N; Zhou, Y, 2012)	0.38
" Donepezil, galantamine and rivastigmine are acetylcholinesterase inhibitors with different pharmacodynamic and pharmacokinetic profiles."	( Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease. Eap, CB; Noetzli, M, 2013)	0.39
" This novel method has been applied to a pharmacokinetic study in rats."	( Highly sensitive LC-MS/MS method for determination of galantamine in rat plasma: application to pharmacokinetic studies in rats. Mullangi, R; Sukumaran, SK; Suresh, PS, 2014)	0.4
" The validated method was successfully applied to monitoring the concentrations and pharmacokinetic studies of two Amaryllidaceous alkaloids in rat plasma after an oral administration of Lycoris radiata extract."	( An LC-MS/MS method for the simultaneous determination of lycorine and galanthamine in rat plasma and its application to pharmacokinetic study of Lycoris radiata extract in rats. Huang, S; Liu, Y; Liu, YB; Zhou, X, 2014)	0.4
"The present investigation was carried out to improve the galantamine bioavailability in brain by intranasal drug delivery through thiolated chitosan nanoparticles and compared to nasal and oral delivery of its solution using pharmacodynamic activity as well as biochemical estimation."	( Nose to Brain Delivery of Galantamine Loaded Nanoparticles: In-vivo Pharmacodynamic and Biochemical Study in Mice. Mishra, DN; Singh, SK, 2019)	0.51
"05) as compared to oral and nasal administration of its solution, by pharmacodynamic study and biochemical estimation of acetylcholinesterase activity in Swiss albino mice brain."	( Nose to Brain Delivery of Galantamine Loaded Nanoparticles: In-vivo Pharmacodynamic and Biochemical Study in Mice. Mishra, DN; Singh, SK, 2019)	0.51
" Cell-based oxidative stress assays and pharmacokinetic studies were performed using C6 glial cell lines, and Sprague Dawley rats, respectively."	( Comparative evaluation of fish oil and butter oil in modulating delivery of galantamine hydrobromide to brain via intranasal route: pharmacokinetic and oxidative stress studies. Katdare, A; Khunt, D; Misra, M; Polaka, SN; Thakkar, S, 2020)	0.56
" Unfortunately, it showed a suboptimal pharmacokinetic profile, which required intracerebroventricular administration for in vivo studies."	( Galantamine-memantine hybrids for Alzheimer's disease: The influence of linker rigidity in biological activity and pharmacokinetic properties. Armirotti, A; Bartolini, M; Basagni, F; Bedeschi, M; Bertorelli, R; Bertozzi, SM; Bottegoni, G; Cavalli, A; Lembo, V; Mellor, IR; Minarini, A; Ortega, JA; Rosini, M; Summa, M, 2023)	0.91

Excerpt	Reference	Relevance
" We investigated the effects of galantamine in patients with a diagnosis of probable vascular dementia or Alzheimer's disease combined with cerebrovascular disease."	( Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Bullock, R; Damaraju, CV; Erkinjuntti, T; Gauthier, S; Kurz, A; Lilienfeld, S, 2002)	0.31
"Cholinesterase inhibitors (ChEIs) could be involved in several drug-drug interactions (DDIs) because of their complex pharmacodynamic and/or pharmacokinetic properties."	( Drug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal, British National Formulary). Bagheri, H; Lapeyre-Mestre, M; Montrastruc, JL; Sommet, A; Tavassoli, N, 2007)	0.34
"The effects of galantamine (GAL) on quality of life (QoL) and cognitive speed, as well its effects combined with nimodipine (NIM) in Alzheimer disease (AD) with cerebrovascular disease (mixed dementia), have not been explored."	( Effects of galantamine and galantamine combined with nimodipine on cognitive speed and quality of life in mixed dementia: a 24-week, randomized, placebo-controlled exploratory trial (the REMIX study). Barbosa, MT; Bottino, CM; Caramelli, P; Charchat-Fichman, H; Chaves, ML; Forlenza, OV; Laks, J; Lawson, FL; Machado, JC; Nitrini, R; Palmini, AL; Vale, Fde A, 2014)	0.4

Excerpt	Reference	Relevance
" Galanthamine has an elimination half-life of 40-50 min, a volume of distribution over 2 liters/kg, a plasma clearance of about 2 liters/h X kg and an oral bioavailability of about 65%."	( Pharmacokinetics of galanthamine hydrobromide (Nivalin) following single intravenous and oral administration in rats. Mihailova, D; Yamboliev, I, 1986)	0.27
" The results showed that risperidone, when administered with galantamine, did not change the bioavailability of galantamine at steady state."	( Pharmacokinetic and safety assessments of galantamine and risperidone after the two drugs are administered alone and together. Huang, F; Janssens, L; Lasseter, KC; Lau, H; Verhaeghe, T; Zhao, Q, 2002)	0.31
" Absolute oral bioavailability of a gavage dose was high in rat (77%) and dog (78%)."	( Pharmacokinetics of galantamine, a cholinesterase inhibitor, in several animal species. Bode, W; Lavrijsen, K; Meuldermans, W; Monbaliu, J; Verhaeghe, T; Willems, B, 2003)	0.32
"5-10 mg/kg), galantamine was rapidly absorbed in both sexes, with an absolute oral bioavailability of 77%."	( Pharmacokinetics and tissue distribution of galantamine and galantamine-related radioactivity after single intravenous and oral administration in the rat. Bode, W; Geerts, R; Lavrijsen, K; Meuldermans, W; van Beijsterveldt, L; Verhaeghe, T; Willems, B, 2004)	0.32
"To assess the steady-state galantamine (GAL) bioavailability of the extended-release 24-mg qd capsule (GAL-ER) with and without food and to evaluate the relative bioavailability of GAL-ER with the immediate-release 12-mg bid tablet (GAL-IR) at steady state."	( Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteers. Brashear, HR; Janssens, L; Truyen, L; Verhaeghe, T; Zhao, Q, 2005)	0.33
"Food had no effect on the GAL bioavailability of GAL-ER at steady state."	( Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteers. Brashear, HR; Janssens, L; Truyen, L; Verhaeghe, T; Zhao, Q, 2005)	0.33
" Pharmacokinetic testing in rats confirmed the improved drug bioavailability and demonstrated an in vitro-in vivo correlation."	( In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo. Brandt, GC; Costantino, HR; Foerder, CA; Leonard, AK; Quay, SC; Sileno, AP, 2007)	0.34
" Memogain has more than 15-fold higher bioavailability in the brain than the same doses of galantamine."	( Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy. Hoeffle-Maas, A; Jordis, U; Koepke, AK; Ludwig, J; Maelicke, A; Maus, A; Samochocki, M, 2010)	0.36
" The secondary objectives were: a) to verify Galantamine bioavailability through buccal delivery; b) to evaluate the permeation enhancement effect of iontophoresis; and, finally, c) to assess any histomorphological changes in the buccal mucosae after transbuccal delivery."	( New prospectives in the delivery of galantamine for elderly patients using the IntelliDrug intraoral device: in vivo animal studies. Campisi, G; De Caro, V; Florena, AM; Giannola, LI; Paderni, C; Wolff, A, 2010)	0.36
" Oral bioavailability was improved by using syringe feeding with donepezil but not galantamine."	( Alternative method of oral dosing for rats. Atcha, Z; Aw, CC; Browne, ER; Goh, CW; Lim, JS; Neo, AH; Pemberton, DJ; Rourke, C, 2010)	0.36
" These results demonstrate that the chronic ingestion of high doses of CAP will decrease the bioavailability of galantamine to a significant extent in rats."	( Food-drug interactions: effect of capsaicin on the pharmacokinetics of galantamine in rats. Lu, YN; Zhai, XJ, 2012)	0.38
" Its poor brain penetration results in lower bioavailability to the target site."	( Galantamine-loaded solid-lipid nanoparticles for enhanced brain delivery: preparation, characterization, in vitro and in vivo evaluations. Chopra, K; Medhi, B; Misra, S; Sinha, VR, 2016)	0.43
" Presence of drug in the olfactory bulb, in turn, increases the drug bioavailability in the brain and reduces the drug degradation as well as wastage of the drug through` systemic clearance."	( Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. Agrawal, M; Alexander, A; Antimisiaris, SG; Chougule, MB; Saraf, S; Shoyele, SA, 2018)	0.48
"The present investigation was carried out to improve the galantamine bioavailability in brain by intranasal drug delivery through thiolated chitosan nanoparticles and compared to nasal and oral delivery of its solution using pharmacodynamic activity as well as biochemical estimation."	( Nose to Brain Delivery of Galantamine Loaded Nanoparticles: In-vivo Pharmacodynamic and Biochemical Study in Mice. Mishra, DN; Singh, SK, 2019)	0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" Therefore, to overcome such issues, various nanoformulations of nutraceuticals have been developed, that allow their effective delivery into the brain owing to reduced particle size, increased lipophilicity, increased bioavailability and avoidance of fast hepatic metabolism."	( Nutraceuticals and their Derived Nano-Formulations for the Prevention and Treatment of Alzheimer's Disease. Fazal, SA; Haque, SE; Iqubal, A; Iqubal, MK; Pottoo, FH, 2022)	0.72
" In this study, a combination of several formulation factors was integrated and exploited to augment the bioavailability of galantamine hydrobromide (GAL) via the intranasal route."	( Nose-to-brain delivery of galantamine loaded nanospray dried polyacrylic acid/taurodeoxycholate mixed matrix as a protective therapy in lipopolysaccharide-induced Alzheimer's in mice model. Elhabak, M; Salama, AAA; Salama, AH, 2023)	0.91

Excerpt	Relevance	Reference
" In order to maximize and prolong positive drug effects, it is important to start early and adjust dosage during the treatment."	( Cholinesterase inhibitors stabilize Alzheimer's disease. Giacobini, E, 2000)	0.31
" Galantamine's adverse effects appear similar to those of other cholinesterase inhibitors, in that it tends to produce gastrointestinal effects acutely and with dosage increases."	( Galantamine for Alzheimer's disease. Olin, J; Schneider, L, 2001)	0.31
" Galantamine's adverse effects appear similar to those of other cholinesterase inhibitors, in that it tends to produce gastrointestinal effects acutely and with dosage increases."	( Galantamine for Alzheimer's disease. Olin, J; Schneider, L, 2001)	0.31
" In addition, although there was not a statistically significant dose-response effect, doses above 8mg/d were, for the most part, consistently statistically significant."	( Galantamine for Alzheimer's disease. Olin, J; Schneider, L, 2001)	0.31
" Excretion of radioactivity was rapid and nearly complete at 96 h after dosing in all species."	( The metabolism and excretion of galantamine in rats, dogs, and humans. Bode, W; Hendrickx, J; Lavrijsen, K; Le Jeune, L; Leempoels, J; Mannens, GS; Meuldermans, W; Snel, CA; van Beijsterveldt, L; Van Osselaer, N; Van Peer, A; Verhaeghe, T, 2002)	0.31
" Galantamine's adverse effects appear similar to those of other cholinesterase inhibitors, in that it tends to produce gastrointestinal symptoms acutely and with dosage increases."	( Galantamine for Alzheimer's disease. Olin, J; Schneider, L, 2002)	0.31
" In addition, although there was not a statistically significant dose-response effect, benefits associated with doses above 8mg/d were, for the most part, consistently statistically significant."	( Galantamine for Alzheimer's disease. Olin, J; Schneider, L, 2002)	0.31
"Cholinesterase inhibitors (ChEIs) are dosed in two phases for the treatment of dementia, an initial dose-escalation phase to achieve a therapeutic dose and a maintenance phase where the therapeutic dose is given for long-term therapy."	( The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Inglis, F, 2002)	0.31
" Parallel groups of healthy Japanese (n = 13; 6 males and 7 females)and Caucasian (n = 12; 6 males and 6 females) subjects matched for weight and age received single oral doses of galantamine 4 mg, or galantamine 8 mg, or placebo in a double-blind, three-way crossover trial according to a randomized dosing schedule."	( Galantamine pharmacokinetics, safety, and tolerability profiles are similar in healthy Caucasian and Japanese subjects. Brett, M; Huang, F; Hust, R; Raoult, A; Van Osselaer, N; Van Peer, A; Verhaeghe, T; Zhao, Q, 2002)	0.31
" The recommended starting dosage is 4 mg (as the hydrobromide) twice daily."	( Galantamine hydrobromide: an agent for Alzheimer's disease. Cutler, NR; Sramek, JJ; Zarotsky, V, 2003)	0.32
"1-1 microM), which correlates with the cerebrospinal fluid concentration of the drug at the recommended daily dosage of 16 to 24 mg."	( Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. Albuquerque, EX; Christner, C; Fehrenbacher, A; Höffle, A; Jostock, R; Lübbert, H; Ludwig, J; Maelicke, A; Pereira, EF; Radina, M; Samochocki, M; Ullmer, C; Zerlin, M, 2003)	0.32
" It is safe and very well tolerated when dosage is escalated gradually."	( Update on Alzheimer drugs (galantamine). Raskind, MA, 2003)	0.32
" NMDA currents recorded in Mg2+-free media without addition of glycine were reversibly potentiated by bath and U-tube applications of galantamine at 10 to 10,000 nM, showing a bell-shaped dose-response relationship."	( Mechanism of action of galantamine on N-methyl-D-aspartate receptors in rat cortical neurons. Marszalec, W; Moriguchi, S; Narahashi, T; Yeh, JZ; Zhao, X, 2004)	0.32
"The authors estimated the effects of each of the three commonly used drugs for Alzheimer disease (donepezil, galantamine, and rivastigmine) in terms of predefined clinical outcomes and trial completion rates, by dosing level, and described differences among them."	( Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Ames, D; Clayton, T; Lai, R; Ritchie, CW, )	0.13
" At concentrations that include their prescribed dosage ranges, donepezil (1-1000 nM) and galantamine (50-1000 nM) increase action potential-dependent dopamine release."	( Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release. Dani, JA; Zhang, L; Zhou, FM, 2004)	0.32
" Three head-to-head trials of ChEIs in the treatment of AD have been published to date, but are limited due to their open-label design, rates of titration, and the drug dosage levels utilised."	( The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease. Herrmann, N; Lanctôt, KL; Thompson, S, 2004)	0.32
" Treatment with galantamine led to a significantly greater proportion of subjects with improved or unchanged global rating scale rating (k=7), at all dosing levels except for 8mg/d ."	( Galantamine for Alzheimer's disease. Loy, C; Schneider, L, 2004)	0.32
" Although there was not a statistically significant dose-response effect, doses above 8mg/d were, for the most part, consistently statistically significant."	( Galantamine for Alzheimer's disease. Loy, C; Schneider, L, 2004)	0.32
" Nefiracetam has been shown to potentiate ACh currents in the alpha4beta2 receptor of rat cortical neurons with a bell-shaped dose-response relationship and the maximum effect at 1 nM."	( Mechanisms of action of cognitive enhancers on neuroreceptors. Marszalec, W; Moriguchi, S; Narahashi, T; Yeh, JZ; Zhao, X, 2004)	0.32
" Results demonstrated a robust dose-response relationship between ADAS-cog/11-K and galantamine dosage compared with baseline and controls at 16 weeks."	( A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population. Choi, S; Ho Lee, J; Hong, I; Hoon Oh, B; Ju, YS; Jung, HY; Kil Yeon, B; Nam Bae, J; Park, J; Suh, GH; Uk Lee, C; Yeon Jung, H, 2004)	0.32
" Higher dosages often did not exert beneficial effects in accordance with inverted U-shaped dose-response curves described for cholinomimetics."	( Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. Abramowski, D; De Deyn, PP; Staufenbiel, M; Van Dam, D, 2005)	0.33
" The author provides information on recommended dosing for all three medications, noting that cholinesterase inhibitors must be titrated carefully."	( Cholinesterase inhibitors in the treatment of dementia. Ellis, JM, 2005)	0.33
"To demonstrate using pharmacokinetic (PK) modeling and simulation, that the PK that the PK parameters for drug exposure with galantamine parameters for drug exposure with galantamine immediate-release (IR) tablet and galantamine extended-release (ER) capsule are comparable in patients with Alzheimer's disease (AD) during in patients with Alzheimer's disease (AD) during the switch from twice-daily IR tablet at steady state to the new once-daily ER capsule, and to support a recommendation that patients receiving the IR tablet at steady state can be successfully switched to the ER capsule at the same daily dosage with no titration period."	( Pharmacokinetic simulation for switching from galantamine immediate-release to extended-release formulation. Brashear, HR; Hing, JP; Kimko, H; Piotrovsky, V; Zhao, Q, 2005)	0.33
" The once-daily dosage regimen of ER galantamine without a titration period should prove convenient for AD patients and their caregivers and should increase treatment compliance."	( Pharmacokinetic simulation for switching from galantamine immediate-release to extended-release formulation. Brashear, HR; Hing, JP; Kimko, H; Piotrovsky, V; Zhao, Q, 2005)	0.33
"The primary objective of this study was to evaluate the efficacy and tolerability of a flexible dosing regimen (16 or 24 mg/day) of galantamine prolonged-release capsule (PRC) compared with placebo in subjects with mild to moderate Alzheimer's disease (AD)."	( Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. Brodaty, H; Corey-Bloom, J; Damaraju, CR; Gold, M; Potocnik, FC; Truyen, L, 2005)	0.33
" The treatment duration was 16 weeks with elevation of the drug dosage every 4 weeks--from 8mg to 12 mg twice a day."	( [Reminyl efficacy in dementia with Levi bodies]. Levin, OS, 2005)	0.33
" We hypothesized that cholinergic malfunction may underlie memory impairment in these subjects and applied a low dosage of an acetylcholinesterase inhibitor and modulator of nicotinic acetylcholine receptors, galantamine (4 mg bid), for 7 days."	( Inhibition of hippocampal function in mild cognitive impairment: targeting the cholinergic hypothesis. Brandenburg, I; Grön, G; Riepe, MW; Wunderlich, AP, 2006)	0.33
" Treatment with galantamine led to a significantly greater proportion of subjects with improved or unchanged global rating scale rating (k = 8 studies), at all dosing levels except for 8 mg/d ."	( Galantamine for Alzheimer's disease and mild cognitive impairment. Loy, C; Schneider, L, 2006)	0.33
" Although there was not a statistically significant dose-response effect, doses above 8 mg/d were, for the most part, consistently statistically significant."	( Galantamine for Alzheimer's disease and mild cognitive impairment. Loy, C; Schneider, L, 2006)	0.33
" Sedation limited higher dosing in one patient, and a second patient experienced sedation and tremor."	( Galantamine treatment of cognitive impairment in bipolar disorder: four cases. Ghaemi, SN; Schrauwen, E, 2006)	0.33
" The reminyl treatment has been conducted in dosage of 16 mg/kg daily during 6 months in 30 patients (20 female, 10 male) aged from 59 to 86 years."	( [Use of reminyl (galantamine) in the treatment of dementia]. Lemeshko, ID; Mazal'skaia, OV; Petrukhin, AS; Pylaeva, OA; Voronkova, KV, 2006)	0.33
" In addition, a formulation containing PYY(3-36) and TJM peptide was dosed intranasally in rabbits, resulting in a dramatic increase in bioavailability."	( Therapeutic utility of a novel tight junction modulating peptide for enhancing intranasal drug delivery. Chen, SC; Costantino, HR; Cui, K; Eiting, K; Farber, K; Houston, ME; Johnson, PH; Leonard, AK; Li, CY; Morris, D; Quay, SC; Sileno, AP, 2006)	0.33
"This study compared dosing and utilization patterns of the cholinesterase inhibitors (ChEIs) donepezil, rivastigmine, and galantamine in the nursing home setting."	( Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis. Dybicz, SB; Erwin, WG; Keohane, DJ; McRae, T; Shah, SN, 2006)	0.33
" The mean daily dosage of donepezil was above the effective dose throughout the study period, whereas the mean daily dosage was below the effective dose for the first 3 months with rivastigmine and did not approach the effective dose for galantamine until month 12."	( Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis. Dybicz, SB; Erwin, WG; Keohane, DJ; McRae, T; Shah, SN, 2006)	0.33
"The results of this study suggest that early effective dosing occurred more often with donepezil than with rivastigmine or galantamine in these nursing home residents."	( Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis. Dybicz, SB; Erwin, WG; Keohane, DJ; McRae, T; Shah, SN, 2006)	0.33
" In vivo studies in rats compared pharmacokinetic (PK) profiles of different formulations dosed intranasally."	( In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo. Brandt, GC; Costantino, HR; Foerder, CA; Leonard, AK; Quay, SC; Sileno, AP, 2007)	0.34
" Nevertheless, whereas in the case of donepezil there seems to be a positive relation between the maximum dosage and response, for galanthamine doses above 24 mg/day do not seem to offer any improvement."	( [Galanthamine versus donepezil in the treatment of Alzheimer's disease]. Garre-Olmo, J; López-Pousa, S; Vilalta-Franch, J, )	0.13
" A 1-week titration may permit dosing flexibility and promote increased adherence to medication regimens."	( One-week dose titration of extended release galantamine in patients with Alzheimer's disease. Amatniek, J; Scharre, DW; Shiovitz, T; Zhu, Y, 2008)	0.35
" We determine the effects of sub-chronic dosing of ChEIs on alpha7 and non-alpha7 nAChRs and determine if differences can be observed between them."	( Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and in vitro. Reid, RT; Sabbagh, MN, 2008)	0.35
" Galantamine treatment increased calcium/calmodulin-dependent protein kinase II (CaMKII) and protein kinase Calpha (PKCalpha) activities with a bell-shaped dose-response curve peaked at 1 microM, thereby increasing the phosphorylation of AMPA receptor, myristoylated alanine-rich protein kinase C, and NMDA receptor as downstream substrates of CaMKII and/or PKCalpha."	( Galantamine enhancement of long-term potentiation is mediated by calcium/calmodulin-dependent protein kinase II and protein kinase C activation. Fukunaga, K; Han, F; Moriguchi, S; Narahashi, T; Shioda, N; Yeh, JZ, 2009)	0.35
" Patients with moderate AD trended toward greater response with the 24 mg/day dosage than with the 16 mg/day dosage."	( Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial. Aronson, S; Kavanagh, S; Schwalen, S; Van Baelen, B, 2009)	0.35
"This post hoc analysis suggests that galantamine 16 mg/day is the optimal dosage for patients with mild AD, as similar efficacy is observed with the 24 mg/day dose."	( Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial. Aronson, S; Kavanagh, S; Schwalen, S; Van Baelen, B, 2009)	0.35
"Twenty-five patients with Alzheimer's disease (AD) in moderate-severe and severe stages received galantamine in dosage 8 mg daily during the 1st month with the following increasing to 16 mg daily."	( [Galantamine (reminyl) in the treatment of severe Alzheimer's disease]. Gavrilova, SI; Kalyn, IaB; Kolykhanov, IV; Selezneva, ND, 2009)	0.35
" A dose-response effect was observed for donepezil, with the highest-dose group at greatest risk (HR=2."	( Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system. Cantor, MD; Farwell, W; Hernandez, RK; Lawler, EV, 2009)	0.35
"05) tests as compared to those dosed with the vehicle."	( Metabolic profiling of rat brain and cognitive behavioral tasks: potential complementary strategies in preclinical cognition enhancement research. Atcha, Z; Aw, CC; Browne, ER; Chan, EC; Chen, WS; Goh, CW; Goh, DP; Neo, AH; New, LS, 2009)	0.35
" We show that galantamine (1 pM-300 microM) inhibits selectively Islow, exhibiting a dual dose-response relationship, in both differentiated N1E-115 cells and CA1 neurones."	( Galantamine inhibits slowly inactivating K+ currents with a dual dose-response relationship in differentiated N1E-115 cells and in CA1 neurones. Costa, PF; Lima, PA; Vicente, MI, 2010)	0.36
"The transbuccal delivery of drugs could assist several categories of chronic, especially elderly, patients in adhering to a correct dosage regimen."	( New prospectives in the delivery of galantamine for elderly patients using the IntelliDrug intraoral device: in vivo animal studies. Campisi, G; De Caro, V; Florena, AM; Giannola, LI; Paderni, C; Wolff, A, 2010)	0.36
" The aim of this study was to assess an alternative oral dosing method that could reduce the distress and morbidity associated with standard gavage techniques."	( Alternative method of oral dosing for rats. Atcha, Z; Aw, CC; Browne, ER; Goh, CW; Lim, JS; Neo, AH; Pemberton, DJ; Rourke, C, 2010)	0.36
" The 3 mg/kg dosage of galanthamine had the most significant inhibition on circulating TNF-alpha level at all the three tested doses."	( Effect of cholinesterase inhibitor galanthamine on circulating tumor necrosis factor alpha in rats with lipopolysaccharide-induced peritonitis. Gan, JX; Jiang, GY; Liu, ZH; Ma, YF; Wu, JS; Xu, SW, 2010)	0.36
" The dosage of ChEI treatment could possibly lead to a different functional outcome."	( Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment. Londos, E; Minthon, L; Wallin, ÅK; Wattmo, C, )	0.13
" The starting dosage was 8 mg once daily."	( Evaluation of the effects of galantamine on cardiac function in elderly patients with Alzheimer's disease. Bozoglu, E; Isik, AT; Kilic, S; Naharci, MI, 2010)	0.36
" We demonstrate that a two-phase trial design in which drug dosing is administered after a certain level of disease severity has been reached, coupled with a method to account more accurately for the progression of the disease, may allow us to compensate for these factors, and thus enable us to make treatment effects more apparent."	( A novel subject synchronization clinical trial design for Alzheimer's disease. DiBernardo, A; Farnum, M; Lobanov, V; Narayan, V; Novak, G; Raghavan, N; Samtani, MN; Schultz, T; Shi, Y; Verbeeck, R; Yang, E, 2012)	0.38
" The results suggest that the transdermal application of galantamine drug-in-adhesive patches might be the alternative dosage form to have good efficacy and tolerability for the treatment of Alzheimer disease."	( Investigation of formulation factors affecting in vitro and in vivo characteristics of a galantamine transdermal system. Ha, JM; Kim, JY; Oh, TO; Park, CW; Park, ES; Rhee, YS; Son, DD, 2012)	0.38
"Socio-demographic characteristics and data on comorbidity, number of medications, type and dosage of CER, use of care, cognitive function, behaviour and nutritional status (weight, Body Mass Index (BMI)) were recorded at the time the diagnosis AD was made and at subsequent outpatient clinic visits."	( Effect of long-term treatment with galantamine on weight of patients with Alzheimer's dementia. Droogsma, E; Huinink, EJ; Schuur, T; van Asselt, DZ; van Steijn, JH, 2013)	0.39
" Demographic variables, quantity and rate of prescriptions, dosage forms and strengths were analyzed."	( [Drugs used for cognitive impairment. Analysis of 1.5 million prescriptions in Argentina]. Arizaga, RL; Demey, I; Rojas, G, 2013)	0.39
" However, as an acetylcholinesterase inhibitor, gastrointestinal side effects limit the dosage and duration of treatment."	( Nasal Application of the Galantamine Pro-drug Memogain Slows Down Plaque Deposition and Ameliorates Behavior in 5X Familial Alzheimer's Disease Mice. Bhattacharya, S; Maelicke, A; Montag, D, 2015)	0.42
" The strategy adopted included (a) in vitro biological assays, against eel AChE (EeAChE) and equine serum BuChE (EqBuChE) in order to determine the compounds IC50 and their dose-response activity, consolidated by (b) molecular docking studies to evaluate the docking poses and interatomic interactions in the case of the hit compounds, validated by STD-NMR studies."	( New cholinesterase inhibitors for Alzheimer's disease: Structure Activity Studies (SARs) and molecular docking of isoquinolone and azepanone derivatives. Arantes, S; Bacalhau, P; Burke, AJ; Caldeira, AT; Goth, A; Guarda, C; Marques, CS; Martins, R; Peixoto, D; San Juan, AA; Silva, M, 2016)	0.43
" (summer snowflake) grown in Turkish habitats (Black Sea Region) and pharmaceutical dosage forms by capillary zone electrophoresis with direct UV detection form."	( Development and validation of a capillary zone electrophoretic method for rapid and sensitive determination of galanthamine: Application in plant and pharmaceuticals. Bulduk, I; Ozkan, SA; Ozkurt, H; Sanli, N; Şanli, S, 2016)	0.43
" To select sub-efficacious doses of both drugs, dose-response studies were first performed on the scopolamine-induced deficits of spontaneous alternation in the Y-maze task and of acquisition and retrieval processes in a passive avoidance task."	( Co-modulation of an allosteric modulator of nicotinic receptor-cholinesterase inhibitor (galantamine) and a 5-HT4 receptor agonist (RS-67333): effect on scopolamine-induced memory deficit in the mouse. Boulouard, M; Dauphin, F; Freret, T; Hamidouche, K; Lecouflet, P; Lelong-Boulouard, V, 2017)	0.46
" We therefore hypothesize a combinatorial antioxidant-metal-chelator approach by formulating a single dosage form that has the ability to prevent the formation of free radicals, plaques and accumulation of iron in the brain."	( Hypothesis: apo-lactoferrin-Galantamine Proteo-alkaloid Conjugate for Alzheimer's disease Intervention. Akilo, OD; Choonara, YE; du Toit, LC; Kumar, P; Pillay, V; Pradeep, P, 2018)	0.48
" However, it exhibits poor brain penetration, low intestinal permeation and requires frequent dosing in AD treatment."	( QbD-steered development of mixed nanomicelles of galantamine: Demonstration of enhanced brain uptake, prolonged systemic retention and improved biopharmaceutical attributes. Beg, S; Dhull, D; Kumar, A; Lohan, S; Raza, K; Saini, S; Sharma, T; Singh, B; Swami, R, 2021)	0.62
"0 mg/kg), donepezil tended to promote depression-like behavior, suggesting a u-shaped dose-response curve for FST immobility."	( Multiple cholinesterase inhibitors have antidepressant-like properties in the mouse forced swim test. Fitzgerald, PJ; Ghimire, A; Hale, PJ; Watson, BO, 2021)	0.62
"These baseline-dependent nicotinic effects on early auditory information processing warrant different dosage and repeated administration assessments in patients with low baseline deviance detection levels."	( An α7 nAChR approach for the baseline-dependent modulation of deviance detection in schizophrenia: A pilot study assessing the combined effect of CDP-choline and galantamine. Blais, CM; Choueiry, J; Fisher, D; Knott, V; Labelle, A; Shah, D; Smith, D, 2023)	0.91

Role	Description
antidote to curare poisoning	A role borne by a molecule that acts to counteract or neutralize the deleterious effects of curare.
EC 3.1.1.7 (acetylcholinesterase) inhibitor	An EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of enzyme acetylcholinesterase (EC 3.1.1.7), which helps breaking down of acetylcholine into choline and acetic acid.
cholinergic drug	Any drug used for its actions on cholinergic systems. Included here are agonists and antagonists, drugs that affect the life cycle of acetylcholine, and drugs that affect the survival of cholinergic neurons.
EC 3.1.1.8 (cholinesterase) inhibitor	An EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of cholinesterase (EC 3.1.1.8).
plant metabolite	Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
alkaloid	Any of the naturally occurring, basic nitrogen compounds (mostly heterocyclic) occurring mostly in the plant kingdom, but also found in bacteria, fungi, and animals. By extension, certain neutral compounds biogenetically related to basic alkaloids are also classed as alkaloids. Amino acids, peptides, proteins, nucleotides, nucleic acids, amino sugars and antibiotics are not normally regarded as alkaloids. Compounds in which the nitrogen is exocyclic (dopamine, mescaline, serotonin, etc.) are usually classed as amines rather than alkaloids.
benzazepine alkaloid
benzazepine alkaloid fundamental parent
organic heterotetracyclic compound
tertiary amino compound	A compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Amaryllidacea alkaloids biosynthesis	2	25
Amaryllidacea alkaloids biosynthesis	2	36

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
TDP1 protein	Homo sapiens (human)	Potency	29.0929	0.0008	11.3822	44.6684	AID686978
67.9K protein	Vaccinia virus	Potency	0.8913	0.0001	8.4406	100.0000	AID720579
histone acetyltransferase KAT2A isoform 1	Homo sapiens (human)	Potency	0.5012	0.2512	15.8432	39.8107	AID504327
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	15.8489	0.0112	12.4002	100.0000	AID1030
vitamin D3 receptor isoform VDRA	Homo sapiens (human)	Potency	89.1251	0.3548	28.0659	89.1251	AID504847
lamin isoform A-delta10	Homo sapiens (human)	Potency	35.4813	0.8913	12.0676	28.1838	AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, ACETYLCHOLINESTERASE	Tetronarce californica (Pacific electric ray)	IC50 (µMol)	0.6520	0.6520	0.6520	0.6520	AID977608
Chain A, Acetylcholinesterase	Tetronarce californica (Pacific electric ray)	IC50 (µMol)	0.3600	0.3600	0.3600	0.3600	AID977608
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Acetylcholinesterase	Electrophorus electricus (electric eel)	IC50 (µMol)	3.6610	0.0000	0.9453	9.9400	AID1063992; AID1073062; AID1077144; AID1129233; AID1140465; AID1167622; AID1230202; AID1246442; AID1267380; AID1273004; AID1315225; AID1317852; AID1322224; AID1328951; AID1335318; AID1337747; AID1339189; AID1389180; AID1400271; AID1426027; AID1427875; AID1466563; AID1466635; AID1491305; AID1493769; AID1498442; AID1498899; AID1507309; AID1557015; AID1593770; AID1594568; AID1597699; AID1636642; AID1780622; AID1796450; AID1797820; AID1800998; AID1801040; AID1801810; AID1801887; AID1802055; AID1802058; AID1802583; AID1802597; AID1802939; AID1802975; AID1854483; AID1861404; AID256692; AID260079; AID271048; AID284418; AID302143; AID30543; AID30544; AID307545; AID315115; AID378482; AID383197; AID421514; AID456905; AID479753; AID480448; AID482856; AID486994; AID514203; AID526489; AID527152; AID569581; AID593738; AID603787; AID635414; AID656680; AID666573; AID726768; AID730448; AID747035; AID749373; AID752001; AID754043; AID765550; AID776491
Acetylcholinesterase	Electrophorus electricus (electric eel)	Ki	1.2976	0.0012	1.2563	8.9000	AID1564162; AID256692; AID260079; AID499448; AID726768
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	134.0000	0.1100	7.1903	10.0000	AID1443980; AID1473738
Acetylcholinesterase	Tetronarce californica (Pacific electric ray)	IC50 (µMol)	0.4880	0.0057	0.4285	5.1200	AID1796450; AID1796451; AID1797820; AID294501; AID30666; AID343772; AID404434
Acetylcholinesterase	Tetronarce californica (Pacific electric ray)	Ki	16.0950	0.0000	0.7671	4.3000	AID1799683
Cholinesterase	Homo sapiens (human)	IC50 (µMol)	681.1987	0.0000	1.5599	10.0000	AID1140466; AID1162590; AID1179994; AID1331321; AID1356517; AID1406252; AID1443224; AID1472441; AID1493770; AID1524946; AID1537270; AID1545272; AID1567163; AID1570261; AID1646342; AID1657596; AID1736860; AID1739254; AID1779364; AID1796482; AID1796572; AID1797821; AID1799735; AID1802080; AID1807566; AID1865085; AID1872733; AID276346; AID298279; AID302144; AID345206; AID362528; AID365699; AID407781; AID422296; AID594821; AID724167; AID746378
Cholinesterase	Homo sapiens (human)	Ki	9.5583	0.0000	1.5173	9.7300	AID1186579; AID1312278; AID694074
Cytochrome P450 3A4	Homo sapiens (human)	IC50 (µMol)	12.7300	0.0001	1.7536	10.0000	AID1322224
Vascular endothelial growth factor receptor 1	Homo sapiens (human)	IC50 (µMol)	0.5900	0.0001	0.2914	7.0000	AID263610
Acetylcholinesterase	Mus musculus (house mouse)	IC50 (µMol)	2.2900	0.0007	1.1181	8.4000	AID1066955; AID1175427
Acetylcholinesterase	Homo sapiens (human)	IC50 (µMol)	27.8215	0.0000	0.9332	10.0000	AID1054126; AID1066956; AID1070090; AID1127083; AID1129497; AID1162589; AID1176926; AID1179993; AID1237656; AID1254737; AID1272326; AID1301459; AID1332254; AID1350115; AID1356515; AID1406251; AID1443223; AID1472442; AID1501977; AID1507310; AID1524945; AID1537269; AID1545271; AID1556710; AID1567161; AID1646341; AID1657594; AID1678836; AID1682145; AID1736859; AID1739253; AID1779363; AID1796482; AID1796572; AID1797820; AID1802080; AID1807563; AID1853195; AID1865084; AID1872732; AID241692; AID262754; AID263610; AID276345; AID281636; AID298278; AID31036; AID311339; AID31163; AID345205; AID362527; AID365698; AID378483; AID381366; AID407780; AID422295; AID446351; AID482855; AID566361; AID568572; AID594820; AID600978; AID600980; AID625193; AID656684; AID670563; AID676724; AID724168; AID729911; AID746379; AID746749
Acetylcholinesterase	Homo sapiens (human)	Ki	0.1685	0.0000	1.2786	9.7300	AID1186578; AID1231568; AID501440; AID694073
Acetylcholinesterase	Bos taurus (cattle)	IC50 (µMol)	4.5300	0.0000	0.6106	8.7000	AID1797820; AID462833
Delta-type opioid receptor	Mus musculus (house mouse)	IC50 (µMol)	8.3973	0.0001	0.7298	10.0000	AID276346
Vascular endothelial growth factor receptor 3	Homo sapiens (human)	IC50 (µMol)	0.5900	0.0001	0.2264	4.9000	AID263610
Vascular endothelial growth factor receptor 2	Homo sapiens (human)	IC50 (µMol)	0.5900	0.0000	0.4830	8.8000	AID263610
Acetylcholinesterase	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.8006	0.0002	0.5259	7.2000	AID31964; AID31968; AID32105; AID333566; AID416453
Kappa-type opioid receptor	Cavia porcellus (domestic guinea pig)	IC50 (µMol)	3.2000	0.0003	0.7123	7.0700	AID514203
Prolyl endopeptidase	Homo sapiens (human)	IC50 (µMol)	200.0000	0.0011	1.9896	9.7500	AID1537274
Small conductance calcium-activated potassium channel protein 3	Rattus norvegicus (Norway rat)	IC50 (µMol)	12.7000	0.0015	1.6858	7.0000	AID754042
Cholinesterase	Equus caballus (horse)	IC50 (µMol)	15.9295	0.0000	2.2214	9.4000	AID1063991; AID1070089; AID1077145; AID1129234; AID1140466; AID1167623; AID1246443; AID1267381; AID1273007; AID1293781; AID1315224; AID1317853; AID1335319; AID1337749; AID1339190; AID1389181; AID1400272; AID1466564; AID1466636; AID1491306; AID1498443; AID1498900; AID1593769; AID1594569; AID1597702; AID1636643; AID1780623; AID1854475; AID1861405; AID421515; AID456906; AID462834; AID479754; AID480449; AID482854; AID486995; AID566384; AID569582; AID603880; AID666575; AID670564; AID729524; AID730447; AID746748; AID749372; AID752000; AID754042; AID765549; AID776489
Cholinesterase	Equus caballus (horse)	Ki	7.7000	0.0020	3.4598	9.3700	AID1564164
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
Carboxylic ester hydrolase	Equus caballus (horse)	IC50 (µMol)	11.4588	0.0051	2.6984	8.5000	AID260080; AID271049; AID294502; AID307546; AID383199; AID593739; AID635415
Carboxylic ester hydrolase	Equus caballus (horse)	Ki	8.0000	0.0020	0.9570	8.0000	AID260080
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Acetylcholinesterase	Homo sapiens (human)	EC50 (µMol)	1.1000	0.0190	0.5755	1.1400	AID73711
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Acetylcholinesterase	Homo sapiens (human)	MIC	0.0000	0.0000	0.0000	0.0000	AID550178
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Cholinesterase	Homo sapiens (human)
learning	Cholinesterase	Homo sapiens (human)
negative regulation of cell population proliferation	Cholinesterase	Homo sapiens (human)
neuroblast differentiation	Cholinesterase	Homo sapiens (human)
peptide hormone processing	Cholinesterase	Homo sapiens (human)
response to alkaloid	Cholinesterase	Homo sapiens (human)
cocaine metabolic process	Cholinesterase	Homo sapiens (human)
negative regulation of synaptic transmission	Cholinesterase	Homo sapiens (human)
response to glucocorticoid	Cholinesterase	Homo sapiens (human)
response to folic acid	Cholinesterase	Homo sapiens (human)
choline metabolic process	Cholinesterase	Homo sapiens (human)
acetylcholine catabolic process	Cholinesterase	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 3A4	Homo sapiens (human)
lipid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
androgen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
calcitriol biosynthetic process from calciol	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 3A4	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A4	Homo sapiens (human)
angiogenesis	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
monocyte chemotaxis	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
positive regulation of cell population proliferation	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
positive regulation of phospholipase C activity	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
cell migration	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
cell differentiation	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
positive regulation of cell migration	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulus	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
vascular endothelial growth factor receptor-1 signaling pathway	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
vascular endothelial growth factor signaling pathway	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
positive regulation of MAP kinase activity	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
positive regulation of MAPK cascade	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
positive regulation of angiogenesis	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
protein autophosphorylation	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathway	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
blood vessel morphogenesis	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
embryonic morphogenesis	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
negative regulation of vascular endothelial cell proliferation	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
hyaloid vascular plexus regression	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
multicellular organism development	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
positive regulation of kinase activity	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
acetylcholine catabolic process in synaptic cleft	Acetylcholinesterase	Homo sapiens (human)
regulation of receptor recycling	Acetylcholinesterase	Homo sapiens (human)
osteoblast development	Acetylcholinesterase	Homo sapiens (human)
acetylcholine catabolic process	Acetylcholinesterase	Homo sapiens (human)
cell adhesion	Acetylcholinesterase	Homo sapiens (human)
nervous system development	Acetylcholinesterase	Homo sapiens (human)
synapse assembly	Acetylcholinesterase	Homo sapiens (human)
receptor internalization	Acetylcholinesterase	Homo sapiens (human)
negative regulation of synaptic transmission, cholinergic	Acetylcholinesterase	Homo sapiens (human)
amyloid precursor protein metabolic process	Acetylcholinesterase	Homo sapiens (human)
positive regulation of protein secretion	Acetylcholinesterase	Homo sapiens (human)
retina development in camera-type eye	Acetylcholinesterase	Homo sapiens (human)
acetylcholine receptor signaling pathway	Acetylcholinesterase	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Acetylcholinesterase	Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathway	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
positive regulation of protein phosphorylation	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
positive regulation of endothelial cell proliferation	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
vasculature development	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
lymph vessel development	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
lymphangiogenesis	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
sprouting angiogenesis	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
respiratory system process	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
positive regulation of cell population proliferation	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
positive regulation of vascular endothelial growth factor production	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
positive regulation of endothelial cell migration	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulus	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
vascular endothelial growth factor signaling pathway	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
negative regulation of apoptotic process	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
positive regulation of MAPK cascade	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
positive regulation of JNK cascade	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
protein autophosphorylation	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathway	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
lung alveolus development	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
blood vessel morphogenesis	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
regulation of blood vessel remodeling	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
positive regulation of protein kinase C signaling	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
positive regulation of cell migration	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
positive regulation of kinase activity	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
multicellular organism development	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
regulation of MAPK cascade	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
angiogenesis	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
branching involved in blood vessel morphogenesis	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
positive regulation of macroautophagy	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
positive regulation of mitochondrial depolarization	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
positive regulation of mitochondrial fission	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
angiogenesis	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
ovarian follicle development	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
vasculogenesis	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
positive regulation of protein phosphorylation	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
positive regulation of endothelial cell proliferation	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
lymph vessel development	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
cell migration involved in sprouting angiogenesis	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
positive regulation of mesenchymal cell proliferation	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
epithelial cell maturation	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
endocardium development	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
endothelium development	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
positive regulation of cell population proliferation	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
regulation of cell shape	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
mesenchymal cell proliferation	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
positive regulation of endothelial cell migration	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
negative regulation of gene expression	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
positive regulation of cell migration	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
positive regulation of BMP signaling pathway	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
embryonic hemopoiesis	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulus	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
vascular endothelial growth factor receptor-2 signaling pathway	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
peptidyl-tyrosine autophosphorylation	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
vascular endothelial growth factor signaling pathway	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
surfactant homeostasis	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
positive regulation of MAPK cascade	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
negative regulation of neuron apoptotic process	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
positive regulation of blood vessel endothelial cell migration	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
cell fate commitment	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
positive regulation of angiogenesis	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
protein autophosphorylation	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathway	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
lung alveolus development	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
post-embryonic camera-type eye morphogenesis	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
epithelial cell proliferation	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
positive regulation of positive chemotaxis	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic process	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
positive regulation of focal adhesion assembly	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
calcium ion homeostasis	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
blood vessel endothelial cell differentiation	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
vascular wound healing	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
semaphorin-plexin signaling pathway	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
stem cell proliferation	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesis	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
regulation of hematopoietic progenitor cell differentiation	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
regulation of bone development	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
cellular response to hydrogen sulfide	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
negative regulation of endothelial cell apoptotic process	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
positive regulation of stem cell proliferation	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
positive regulation of endothelial cell chemotaxis	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
positive regulation of vasculogenesis	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
regulation of MAPK cascade	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
multicellular organism development	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
cell migration	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
endothelial cell differentiation	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
positive regulation of kinase activity	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
proteolysis	Prolyl endopeptidase	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
amyloid-beta binding	Cholinesterase	Homo sapiens (human)
catalytic activity	Cholinesterase	Homo sapiens (human)
acetylcholinesterase activity	Cholinesterase	Homo sapiens (human)
cholinesterase activity	Cholinesterase	Homo sapiens (human)
protein binding	Cholinesterase	Homo sapiens (human)
hydrolase activity, acting on ester bonds	Cholinesterase	Homo sapiens (human)
enzyme binding	Cholinesterase	Homo sapiens (human)
choline binding	Cholinesterase	Homo sapiens (human)
identical protein binding	Cholinesterase	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
steroid binding	Cytochrome P450 3A4	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A4	Homo sapiens (human)
protein binding	Cytochrome P450 3A4	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A4	Homo sapiens (human)
enzyme binding	Cytochrome P450 3A4	Homo sapiens (human)
heme binding	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D3 25-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
quinine 3-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activity	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
vascular endothelial growth factor receptor activity	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
protein binding	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
ATP binding	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
growth factor binding	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
placental growth factor receptor activity	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
amyloid-beta binding	Acetylcholinesterase	Homo sapiens (human)
acetylcholinesterase activity	Acetylcholinesterase	Homo sapiens (human)
cholinesterase activity	Acetylcholinesterase	Homo sapiens (human)
protein binding	Acetylcholinesterase	Homo sapiens (human)
collagen binding	Acetylcholinesterase	Homo sapiens (human)
hydrolase activity	Acetylcholinesterase	Homo sapiens (human)
serine hydrolase activity	Acetylcholinesterase	Homo sapiens (human)
acetylcholine binding	Acetylcholinesterase	Homo sapiens (human)
protein homodimerization activity	Acetylcholinesterase	Homo sapiens (human)
laminin binding	Acetylcholinesterase	Homo sapiens (human)
amyloid-beta binding	Acetylcholinesterase	Bos taurus (cattle)
protein binding	Acetylcholinesterase	Bos taurus (cattle)
transmembrane receptor protein tyrosine kinase activity	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
vascular endothelial growth factor receptor activity	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
protein binding	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
ATP binding	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
growth factor binding	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
protein phosphatase binding	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
protein homodimerization activity	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
protein tyrosine kinase activity	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activity	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
vascular endothelial growth factor receptor activity	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
integrin binding	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
protein binding	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
ATP binding	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
coreceptor activity	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
growth factor binding	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
vascular endothelial growth factor binding	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
identical protein binding	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
cadherin binding	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
Hsp90 protein binding	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
serine-type endopeptidase activity	Prolyl endopeptidase	Homo sapiens (human)
protein binding	Prolyl endopeptidase	Homo sapiens (human)
serine-type peptidase activity	Prolyl endopeptidase	Homo sapiens (human)
oligopeptidase activity	Prolyl endopeptidase	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
extracellular region	Cholinesterase	Homo sapiens (human)
nuclear envelope lumen	Cholinesterase	Homo sapiens (human)
endoplasmic reticulum lumen	Cholinesterase	Homo sapiens (human)
blood microparticle	Cholinesterase	Homo sapiens (human)
plasma membrane	Cholinesterase	Homo sapiens (human)
extracellular space	Cholinesterase	Homo sapiens (human)
cytoplasm	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A4	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A4	Homo sapiens (human)
extracellular space	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
endosome	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
plasma membrane	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
focal adhesion	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
actin cytoskeleton	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
receptor complex	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
plasma membrane	Vascular endothelial growth factor receptor 1	Homo sapiens (human)
extracellular region	Acetylcholinesterase	Homo sapiens (human)
basement membrane	Acetylcholinesterase	Homo sapiens (human)
extracellular space	Acetylcholinesterase	Homo sapiens (human)
nucleus	Acetylcholinesterase	Homo sapiens (human)
Golgi apparatus	Acetylcholinesterase	Homo sapiens (human)
plasma membrane	Acetylcholinesterase	Homo sapiens (human)
cell surface	Acetylcholinesterase	Homo sapiens (human)
membrane	Acetylcholinesterase	Homo sapiens (human)
neuromuscular junction	Acetylcholinesterase	Homo sapiens (human)
synaptic cleft	Acetylcholinesterase	Homo sapiens (human)
synapse	Acetylcholinesterase	Homo sapiens (human)
perinuclear region of cytoplasm	Acetylcholinesterase	Homo sapiens (human)
side of membrane	Acetylcholinesterase	Homo sapiens (human)
synapse	Acetylcholinesterase	Bos taurus (cattle)
side of membrane	Acetylcholinesterase	Bos taurus (cattle)
extracellular region	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
nucleoplasm	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
cytosol	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
plasma membrane	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
receptor complex	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
plasma membrane	Vascular endothelial growth factor receptor 3	Homo sapiens (human)
extracellular region	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
nucleus	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
endosome	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
early endosome	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
endoplasmic reticulum	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
Golgi apparatus	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
plasma membrane	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
external side of plasma membrane	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
cell junction	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
membrane raft	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
anchoring junction	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
sorting endosome	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
plasma membrane	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
receptor complex	Vascular endothelial growth factor receptor 2	Homo sapiens (human)
nucleus	Prolyl endopeptidase	Homo sapiens (human)
cytoplasm	Prolyl endopeptidase	Homo sapiens (human)
cytosol	Prolyl endopeptidase	Homo sapiens (human)
membrane	Prolyl endopeptidase	Homo sapiens (human)
cytosol	Prolyl endopeptidase	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (585)

Assay ID	Title	Year	Journal	Article
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID44417	Ratio of inhibitory activity against butyrylcholinesterase (BChE) to that of acetylcholinesterase (AChE)	2003	Bioorganic & medicinal chemistry letters, Jul-21, Volume: 13, Issue:14	Synthesis and structure-activity relationships of open D-Ring galanthamine analogues.
AID256692	Inhibitory activity AChE from Electrophorus electricus using ATCh substrate and DTNB by spectrophotometry	2005	Journal of medicinal chemistry, Dec-29, Volume: 48, Issue:26	Synthesis of tricyclic 1,3-oxazin-4-ones and kinetic analysis of cholesterol esterase and acetylcholinesterase inhibition.
AID271048	Inhibition of electric eel AChE	2006	Journal of medicinal chemistry, Sep-07, Volume: 49, Issue:18	Homobivalent quinazolinimines as novel nanomolar inhibitors of cholinesterases with dirigible selectivity toward butyrylcholinesterase.
AID307546	Inhibition of equine serum BuChE	2007	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13	Derivatives of oxoisoaporphine alkaloids: a novel class of selective acetylcholinesterase inhibitors.
AID1507318	Inhibition of equine serum BChE at 1 mM	2017	European journal of medicinal chemistry, Aug-18, Volume: 136	Discorhabdin alkaloids from Antarctic Latrunculia spp. sponges as a new class of cholinesterase inhibitors.
AID499448	Competitive inhibition of Electrophorus electricus AChE by Lineweaver-Burke plot analysis	2010	Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16	Multipotent drugs with cholinergic and neuroprotective properties for the treatment of Alzheimer and neuronal vascular diseases. I. Synthesis, biological assessment, and molecular modeling of simple and readily available 2-aminopyridine-, and 2-chloropyri
AID1070090	Inhibition of AChE (unknown origin) using acetylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition by Ellman's method	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Ionic liquid mediated synthesis of mono- and bis-spirooxindole-hexahydropyrrolidines as cholinesterase inhibitors and their molecular docking studies.
AID48733	Maximum reversal of vecuronium-induced neuromuscular block in-vivo in anaesthetised cats; NT denotes not tested	2002	Bioorganic & medicinal chemistry letters, Sep-16, Volume: 12, Issue:18	Quaternary salts of E2020 analogues as acetylcholinesterase inhibitors for the reversal of neuromuscular block.
AID480448	Inhibition of electric eel AChE by modified Ellman's method	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.
AID1076766	Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of glutamate-induced toxicity by measuring cell viability at 1 uM pretreated for 24 hrs followed by glutamate challenge measured after 24 hrs by MTT assay relat	2014	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6	Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1350115	Inhibition of human erythrocyte AChE using S-acetylthiocholine iodide as substrate pretreated for 20 mins followed by substrate addition measured after 30 mins by Ellman's method	2018	Journal of natural products, 02-23, Volume: 81, Issue:2	Mucroniferanines A-G, Isoquinoline Alkaloids from Corydalis mucronifera.
AID1498449	Inhibition of electric eel AChE at 12.5 ug using acetylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition measured every 5 mins for 15 mins by spectrophotometric method relative to control	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	A cascade synthesis, in vitro cholinesterases inhibitory activity and docking studies of novel Tacrine-pyranopyrazole derivatives.
AID1406251	Inhibition of AChE (unknown origin)	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Multi-target-directed ligands for treating Alzheimer's disease: Butyrylcholinesterase inhibitors displaying antioxidant and neuroprotective activities.
AID749371	Selectivity ratio of IC50 for equine serum BuChE to IC50 for electric eel AChE	2013	Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11	Microwave assisted synthesis, cholinesterase enzymes inhibitory activities and molecular docking studies of new pyridopyrimidine derivatives.
AID1567160	Inhibition of human recombinant AChE at 25 uM using acetylthiocholine iodide as substrate preincubated for 20 mins followed by substrate addition by Ellman's spectrophotometric method relative to control	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery of novel benzofuran-based compounds with neuroprotective and immunomodulatory properties for Alzheimer's disease treatment.
AID1271111	Inhibition of BuChE (unknown origin) using butyrylthiocholine iodide as substrate by Ellman spectrophotometric method	2016	European journal of medicinal chemistry, Jan-01, Volume: 107	Synthesis and evaluation of bis-thiazole derivatives as new anticancer agents.
AID569581	Inhibition of electric eel AChE by Ellman's method	2011	Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3	Probing the mid-gorge of cholinesterases with spacer-modified bivalent quinazolinimines leads to highly potent and selective butyrylcholinesterase inhibitors.
AID376663	Inhibition of AChE	2006	Journal of natural products, May, Volume: 69, Issue:5	Bioactive diterpenes from the fruits of Detarium microcarpum.
AID593737	Ratio of IC50 for equine serum Butyrylcholinesterase to IC50 for electric eel Acetylcholinesterase	2011	Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7	Synthesis, biological evaluation and molecular modeling of novel triazole-containing berberine derivatives as acetylcholinesterase and β-amyloid aggregation inhibitors.
AID1466636	Inhibition of horse serum BChE using butyrylcholine chloride as substrate preincubated for 15 mins followed by substrate addition by spectrophotometric method	2017	Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13	Antioxidant and anticholinesterase potential of diterpenoid alkaloids from Aconitum heterophyllum.
AID1556703	Inhibition of AChE in human erythrocytes using acetylthiocholine iodide as substrate at 100 uM preincubated with enzyme for 10 mins followed by substrate addition measured for 15 mins by Ellman's method relative to control	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Carboxamides vs. methanimines: Crystal structures, binding interactions, photophysical studies, and biological evaluation of (indazole-5-yl)methanimines as monoamine oxidase B and acetylcholinesterase inhibitors.
AID108857	Active dose for reversal of Scopolamine dementia(SDDA) activity in mouse administered subcutaneously	1995	Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18	Synthesis and evaluation of 5-amino-5,6,7,8-tetrahydroquinolinones as potential agents for the treatment of Alzheimer's disease.
AID600980	Inhibition of human erythrocytes BChE	2011	European journal of medicinal chemistry, Jun, Volume: 46, Issue:6	Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease.
AID1498899	Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition by Ellman's method	2018	Bioorganic & medicinal chemistry, 07-30, Volume: 26, Issue:13	Developing hybrid molecule therapeutics for diverse enzyme inhibitory action: Active role of coumarin-based structural leads in drug discovery.
AID603880	Inhibition of equine serum BChE by colorimetric Ellman's assay	2011	European journal of medicinal chemistry, Jul, Volume: 46, Issue:7	Mycobacterium tuberculosis and cholinesterase inhibitors from Voacanga globosa.
AID729911	Inhibition of AChE (unknown origin) using acetylthiocholine iodide substrate by Ellman's method based spectrophotometry	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	Synthesis and discovery of novel piperidone-grafted mono- and bis-spirooxindole-hexahydropyrrolizines as potent cholinesterase inhibitors.
AID362527	Inhibition of acetylcholinesterase	2008	Journal of natural products, Aug, Volume: 71, Issue:8	Bioactive 5alpha-pregnane-type steroidal alkaloids from Sarcococca hookeriana.
AID437947	Antibacterial activity against Bacillus subtilis after 18 hrs	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis, spectral characterization and biological evaluation of phosphorylated derivatives of galanthamine.
AID1315224	Inhibition of equine serum BuChE using ATCI as substrate preincubated for 30 mins followed by substrate addition measured after 5 mins by DTNB-based spectrophotometric analysis	2016	Journal of natural products, 05-27, Volume: 79, Issue:5	Alkaloids from Hippeastrum argentinum and Their Cholinesterase-Inhibitory Activities: An in Vitro and in Silico Study.
AID1646341	Inhibition of AChE (unknown origin)	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Design, synthesis and cholinesterase inhibitory activity of novel spiropyrrolidine tethered imidazole heterocyclic hybrids.
AID1507309	Inhibition of electric eel AChE	2017	European journal of medicinal chemistry, Aug-18, Volume: 136	Discorhabdin alkaloids from Antarctic Latrunculia spp. sponges as a new class of cholinesterase inhibitors.
AID1077156	Neuroprotective activity in rat PC12 cells assessed as decrease in amyloid beta (1 to 42)-induced cytotoxicity at 0.08 to 10 uM after 24 hrs by MTT assay	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	Design, synthesis and biological evaluation of D-ring opened galantamine analogs as multifunctional anti-Alzheimer agents.
AID639464	Neuroprotective activity against okadaic acid-induced cell death in human SH-SY5Y cells assessed as LDH release at 0.3 uM treated 24 hrs before okadaic acid challenge measured after 24 hrs relative to control	2011	European journal of medicinal chemistry, Jun, Volume: 46, Issue:6	N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease.
AID1498455	Inhibition of electric eel AChE at 0.098 ug using acetylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition measured every 5 mins for 15 mins by spectrophotometric method relative to control	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	A cascade synthesis, in vitro cholinesterases inhibitory activity and docking studies of novel Tacrine-pyranopyrazole derivatives.
AID1578097	Antitrypanosomal activity against Leishmania donovani	2019	Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20	Antiprotozoal alkaloid principles of the plant family Amaryllidaceae.
AID1545272	Inhibition of human Cholinesterase	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Anti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer's disease (1998-2018).
AID1066956	Inhibition of AChE (unknown origin) using 2-nitrobenzoate-5-mercaptothiocholine as substrate after 15 to 60 mins by microplate assay	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Synthesis of aminoalkyl-substituted coumarin derivatives as acetylcholinesterase inhibitors.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID729526	Selectivity index, ratio of IC50 for AChE (unknown origin) to IC50 for equine serum BuChE	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	Synthesis and discovery of novel piperidone-grafted mono- and bis-spirooxindole-hexahydropyrrolizines as potent cholinesterase inhibitors.
AID527152	Inhibition of electric eel AChE by Ellman's method	2010	Journal of natural products, Oct-22, Volume: 73, Issue:10	Characterization of Acetylcholinesterase Inhibitory Constituents from Annona glabra Assisted by HPLC Microfractionation.
AID1076772	Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of amyloid beta 1 to 42-induced toxicity by measuring cell viability at 10 nM pretreated for 24 hrs followed by amyloid beta 1 to 42 challenge measured after 24	2014	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6	Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
AID676724	Inhibition of human AChE pre-incubated for 10 mins before acetylthiocholine iodide substrate addition	2012	Journal of natural products, Jul-27, Volume: 75, Issue:7	Geranylphenazinediol, an acetylcholinesterase inhibitor produced by a Streptomyces species.
AID1301458	Inhibition AChE (unknown origin) using ATCI as substrate assessed as hydrolysis of ATCI at 5 uM measured every 1 min for 10 times	2016	Journal of natural products, Feb-26, Volume: 79, Issue:2	Bioactive Constituents of Glycyrrhiza uralensis (Licorice): Discovery of the Effective Components of a Traditional Herbal Medicine.
AID1337749	Inhibition of horse serum BChE pretreated for 20 mins followed by butyrylthiocholine iodide substrate addition measured for 5 mins by Ellman's method	2017	European journal of medicinal chemistry, Jan-05, Volume: 125	New azepino[4,3-b]indole derivatives as nanomolar selective inhibitors of human butyrylcholinesterase showing protective effects against NMDA-induced neurotoxicity.
AID48700	Mean arterial pressure change was detected in anaesthetised cats on administration of the compound	2002	Bioorganic & medicinal chemistry letters, Sep-16, Volume: 12, Issue:18	Quaternary salts of E2020 analogues as acetylcholinesterase inhibitors for the reversal of neuromuscular block.
AID437950	Antioxidant activity in Wistar rat brain assessed as catalase content	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis, spectral characterization and biological evaluation of phosphorylated derivatives of galanthamine.
AID746377	Inhibition of BuChE (unknown origin) at 10 uM by Ellman method	2013	Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9	Design, synthesis and biological activity of multifunctional α,β-unsaturated carbonyl scaffolds for Alzheimer's disease.
AID666578	Selectivity ratio of IC50 for equine serum butyrylcholinesterase to IC50 for electric eel acetylcholine esterase	2012	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13	Design, synthesis, and evaluation of indanone derivatives as acetylcholinesterase inhibitors and metal-chelating agents.
AID1807563	Inhibition of human AChE using acetylthiocholine as substrate by Ellman's method	2021	Bioorganic & medicinal chemistry letters, 11-01, Volume: 51	Derivatives of montanine-type alkaloids and their implication for the treatment of Alzheimer's disease: Synthesis, biological activity and in silico study.
AID1272326	Inhibition of human acetylcholine esterase preincubated for 10 mins followed by the addition of 550 uM of acetylcholine iodide as substrate measured after 20 mins by Ellman's method	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Cardanol-derived AChE inhibitors: Towards the development of dual binding derivatives for Alzheimer's disease.
AID416455	Selectivity ratio of IC50 for rat serum BChE to IC50 for rat cortex AChE	2009	European journal of medicinal chemistry, Feb, Volume: 44, Issue:2	Design, synthesis and evaluation of galanthamine derivatives as acetylcholinesterase inhibitors.
AID1179993	Inhibition of AChE (unknown origin)	2014	Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15	Coumarin hybrids as novel therapeutic agents.
AID1077153	Inhibition of amyloid beta (1 to 42) aggregation (unknown origin) at 5 to 100 uM after 1 hr by thioflavin T fluorescence assay	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	Design, synthesis and biological evaluation of D-ring opened galantamine analogs as multifunctional anti-Alzheimer agents.
AID1501977	Inhibition of AChE (unknown origin)	2017	Journal of natural products, 09-22, Volume: 80, Issue:9	Acetylcholinesterase Inhibitory Alkaloids from the Whole Plants of Zephyranthes carinata.
AID1493769	Inhibition of electric eel AChE using acetylthiocholine as substrate preincubated for 15 mins followed by substrate addition measured after 5 mins by Ellman's method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	2-Arylbenzofurans from Artocarpus lakoocha and methyl ether analogs with potent cholinesterase inhibitory activity.
AID383197	Inhibition of electric eel AChE type 6S by Ellman's assay	2008	Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8	Design, synthesis and pharmacological evaluation of hybrid molecules out of quinazolinimines and lipoic acid lead to highly potent and selective butyrylcholinesterase inhibitors with antioxidant properties.
AID1854483	Inhibition of electric eel AChE using acetylthiocholine iodide as substrate pre-incubated for 5 mins followed by substrate addition and measured after 6 mins by Ellman's method	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	New naphtho/thienobenzo-triazoles with interconnected anti-inflammatory and cholinesterase inhibitory activity.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1129497	Inhibition of human AChE by spectrophotometry	2014	Journal of natural products, Apr-25, Volume: 77, Issue:4	Alkaloids from the roots of Stichoneuron caudatum and their acetylcholinesterase inhibitory activities.
AID302144	Inhibition of human serum BuChE by Ellman's method	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	New potent acetylcholinesterase inhibitors in the tetracyclic triterpene series.
AID1267380	Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 5 mins followed by substrate addition measured after 5 mins by Ellman's method	2016	European journal of medicinal chemistry, Jan-01, Volume: 107	Synthesis, pharmacological assessment, molecular modeling and in silico studies of fused tricyclic coumarin derivatives as a new family of multifunctional anti-Alzheimer agents.
AID1646344	Selectivity ratio of IC50 for AChE (unknown origin) to IC50 for BChE (unknown origin)	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Design, synthesis and cholinesterase inhibitory activity of novel spiropyrrolidine tethered imidazole heterocyclic hybrids.
AID716206	Selectivity index, ratio of IC50 for electric eel AChE to horse BChE	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Tacrine-silibinin codrug shows neuro- and hepatoprotective effects in vitro and pro-cognitive and hepatoprotective effects in vivo.
AID31163	Ex vivo inhibition of human erythrocyte Acetylcholinesterase.	2002	Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17	Anticholinesterase activity of compounds related to geneserine tautomers. N-Oxides and 1,2-oxazines.
AID1524947	Selectivity index, ratio of IC50 for inhibition of AChE (unknown origin) to IC50 for inhibition of BChE (unknown origin)	2019	Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10	Bioactivity-guided identification of flavonoids with cholinesterase and β-amyloid peptide aggregation inhibitory effects from the seeds of Millettia pachycarpa.
AID1537269	Inhibition of human AChE using acetylthiocholine iodide as substrate measured for 1 min by Ellman's method	2019	Journal of natural products, 02-22, Volume: 82, Issue:2	Isoquinoline Alkaloids from Berberis vulgaris as Potential Lead Compounds for the Treatment of Alzheimer's Disease.
AID276345	Inhibition of AChE	2006	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 16, Issue:22	6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors.
AID1077158	Antialzheimer activity in Wistar rat scopolamine-induced cognition impairment model assessed as total exploration time at 1 umol/100 g body weight, ip treated for 5 mins prior to scopolamine-challenge by eight-arm radial maze test relative to control	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	Design, synthesis and biological evaluation of D-ring opened galantamine analogs as multifunctional anti-Alzheimer agents.
AID437944	Inhibition of catalase in Wistar rat brain	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis, spectral characterization and biological evaluation of phosphorylated derivatives of galanthamine.
AID1578098	Antitrypanosomal activity against Trypanosoma brucei rhodesiense	2019	Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20	Antiprotozoal alkaloid principles of the plant family Amaryllidaceae.
AID1129237	Selectivity ratio of IC50 for electric eel AChE to IC50 for equine serum BChE	2014	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7	Synthesis and discovery of highly functionalized mono- and bis-spiro-pyrrolidines as potent cholinesterase enzyme inhibitors.
AID1537277	Permeability of the compound after 2.45 hrs by PAMPA	2019	Journal of natural products, 02-22, Volume: 82, Issue:2	Isoquinoline Alkaloids from Berberis vulgaris as Potential Lead Compounds for the Treatment of Alzheimer's Disease.
AID1175431	Reversal of scopolamine-induced memory deficit in ICR mouse assessed as latency time at 1 mg/kg, po administered 30 min before acquisition trial by passive avoidance test (Rvb =271.0 +/- 14.49 seconds)	2015	Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1	Synthesis of aminoalkyl-substituted aurone derivatives as acetylcholinesterase inhibitors.
AID656684	Inhibition of human AChE by Ellman's method	2012	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8	Prospective acetylcholinesterase inhibitory activity of indole and its analogs.
AID707697	Inhibition of mouse recombinant GST-tagged CLK3 expressed in Escherichia coli using GRSRSRSRSRSR as substrate and [gamma33P]ATP at 10 uM after 30 mins by scintillation counting	2012	Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21	Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B.
AID1498443	Inhibition of horse serum BChE using butyrylthiocholine chloride as substrate preincubated for 15 mins followed by substrate addition measured every 5 mins for 15 mins by spectrophotometric method	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	A cascade synthesis, in vitro cholinesterases inhibitory activity and docking studies of novel Tacrine-pyranopyrazole derivatives.
AID1140466	Inhibition of BuChE in equine serum using S-butyrylthiocholine iodide as substrate preincubated with enzyme for 6 mins followed by substrate addition by Ellman's method	2014	Bioorganic & medicinal chemistry letters, May-15, Volume: 24, Issue:10	Design, synthesis and biological evaluation of benzylisoquinoline derivatives as multifunctional agents against Alzheimer's disease.
AID1246446	Selectivity index, ratio of IC50 for horse serum butyrylcholinesterase to IC50 for electric eel acetylcholinesterase	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Potential of aryl-urea-benzofuranylthiazoles hybrids as multitasking agents in Alzheimer's disease.
AID1498442	Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition measured every 5 mins for 15 mins by spectrophotometric method	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	A cascade synthesis, in vitro cholinesterases inhibitory activity and docking studies of novel Tacrine-pyranopyrazole derivatives.
AID114806	Compound was evaluated for the cholinergic activity in vivo in mice, by administering the compound intraperitoneally and observation of the salivation was made after 30 min	1994	Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5	Novel [2-(4-piperidinyl)ethyl](thio)ureas: synthesis and antiacetylcholinesterase activity.
AID462834	Inhibition of equine serum BChE by Ellman's method	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Acetylcholinesterase inhibitors from the toadstool Cortinarius infractus.
AID1564164	Inhibition of equine serum BuChE assessed as dissociation constant for enzyme-inhibitor complex using butyrylthiocholine iodide as substrate measured for 125 secs by Ellman's method	2019	European journal of medicinal chemistry, Nov-01, Volume: 181	Tacrine-O-protected phenolics heterodimers as multitarget-directed ligands against Alzheimer's disease: Selective subnanomolar BuChE inhibitors.
AID1077146	Selectivity ratio of IC50 for electric eel AChE to IC50 for equine serum BChE	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	Design, synthesis and biological evaluation of D-ring opened galantamine analogs as multifunctional anti-Alzheimer agents.
AID1498461	Inhibition of horse serum BChE at 3.125 ug using butyrylthiocholine chloride as substrate preincubated for 15 mins followed by substrate addition measured every 5 mins for 15 mins by spectrophotometric method relative to control	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	A cascade synthesis, in vitro cholinesterases inhibitory activity and docking studies of novel Tacrine-pyranopyrazole derivatives.
AID1498464	Inhibition of horse serum BChE at 25 ug using butyrylthiocholine chloride as substrate preincubated for 15 mins followed by substrate addition measured every 5 mins for 15 mins by spectrophotometric method relative to control	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	A cascade synthesis, in vitro cholinesterases inhibitory activity and docking studies of novel Tacrine-pyranopyrazole derivatives.
AID1524946	Inhibition of BChE (unknown origin) using butyrylthiocholine iodide as substrate by spectrophotometry based Ellman's method	2019	Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10	Bioactivity-guided identification of flavonoids with cholinesterase and β-amyloid peptide aggregation inhibitory effects from the seeds of Millettia pachycarpa.
AID175557	Effect after an intraperitoneal dose of 0.3 mg/kg on amnesia induced in passive avoidance test in rats by Scopolamine	1994	Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5	Novel [2-(4-piperidinyl)ethyl](thio)ureas: synthesis and antiacetylcholinesterase activity.
AID1162589	Inhibition of human recombinant AChE using acetylthiocholine iodide substrate incubated for 15 mins by spectrophotometry based Ellman's method	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	Design, synthesis and biological evaluation of novel 6H-benzo[c]chromen-6-one, and 7,8,9,10-tetrahydro-benzo[c]chromen-6-one derivatives as potential cholinesterase inhibitors.
AID1593770	Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition and measured after 30 mins by Ellman's method	2019	Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12	Dispiropyrrolidinyl-piperidone embedded indeno[1,2-b]quinoxaline heterocyclic hybrids: Synthesis, cholinesterase inhibitory activity and their molecular docking simulation.
AID781328	pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 2005	2014	Pharmaceutical research, Apr, Volume: 31, Issue:4	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1293781	Inhibition of equine BChE using S-butyrylthiocholine chloride as substrate by Ellman's method	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	2-Phenylbenzofuran derivatives as butyrylcholinesterase inhibitors: Synthesis, biological activity and molecular modeling.
AID1646342	Inhibition of BChE (unknown origin)	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Design, synthesis and cholinesterase inhibitory activity of novel spiropyrrolidine tethered imidazole heterocyclic hybrids.
AID32110	Inhibitory dose for anticholinesterase activity by ex vivo determination in rat salivary gland after intraperitoneal administration	1994	Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5	Novel [2-(4-piperidinyl)ethyl](thio)ureas: synthesis and antiacetylcholinesterase activity.
AID437941	Antioxidant activity in Wistar rat brain assessed as inhibition of lipid peroxidation	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis, spectral characterization and biological evaluation of phosphorylated derivatives of galanthamine.
AID1347777	Inhibition of amyloid beta (25 to 35 residues) (unknown origin) aggregation at 50 ug/ml after 24 to 48 hrs by thioflavin T dye based confocal laser scanning microscopy
AID1678839	Effect on locomotory activity in STZ-induced mouse model of Alzheimer's disease assessed as number of crossing 0.5 mg/kg, ip treated from 3 to 12 days by open field test (Rvb = 114.00 +/- 3.12 No_unit)	2020	RSC medicinal chemistry, Feb-01, Volume: 11, Issue:2	Structure-activity relationships of sulfonamides derived from carvacrol and their potential for the treatment of Alzheimer's disease.
AID746748	Inhibition of equine serum BuChE using S-butyrylthiocholine chloride as substrate incubated for 15 mins prior to substrate addition measured after 30 mins by Ellman's method	2013	Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10	A facile chemo-, regio- and stereoselective synthesis and cholinesterase inhibitory activity of spirooxindole-pyrrolizine-piperidine hybrids.
AID1127083	Inhibition of AChE (unknown origin) by Ellman colorimetric method	2014	European journal of medicinal chemistry, May-06, Volume: 78	Design, synthesis, acetylcholinesterase inhibition and larvicidal activity of girgensohnine analogs on Aedes aegypti, vector of dengue fever.
AID480456	Inhibition of dexamethasone-induced human NR1-1a/NR2B receptor-mediated excitotoxicity in (S)-glutamate/glycine-stimulated mouse L13-E6 cells assessed as LDH release at 25 uM after 30 mins	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.
AID1491306	Inhibition of equine serum BChE using butyrylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition measured for 30 mins by Ellman's method	2017	European journal of medicinal chemistry, Sep-08, Volume: 137	Isosteroidal alkaloids as potent dual-binding site inhibitors of both acetylcholinesterase and butyrylcholinesterase from the bulbs of Fritillaria walujewii.
AID1854475	Inhibition of equine serum BuChE using S-butyrylthiocholine iodide as substrate pre-incubated for 5 mins followed by substrate addition and measured after 6 mins by Ellman's method	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	New naphtho/thienobenzo-triazoles with interconnected anti-inflammatory and cholinesterase inhibitory activity.
AID1564174	Selectivity index, ratio of IC50 for human recombinant AChE expressed in HEK293 cells to IC50 for human serum BuChE	2019	European journal of medicinal chemistry, Nov-01, Volume: 181	Tacrine-O-protected phenolics heterodimers as multitarget-directed ligands against Alzheimer's disease: Selective subnanomolar BuChE inhibitors.
AID688350	Cytotoxicity against human G361 cells after 72 hrs by Calcein AM assay	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	Apoptosis-inducing effects of distichamine and narciprimine, rare alkaloids of the plant family Amaryllidaceae.
AID600979	Inhibition of human plasma AChE	2011	European journal of medicinal chemistry, Jun, Volume: 46, Issue:6	Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease.
AID1498448	Inhibition of electric eel AChE at 6.25 ug using acetylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition measured every 5 mins for 15 mins by spectrophotometric method relative to control	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	A cascade synthesis, in vitro cholinesterases inhibitory activity and docking studies of novel Tacrine-pyranopyrazole derivatives.
AID550178	Inhibition of AChE assessed as minimum drug level causing white zone of enzyme inhibition by TLC bioautography assay	2010	Journal of natural products, Nov-29, Volume: 73, Issue:11	Phytochemical investigations of Stemona curtisii and synthetic studies on stemocurtisine alkaloids.
AID1315223	Selectivity index, ratio of IC50 for electric eel AChE to IC50 for equine serum BuChE	2016	Journal of natural products, 05-27, Volume: 79, Issue:5	Alkaloids from Hippeastrum argentinum and Their Cholinesterase-Inhibitory Activities: An in Vitro and in Silico Study.
AID635416	Selectivity ratio of IC50 for equine serum BuChE to IC50 for electric eel AChE	2011	Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23	Benzenediol-berberine hybrids: multifunctional agents for Alzheimer's disease.
AID437957	Antibacterial activity against Klebsiella pneumoniae at 2 mg/mL after 18 hrs by disc diffusion assay	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis, spectral characterization and biological evaluation of phosphorylated derivatives of galanthamine.
AID1443226	Selectivity index, ratio of IC50 for acetylcholinesterase (unknown origin) to IC50 for butyrylcholinesterase (unknown origin)	2017	Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7	Green synthesis of novel spiro-indenoquinoxaline derivatives and their cholinesterases inhibition activity.
AID1054126	Inhibition of human AChE	2013	Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19	Divergent structure-activity relationships of structurally similar acetylcholinesterase inhibitors.
AID688349	Cytotoxicity against human HeLa cells after 72 hrs by Calcein AM assay	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	Apoptosis-inducing effects of distichamine and narciprimine, rare alkaloids of the plant family Amaryllidaceae.
AID271049	Inhibition of horse serum BChE	2006	Journal of medicinal chemistry, Sep-07, Volume: 49, Issue:18	Homobivalent quinazolinimines as novel nanomolar inhibitors of cholinesterases with dirigible selectivity toward butyrylcholinesterase.
AID1678840	Effect on behavioral activity in STZ-induced mouse model of Alzheimer's disease assessed as rearing at 0.5 mg/kg, ip treated from 3 to 12 days by open field test (Rvb = 53.60 +/- 1.62 No_unit)	2020	RSC medicinal chemistry, Feb-01, Volume: 11, Issue:2	Structure-activity relationships of sulfonamides derived from carvacrol and their potential for the treatment of Alzheimer's disease.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1337747	Inhibition of electric eel AChE pretreated for 20 mins followed by acetylthiocholine iodide substrate addition measured for 5 mins by Ellman's method	2017	European journal of medicinal chemistry, Jan-05, Volume: 125	New azepino[4,3-b]indole derivatives as nanomolar selective inhibitors of human butyrylcholinesterase showing protective effects against NMDA-induced neurotoxicity.
AID1636643	Inhibition of equine serum BuChE preincubated for 6 mins followed by addition of S-butyrylthiocholine iodide by Ellman's method	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Synthesis and evaluation of novel 1,2,3-triazole-based acetylcholinesterase inhibitors with neuroprotective activity.
AID726768	Competitive inhibition of Electrophorus electricus AChE using acetylcholine as substrate by Lineweaver-Burk plot method	2013	Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5	Acetylcholinesterase immobilized capillary reactors-tandem mass spectrometry: an on-flow tool for ligand screening.
AID1194501	Inhibition of BchE in human plasma incubated for 30 mins using butyrylthiocholine substrate at 37 degC by DTNB dye based spectrophotometry	2015	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 25, Issue:8	New septanoside and 20-hydroxyecdysone septanoside derivative from Atriplex portulacoides roots with preliminary biological activities.
AID1366158	Antibacterial activity against Escherichia coli incubated overnight by two-fold serial dilution method	2017	Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22	Antibacterial constituents of the plant family Amaryllidaceae.
AID378483	Inhibition of human AChE by Ellman's assay	2006	Journal of natural products, Sep, Volume: 69, Issue:9	Taspine: bioactivity-guided isolation and molecular ligand-target insight of a potent acetylcholinesterase inhibitor from Magnolia x soulangiana.
AID707053	Displacement of [3H]MK-801 from NMDAR in Sprague-Dawley rat cerebral cortex homogenates after 2 hrs by liquid scintillation counting	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease.
AID73711	In vitro reversal of vecuronium-induced neuromuscular block in guinea pig hemi-diaphragm.	2002	Bioorganic & medicinal chemistry letters, Sep-16, Volume: 12, Issue:18	Quaternary salts of E2020 analogues as acetylcholinesterase inhibitors for the reversal of neuromuscular block.
AID707052	Displacement of [3H]Ifenprodil from NMDAR-2B in Sprague-Dawley rat frontal cortex homogenates after 2 hrs by liquid scintillation counting	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease.
AID729524	Inhibition of equine serum BuChE using S-butyrylthiocholine chloride substrate by Ellman's method based spectrophotometry	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	Synthesis and discovery of novel piperidone-grafted mono- and bis-spirooxindole-hexahydropyrrolizines as potent cholinesterase inhibitors.
AID688347	Cytotoxicity against human K562 cells after 72 hrs by Calcein AM assay	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	Apoptosis-inducing effects of distichamine and narciprimine, rare alkaloids of the plant family Amaryllidaceae.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1140467	Selectivity index, ratio of IC50 for BuChE in equine serum to IC50 for electric eel AChE	2014	Bioorganic & medicinal chemistry letters, May-15, Volume: 24, Issue:10	Design, synthesis and biological evaluation of benzylisoquinoline derivatives as multifunctional agents against Alzheimer's disease.
AID1524945	Inhibition of AChE (unknown origin) using acetylthiocholine iodide as substrate by spectrophotometry based Ellman's method	2019	Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10	Bioactivity-guided identification of flavonoids with cholinesterase and β-amyloid peptide aggregation inhibitory effects from the seeds of Millettia pachycarpa.
AID378484	Inhibition of horse serum BuChE by Ellman's method	2006	Journal of natural products, Sep, Volume: 69, Issue:9	Taspine: bioactivity-guided isolation and molecular ligand-target insight of a potent acetylcholinesterase inhibitor from Magnolia x soulangiana.
AID281638	Increase in extracellular acetylcholine at 1 uM in urethane anesthetized Sprague-Dawley rat nucleus accumbens	2004	Journal of medicinal chemistry, Dec-02, Volume: 47, Issue:25	Acetylcholinesterase inhibitory activity of scopolin and scopoletin discovered by virtual screening of natural products.
AID1570261	Inhibition of BuChE (unknown origin)	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	Triazole derivatives as inhibitors of Alzheimer's disease: Current developments and structure-activity relationships.
AID1400271	Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 10 mins followed by substrate addition measured for 5 mins by Ellman's method	2018	Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17	Design, synthesis, and biological evaluation of selective and potent Carbazole-based butyrylcholinesterase inhibitors.
AID1678843	Antioxidant activity in STZ-induced mouse model of Alzheimer's disease assessed as increase in GSH level in brain at 0.5 mg/kg, ip treated from 3 to 12 days starting from 3 days post initial STZ stimulation and measured on day 17 by spectrophotometric met	2020	RSC medicinal chemistry, Feb-01, Volume: 11, Issue:2	Structure-activity relationships of sulfonamides derived from carvacrol and their potential for the treatment of Alzheimer's disease.
AID482856	Inhibition of electric eel AChE by Ellman's method	2010	Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14	Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID486995	Inhibition of equine serum BuChE by Ellman's method	2010	Bioorganic & medicinal chemistry, Jun-15, Volume: 18, Issue:12	Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase.
AID514203	Inhibition of electric eel AChE by Ellman's method	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Morphinans and isoquinolines: acetylcholinesterase inhibition, pharmacophore modeling, and interaction with opioid receptors.
AID1167622	Inhibition of electric eel AChE using acetylthiocholine iodide as substrate incubated for 6 mins by spectrophotometric method	2014	Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21	Design, synthesis and evaluation of novel tacrine-(β-carboline) hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID607923	Inhibition of acetylcholinesterase by TLC bioautography	2011	Journal of natural products, Jan-28, Volume: 74, Issue:1	Phytochemical studies on Stemona aphylla: isolation of a new stemofoline alkaloid and six new stemofurans.
AID492427	Antimalarial activity against Plasmodium falciparum K1	2009	Bioorganic & medicinal chemistry, May-01, Volume: 17, Issue:9	Antimalarials from nature.
AID569583	Selectivity ratio of IC50 for electric eel AChE to IC50 for equine serum BChE	2011	Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3	Probing the mid-gorge of cholinesterases with spacer-modified bivalent quinazolinimines leads to highly potent and selective butyrylcholinesterase inhibitors.
AID501440	Inhibition of AChE by Ellman's assay	2010	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17	Structure-activity studies on acetylcholinesterase inhibition in the lycorine series of Amaryllidaceae alkaloids.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1466563	Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition by spectrophotometric analysis
AID1077145	Inhibition of equine serum BChE using butyrylthiocholine iodide as substrate preincubated for 5 mins followed by substrate addition measured after 5 mins by Ellman's method	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	Design, synthesis and biological evaluation of D-ring opened galantamine analogs as multifunctional anti-Alzheimer agents.
AID594821	Inhibition of BChE	2011	Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9	(+)-Arisugacin A--computational evidence of a dual binding site covalent inhibitor of acetylcholinesterase.
AID670570	Inhibition of amyloid beta (1 to 40) fibril formation at 10 uM coincubated with amyloid beta (1 to 40) peptide after 72 hrs by transmission electron microscopic analysis	2012	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14	Development and evaluation of multifunctional agents for potential treatment of Alzheimer's disease: application to a pyrimidine-2,4-diamine template.
AID1472442	Inhibition of AChE (unknown origin)	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.
AID1126155	Inhibition of AChE (unknown origin) assessed as minimum inhibitory concentration by bioautographic TLC assay	2014	Journal of natural products, Apr-25, Volume: 77, Issue:4	Marsupellins A-F, ent-longipinane-type sesquiterpenoids from the Chinese liverwort Marsupella alpine with acetylcholinesterase inhibitory activity.
AID480454	Inhibition of dexamethasone-induced human NR1-1a/NR2A receptor-mediated excitotoxicity in (S)-glutamate/glycine-stimulated mouse L12-G10 cells assessed as LDH release at 25 uM after 30 mins	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.
AID656683	Inhibition of electric eel AChE using acetylcholine iodide as substrate at 3.4 X 10'-4 M measured every 5 sec for 2 mins by Ellman's method	2012	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8	Prospective acetylcholinesterase inhibitory activity of indole and its analogs.
AID1854481	Inhibition of equine serum BuChE using S-butyrylthiocholine iodide as substrate pre-incubated for 5 mins followed by substrate addition at 60 uM and measured after 6 mins by Ellman's method relative to control	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	New naphtho/thienobenzo-triazoles with interconnected anti-inflammatory and cholinesterase inhibitory activity.
AID1498445	Inhibition of electric eel AChE at 0.781 ug using acetylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition measured every 5 mins for 15 mins by spectrophotometric method relative to control	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	A cascade synthesis, in vitro cholinesterases inhibitory activity and docking studies of novel Tacrine-pyranopyrazole derivatives.
AID8002	Observed volume of distribution	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID479754	Inhibition of Equine serum BChE after 2 mins by colorimetric Ellman assay	2010	Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9	Bivalent 5,8,9,13b-tetrahydro-6H-isoquino[1,2-a]isoquinolines and -isoquinolinium salts: novel heterocyclic templates for butyrylcholinesterase inhibitors.
AID747035	Inhibition of electric eel AChE using acetylthiocholine iodide as substrate after 15 mins by Ellman's method	2013	Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10	Novel racemic tetrahydrocurcuminoid dihydropyrimidinone analogues as potent acetylcholinesterase inhibitors.
AID383199	Inhibition of equine serum BuChE by Ellman's assay	2008	Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8	Design, synthesis and pharmacological evaluation of hybrid molecules out of quinazolinimines and lipoic acid lead to highly potent and selective butyrylcholinesterase inhibitors with antioxidant properties.
AID49086	Change in response to vagal stimulation was detected in anaesthetised cats on administration of the compound; NT denotes not tested	2002	Bioorganic & medicinal chemistry letters, Sep-16, Volume: 12, Issue:18	Quaternary salts of E2020 analogues as acetylcholinesterase inhibitors for the reversal of neuromuscular block.
AID1498450	Inhibition of electric eel AChE at 25 ug using acetylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition measured every 5 mins for 15 mins by spectrophotometric method relative to control	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	A cascade synthesis, in vitro cholinesterases inhibitory activity and docking studies of novel Tacrine-pyranopyrazole derivatives.
AID749370	Selectivity ratio of IC50 for electric eel AChE to IC50 for equine serum BuChE	2013	Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11	Microwave assisted synthesis, cholinesterase enzymes inhibitory activities and molecular docking studies of new pyridopyrimidine derivatives.
AID1328975	Neurotoxicity in human SH-SY5Y cells assessed as decrease in cell viability at 1 uM after 24 hrs by XTT assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Avarol derivatives as competitive AChE inhibitors, non hepatotoxic and neuroprotective agents for Alzheimer's disease.
AID1066954	Inhibition of ICR mouse brain AChE using acetylthiocholine iodide as substrate at 100 uM incubated 10 mins prior to substrate addition measured after 10 mins by Ellman's method	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Synthesis of aminoalkyl-substituted coumarin derivatives as acetylcholinesterase inhibitors.
AID276346	Inhibition of BChE	2006	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 16, Issue:22	6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID437943	Inhibition of superoxide dismutase in Wistar rat brain	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis, spectral characterization and biological evaluation of phosphorylated derivatives of galanthamine.
AID1807566	Inhibition of human BuChE using butyrylthiocholine chloride as substrate by Ellman's method	2021	Bioorganic & medicinal chemistry letters, 11-01, Volume: 51	Derivatives of montanine-type alkaloids and their implication for the treatment of Alzheimer's disease: Synthesis, biological activity and in silico study.
AID724167	Inhibition of butyrylcholinesterase (unknown origin)	2013	Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1	Design, synthesis and biological evaluation of coumarin alkylamines as potent and selective dual binding site inhibitors of acetylcholinesterase.
AID44289	In vitro inhibitory activity against Butyrylcholinesterase (BChE) in human serum	2003	Bioorganic & medicinal chemistry letters, Jul-21, Volume: 13, Issue:14	Synthesis and structure-activity relationships of open D-Ring galanthamine analogues.
AID1498453	Inhibition of electric eel AChE at 0.024 ug using acetylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition measured every 5 mins for 15 mins by spectrophotometric method relative to control	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	A cascade synthesis, in vitro cholinesterases inhibitory activity and docking studies of novel Tacrine-pyranopyrazole derivatives.
AID1389179	Inhibition of electric eel AChE at 10 uM using acetylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition and measured for 45 mins by Ellmans microplate assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	In silico studies, synthesis and pharmacological evaluation to explore multi-targeted approach for imidazole analogues as potential cholinesterase inhibitors with neuroprotective role for Alzheimer's disease.
AID486994	Inhibition of electric eel AChE by Ellman's assay	2010	Bioorganic & medicinal chemistry, Jun-15, Volume: 18, Issue:12	Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase.
AID754042	Inhibition of equine serum BChE using S-butyrylthiocholine iodide as substrate preincubated for 6 mins prior to substrate addition measured at 60 to 180 seconds by Ellman's method	2013	European journal of medicinal chemistry, Jun, Volume: 64	Design, synthesis and evaluation of novel tacrine-coumarin hybrids as multifunctional cholinesterase inhibitors against Alzheimer's disease.
AID437951	Antioxidant activity in Wistar rat brain assessed as lipid peroxidation	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis, spectral characterization and biological evaluation of phosphorylated derivatives of galanthamine.
AID1406252	Inhibition of BChE (unknown origin)	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Multi-target-directed ligands for treating Alzheimer's disease: Butyrylcholinesterase inhibitors displaying antioxidant and neuroprotective activities.
AID479753	Inhibition of Electric eel AChE after 2 mins by colorimetric Ellman assay	2010	Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9	Bivalent 5,8,9,13b-tetrahydro-6H-isoquino[1,2-a]isoquinolines and -isoquinolinium salts: novel heterocyclic templates for butyrylcholinesterase inhibitors.
AID437956	Antibacterial activity against Escherichia coli at 1 mg/mL after 18 hrs by disc diffusion assay	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis, spectral characterization and biological evaluation of phosphorylated derivatives of galanthamine.
AID1162591	Selectivity index, ratio of IC50 for human recombinant BuChE to IC50 for human recombinant AChE	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	Design, synthesis and biological evaluation of novel 6H-benzo[c]chromen-6-one, and 7,8,9,10-tetrahydro-benzo[c]chromen-6-one derivatives as potential cholinesterase inhibitors.
AID31968	Inhibition against acetylcholinesterase (AChE)	1994	Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5	Novel [2-(4-piperidinyl)ethyl](thio)ureas: synthesis and antiacetylcholinesterase activity.
AID1567161	Inhibition of human recombinant AChE using acetylthiocholine iodide as substrate preincubated for 20 mins followed by substrate addition by Ellman's spectrophotometric method	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery of novel benzofuran-based compounds with neuroprotective and immunomodulatory properties for Alzheimer's disease treatment.
AID724168	Inhibition of acetylcholinesterase (unknown origin)	2013	Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1	Design, synthesis and biological evaluation of coumarin alkylamines as potent and selective dual binding site inhibitors of acetylcholinesterase.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1271110	Inhibition of BuChE (unknown origin) using butyrylthiocholine iodide as substrate at 80 ug/ml by Ellman spectrophotometric method	2016	European journal of medicinal chemistry, Jan-01, Volume: 107	Synthesis and evaluation of bis-thiazole derivatives as new anticancer agents.
AID730446	Lipophilicity, log P of the compound by HPLC analysis	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	Synthesis and in vitro evaluation of new derivatives of 2-substituted-6-fluorobenzo[d]thiazoles as cholinesterase inhibitors.
AID7783	Unbound fraction (plasma)	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID260079	Inhibitory activity against AChE from electric eel	2006	Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3	Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum.
AID1254737	Inhibition of AChE (unknown origin)	2015	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 25, Issue:21	A computational view on the significance of E-ring in binding of (+)-arisugacin A to acetylcholinesterase.
AID1657594	Inhibition of human AChE using acetylthiocholine iodide as substrate measured for 1 min by spectrophotometric based Ellman's method	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Aromatic Esters of the Crinane Amaryllidaceae Alkaloid Ambelline as Selective Inhibitors of Butyrylcholinesterase.
AID1678838	Anxiolytic-like activity in STZ-induced mouse model of Alzheimer's disease assessed as open arm frequency at 0.5 mg/kg, ip treated from 3 to 12 days starting from 3 days post initial STZ stimulation and measured on day 14 by elevated plus maze test (Rvb =	2020	RSC medicinal chemistry, Feb-01, Volume: 11, Issue:2	Structure-activity relationships of sulfonamides derived from carvacrol and their potential for the treatment of Alzheimer's disease.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID666575	Inhibition of equine serum butyrylcholinesterase using butyrylthiocholine chloride as substrate incubated for 15 mins prior to substrate addition measured every 1 min by Ellman's assay	2012	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13	Design, synthesis, and evaluation of indanone derivatives as acetylcholinesterase inhibitors and metal-chelating agents.
AID345206	Inhibition of human serum BChE by Ellman's assay	2008	Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22	Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 4. Further investigation on the inner spacer.
AID437958	Antibacterial activity against Staphylococcus aureus at 2 mg/mL after 18 hrs by disc diffusion assay	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis, spectral characterization and biological evaluation of phosphorylated derivatives of galanthamine.
AID694076	Relative selectivity ratio, ratio of compound selectivity ratio to tacrine selectivity ratio for human recombinant BChE Ki to human recombinant AChE Ki	2012	Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22	Design, synthesis, and bioevaluation of benzamides: novel acetylcholinesterase inhibitors with multi-functions on butylcholinesterase, Aβ aggregation, and β-secretase.
AID1443223	Inhibition of acetylcholinesterase (unknown origin) using acetylthiocholine as substrate preincubated for 20 mins followed by substrate addition by Ellmans method	2017	Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7	Green synthesis of novel spiro-indenoquinoxaline derivatives and their cholinesterases inhibition activity.
AID1331321	Inhibition of BuChE (unknown origin) by spectrophotometric analysis based Ellman's assay	2017	Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2	Synthesis and application of β-carbolines as novel multi-functional anti-Alzheimer's disease agents.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID730447	Inhibition of equine BChE using after 10 mins by Ellman's method	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	Synthesis and in vitro evaluation of new derivatives of 2-substituted-6-fluorobenzo[d]thiazoles as cholinesterase inhibitors.
AID1739259	Inhibition of AChE (unknown origin) at 10 uM preincubated for 30 mins followed by substrate addition acetylthiocholineiodide measured after 40 mins by Ellman's method relative to control	2020	European journal of medicinal chemistry, Aug-15, Volume: 200	Simple analogues of natural product chelerythrine: Discovery of a novel anticholinesterase 2-phenylisoquinolin-2-ium scaffold with excellent potency against acetylcholinesterase.
AID281636	Inhibition of AChE by microplate assay	2004	Journal of medicinal chemistry, Dec-02, Volume: 47, Issue:25	Acetylcholinesterase inhibitory activity of scopolin and scopoletin discovered by virtual screening of natural products.
AID1312278	Inhibition of BChE (unknown origin) pre-incubated for 15 mins before S-butyrylthiocholine chloride substrate addition and measured after 30 mins by colorimetric Ellman's method	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Cholinesterase inhibitory activity of isoquinoline alkaloids from three Cryptocarya species (Lauraceae).
AID751999	Selectivity index, ratio of IC50 for equine serum BuChE to IC50 for electric eel AChE	2013	Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9	Design, synthesis and evaluation of flavonoid derivatives as potential multifunctional acetylcholinesterase inhibitors against Alzheimer's disease.
AID1443224	Inhibition of butyrylcholinesterase (unknown origin) using acetylthiocholine as substrate preincubated for 20 mins followed by substrate addition by Ellmans method	2017	Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7	Green synthesis of novel spiro-indenoquinoxaline derivatives and their cholinesterases inhibition activity.
AID420064	Inhibition of human CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline	2009	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12	Selective cytochrome P450 3A4 inhibitory activity of Amaryllidaceae alkaloids.
AID1493770	Inhibition of BChE (unknown origin) using thiocholine as substrate preincubated for 15 mins followed by substrate addition measured after 5 mins by Ellman's method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	2-Arylbenzofurans from Artocarpus lakoocha and methyl ether analogs with potent cholinesterase inhibitory activity.
AID32105	Acetylcholinesterase inhibitory activity in rat striatal homogenates	1995	Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18	Synthesis and evaluation of 5-amino-5,6,7,8-tetrahydroquinolinones as potential agents for the treatment of Alzheimer's disease.
AID479755	Selectivity ratio of IC50 for Electric eel AChE to IC50 for equine serum BChE	2010	Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9	Bivalent 5,8,9,13b-tetrahydro-6H-isoquino[1,2-a]isoquinolines and -isoquinolinium salts: novel heterocyclic templates for butyrylcholinesterase inhibitors.
AID1853195	Inhibition of human acetylcholinesterase using acetylthiocholine iodide as substrate incubated for 15 mins by Ellman's method	2022	RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12	Pyrazolines as potential anti-Alzheimer's agents: DFT, molecular docking, enzyme inhibition and pharmacokinetic studies.
AID746378	Inhibition of BuChE (unknown origin) by Ellman method	2013	Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9	Design, synthesis and biological activity of multifunctional α,β-unsaturated carbonyl scaffolds for Alzheimer's disease.
AID437946	Antibacterial activity against Klebsiella pneumoniae after 18 hrs	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis, spectral characterization and biological evaluation of phosphorylated derivatives of galanthamine.
AID1301459	Inhibition AChE (unknown origin) using ATCI as substrate assessed as hydrolysis of ATCI after 10 mins measured every 1 min for 10 times	2016	Journal of natural products, Feb-26, Volume: 79, Issue:2	Bioactive Constituents of Glycyrrhiza uralensis (Licorice): Discovery of the Effective Components of a Traditional Herbal Medicine.
AID1129236	Selectivity ratio of IC50 for equine serum BChE to IC50 for electric eel AChE	2014	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7	Synthesis and discovery of highly functionalized mono- and bis-spiro-pyrrolidines as potent cholinesterase enzyme inhibitors.
AID1389178	Inhibition of equine serum BChE at 10 uM using S-butyrylthiocholine chloride as substrate preincubated for 15 mins followed by substrate addition and measured for 45 mins by Ellmans microplate assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	In silico studies, synthesis and pharmacological evaluation to explore multi-targeted approach for imidazole analogues as potential cholinesterase inhibitors with neuroprotective role for Alzheimer's disease.
AID776491	Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 6 mins followed by substrate addition by Ellmans method	2013	European journal of medicinal chemistry, Nov, Volume: 69	Multifunctional tacrine-flavonoid hybrids with cholinergic, β-amyloid-reducing, and metal chelating properties for the treatment of Alzheimer's disease.
AID1246442	Inhibition of electric eel acetylcholinesterase using acetylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition by Ellman's method	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Potential of aryl-urea-benzofuranylthiazoles hybrids as multitasking agents in Alzheimer's disease.
AID175561	Effect after an intraperitoneal dose of 3.0 mg/kg on amnesia induced in passive avoidance test in rats by Scopolamine	1994	Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5	Novel [2-(4-piperidinyl)ethyl](thio)ureas: synthesis and antiacetylcholinesterase activity.
AID1328976	Neurotoxicity in human SH-SY5Y cells assessed as decrease in cell viability at 25 to 50 uM after 24 hrs by XTT assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Avarol derivatives as competitive AChE inhibitors, non hepatotoxic and neuroprotective agents for Alzheimer's disease.
AID1594570	Selectivity index, ratio of IC50 for equine serum BChE to IC50 for electric eel AChE	2019	Bioorganic & medicinal chemistry letters, 06-01, Volume: 29, Issue:11	Design, synthesis, evaluation and molecular modeling study of 4-N-phenylaminoquinolines for Alzheimer disease treatment.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID378485	Inhibition of human AChE at 100 uM by Ellman's assay	2006	Journal of natural products, Sep, Volume: 69, Issue:9	Taspine: bioactivity-guided isolation and molecular ligand-target insight of a potent acetylcholinesterase inhibitor from Magnolia x soulangiana.
AID569582	Inhibition of equine serum BChE by Ellman's method	2011	Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3	Probing the mid-gorge of cholinesterases with spacer-modified bivalent quinazolinimines leads to highly potent and selective butyrylcholinesterase inhibitors.
AID1886770	Cognitive enhancing effect in amyloid beta (1 to 42)-induced ICR mouse model assessed as reduction in latency at 1 mg/kg, icv measured on day 14 by Morris Water maze method
AID1634701	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production at 200 uM after 24 hrs by Griess assay	2016	Journal of natural products, Apr-22, Volume: 79, Issue:4	Galanthamine, Plicamine, and Secoplicamine Alkaloids from Zephyranthes candida and Their Anti-acetylcholinesterase and Anti-inflammatory Activities.
AID307547	Selectivity for electric eel AChE over equine serum BuChE	2007	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13	Derivatives of oxoisoaporphine alkaloids: a novel class of selective acetylcholinesterase inhibitors.
AID1646343	Selectivity ratio of IC50 for BChE (unknown origin) to IC50 for AChE (unknown origin)	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Design, synthesis and cholinesterase inhibitory activity of novel spiropyrrolidine tethered imidazole heterocyclic hybrids.
AID1335318	Inhibition of electric eel acetylcholinesterase using acetylthiocholine iodide as substrate by Ellman's method	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	New piperidine-hydrazone derivatives: Synthesis, biological evaluations and molecular docking studies as AChE and BChE inhibitors.
AID635417	Inhibition of equine serum BuChE using acetylcholine as substrate preincubated for 15 mins by Ellman's method	2011	Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23	Benzenediol-berberine hybrids: multifunctional agents for Alzheimer's disease.
AID1593772	Selectivity index, ratio of IC50 for electric eel AChE to IC50 for equine serum BChE	2019	Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12	Dispiropyrrolidinyl-piperidone embedded indeno[1,2-b]quinoxaline heterocyclic hybrids: Synthesis, cholinesterase inhibitory activity and their molecular docking simulation.
AID603899	Inhibition of electric eel AChE at 10'-4.3 M by colorimetric Ellman's assay	2011	European journal of medicinal chemistry, Jul, Volume: 46, Issue:7	Mycobacterium tuberculosis and cholinesterase inhibitors from Voacanga globosa.
AID670566	Inhibition of BACE1	2012	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14	Development and evaluation of multifunctional agents for potential treatment of Alzheimer's disease: application to a pyrimidine-2,4-diamine template.
AID1246443	Inhibition of horse serum butyrylcholinesterase using butyrylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition by Ellman's method	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Potential of aryl-urea-benzofuranylthiazoles hybrids as multitasking agents in Alzheimer's disease.
AID1493747	Inhibition of electric eel AChE at 3 uM using acetylthiocholine iodide as substrate measured for 0.5 to 1.5 mins post substrate addition by spectrophotometry based Ellman's method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biochemical evaluation of novel multi-target inhibitors as potential anti-Parkinson agents.
AID1466635	Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition by spectrophotometric method	2017	Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13	Antioxidant and anticholinesterase potential of diterpenoid alkaloids from Aconitum heterophyllum.
AID1126156	Inhibition of AChE (unknown origin) using acetylthiocholine as substrate at 5 uM preincubated for 15 mins measured after 30 mins by Ellman's method	2014	Journal of natural products, Apr-25, Volume: 77, Issue:4	Marsupellins A-F, ent-longipinane-type sesquiterpenoids from the Chinese liverwort Marsupella alpine with acetylcholinesterase inhibitory activity.
AID1736863	Selectivity ratio of IC50 for human erythrocyte AChE to IC50 for human plasma BuChE	2020	European journal of medicinal chemistry, Apr-01, Volume: 191	Design, synthesis and biological evaluation of 2,3-dihydro-5,6-dimethoxy-1H-inden-1-one and piperazinium salt hybrid derivatives as hAChE and hBuChE enzyme inhibitors.
AID1498458	Inhibition of horse serum BChE at 0.391 ug using butyrylthiocholine chloride as substrate preincubated for 15 mins followed by substrate addition measured every 5 mins for 15 mins by spectrophotometric method relative to control	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	A cascade synthesis, in vitro cholinesterases inhibitory activity and docking studies of novel Tacrine-pyranopyrazole derivatives.
AID462836	Selectivity ratio of IC50 for equine serum BChE to IC50 for bovine AChE	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Acetylcholinesterase inhibitors from the toadstool Cortinarius infractus.
AID1524942	Inhibition of BChE (unknown origin) at 100 ug/mL using butyrylthiocholine iodide as substrate by spectrophotometry based Ellman's method	2019	Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10	Bioactivity-guided identification of flavonoids with cholinesterase and β-amyloid peptide aggregation inhibitory effects from the seeds of Millettia pachycarpa.
AID1167624	Selectivity ratio of IC50 for equine serum BChE to IC50 for electric eel AChE	2014	Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21	Design, synthesis and evaluation of novel tacrine-(β-carboline) hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID1347778	Disaggregation of amyloid beta (25 to 35 residues) (unknown origin) preformed fibrils at 50 ug/ml after 96 hrs to 9 days by thioflavin T dye based confocal laser scanning microscopy
AID1657596	Inhibition of human BuChE using butyrylthiocholine iodide as substrate measured for 1 min by spectrophotometric based Ellman's method	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Aromatic Esters of the Crinane Amaryllidaceae Alkaloid Ambelline as Selective Inhibitors of Butyrylcholinesterase.
AID480449	Inhibition of equine serum BChE by modified Ellman's method	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.
AID1597699	Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 20 mins followed by substrate addition and measured upto 5 mins by Ellman's method	2019	European journal of medicinal chemistry, Sep-01, Volume: 177	Investigating 1,2,3,4,5,6-hexahydroazepino[4,3-b]indole as scaffold of butyrylcholinesterase-selective inhibitors with additional neuroprotective activities for Alzheimer's disease.
AID1162590	Inhibition of human recombinant BuChE using butyrylthiocholine iodide substrate incubated for 15 mins by spectrophotometry based Ellman's method	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	Design, synthesis and biological evaluation of novel 6H-benzo[c]chromen-6-one, and 7,8,9,10-tetrahydro-benzo[c]chromen-6-one derivatives as potential cholinesterase inhibitors.
AID670565	Selectivity ratio of IC50 for human AChE to IC50 for equine BuChE	2012	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14	Development and evaluation of multifunctional agents for potential treatment of Alzheimer's disease: application to a pyrimidine-2,4-diamine template.
AID436266	Inhibition of acetylcholinesterase	2008	Journal of natural products, Nov, Volume: 71, Issue:11	Synthesis and biological activities of thio-avarol derivatives.
AID1063991	Inhibition of equine serum butyrylcholinesterase using S-butyrylthiocholine chloride as substrate preincubated for 15 mins followed by substrate addition measured for 30 mins by Ellman's method	2014	Bioorganic & medicinal chemistry, Jan-15, Volume: 22, Issue:2	Cholinesterase inhibitory activity versus aromatic core multiplicity: a facile green synthesis and molecular docking study of novel piperidone embedded thiazolopyrimidines.
AID1779364	Inhibition of human serum BuChe using butyrylthiocholine iodide as substrate incubated for 25 mins by DTNB reagent based Ellman's method	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	"Clicking" fragment leads to novel dual-binding cholinesterase inhibitors.
AID482853	Selectivity ratio of IC50 for equine serum BuChE to IC50 for electric eel AChE	2010	Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14	Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives.
AID776489	Inhibition of equine serum BuChE using S-butyrylcholinesterase iodide as substrate preincubated for 6 mins followed by substrate addition by Ellmans method	2013	European journal of medicinal chemistry, Nov, Volume: 69	Multifunctional tacrine-flavonoid hybrids with cholinergic, β-amyloid-reducing, and metal chelating properties for the treatment of Alzheimer's disease.
AID482868	Neuroprotective activity in human SH-SY5Y cells assessed as protection against okadaic acid-induced cell death at 1 uM after 24 hrs by MTT assay	2010	Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14	Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives.
AID48159	Change in heart rate was detected in anaesthetised cats on administration of the compound; NT denotes not tested	2002	Bioorganic & medicinal chemistry letters, Sep-16, Volume: 12, Issue:18	Quaternary salts of E2020 analogues as acetylcholinesterase inhibitors for the reversal of neuromuscular block.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID30666	Inhibitory activity against acetylcholinesterase (AChE) from Torpedo californica (Reversible type of inhibition)	2003	Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10	Synthesis, anticholinesterase activity and structure-activity relationships of m-Aminobenzoic acid derivatives.
AID262754	Anticholinesterase activity against human erythrocyte AChE	2006	Journal of medicinal chemistry, Apr-06, Volume: 49, Issue:7	Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine.
AID1807565	Inhibition of human BuChE at 100 uM using butyrylthiocholine chloride as substrate by Ellman's method	2021	Bioorganic & medicinal chemistry letters, 11-01, Volume: 51	Derivatives of montanine-type alkaloids and their implication for the treatment of Alzheimer's disease: Synthesis, biological activity and in silico study.
AID1807567	Selectivity index, ratio of IC50 for human AChE to IC50 for human BuChe	2021	Bioorganic & medicinal chemistry letters, 11-01, Volume: 51	Derivatives of montanine-type alkaloids and their implication for the treatment of Alzheimer's disease: Synthesis, biological activity and in silico study.
AID362528	Inhibition of butyrylcholinesterase	2008	Journal of natural products, Aug, Volume: 71, Issue:8	Bioactive 5alpha-pregnane-type steroidal alkaloids from Sarcococca hookeriana.
AID1347783	Inhibition of amyloid beta (25 to 35 residues) (unknown origin) aggregation at 50 ug/ml after 24 to 48 hrs by FTIR spectroscopy
AID1322224	Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition measured every 15 secs for 5 to 10 mins by Ellman's method	2016	Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22	Synthesis and evaluation of dihydropyrimidinone-derived selenoesters as multi-targeted directed compounds against Alzheimer's disease.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1636644	Selectivity ratio of IC50 for equine serum BuChE to IC50 for electric eel AChE	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Synthesis and evaluation of novel 1,2,3-triazole-based acetylcholinesterase inhibitors with neuroprotective activity.
AID1176926	Inhibition of AChE (unknown origin) assessed as reduction in acetylthiocholine iodide hydrolysis after 15 mins by Ellman method	2015	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3	Sulfonamides as multifunctional agents for Alzheimer's disease.
AID1498900	Inhibition of equine serum BChE using butyrylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition by Ellman's method	2018	Bioorganic & medicinal chemistry, 07-30, Volume: 26, Issue:13	Developing hybrid molecule therapeutics for diverse enzyme inhibitory action: Active role of coumarin-based structural leads in drug discovery.
AID1076771	Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of amyloid beta 1 to 42-induced toxicity by measuring cell viability at 100 nM pretreated for 24 hrs followed by amyloid beta 1 to 42 challenge measured after 2	2014	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6	Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
AID1076770	Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of amyloid beta 1 to 42-induced toxicity by measuring cell viability at 1 uM pretreated for 24 hrs followed by amyloid beta 1 to 42 challenge measured after 24	2014	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6	Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1271108	Inhibition of electric eel AChE using acetylthiocholine iodide as substrate at 80 ug/ml by Ellman spectrophotometric method	2016	European journal of medicinal chemistry, Jan-01, Volume: 107	Synthesis and evaluation of bis-thiazole derivatives as new anticancer agents.
AID1176928	Inhibition of BuChE (unknown origin) assessed as reduction in S-butyrylthiocholine chloride hydrolysis at 10 uM after 15 mins by Ellman method	2015	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3	Sulfonamides as multifunctional agents for Alzheimer's disease.
AID1493748	Inhibition of horse serum BuChE at 3 uM using butyrylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition measured after 10 mins by spectrophotometry based-Ellman's method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biochemical evaluation of novel multi-target inhibitors as potential anti-Parkinson agents.
AID1886774	Cognitive enhancing effect in amyloid beta (1 to 42)-induced ICR mouse model assessed as reduction in amyloid beta (1 to 42) peptide level in brain at 2.5 mg/kg, icv measured on day 14 by ELISA
AID694075	Selectivity ratio of Ki for human recombinant BChE to Ki for human recombinant AChE	2012	Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22	Design, synthesis, and bioevaluation of benzamides: novel acetylcholinesterase inhibitors with multi-functions on butylcholinesterase, Aβ aggregation, and β-secretase.
AID1498446	Inhibition of electric eel AChE at 1.563 ug using acetylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition measured every 5 mins for 15 mins by spectrophotometric method relative to control	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	A cascade synthesis, in vitro cholinesterases inhibitory activity and docking studies of novel Tacrine-pyranopyrazole derivatives.
AID594820	Inhibition of AChE-induced amyloid beta aggregation	2011	Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9	(+)-Arisugacin A--computational evidence of a dual binding site covalent inhibitor of acetylcholinesterase.
AID746749	Inhibition of AChE (unknown origin) using acetylthiocholine iodide as substrate incubated for 15 mins prior to substrate addition measured after 30 mins by Ellman's method	2013	Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10	A facile chemo-, regio- and stereoselective synthesis and cholinesterase inhibitory activity of spirooxindole-pyrrolizine-piperidine hybrids.
AID1075992	Inhibition of electric eel acetylcholinesterase type VI-S using acetylthiocholine iodide as substrate measured every 30s for 5 mins by Ellman's spectrophotometric method	2014	European journal of medicinal chemistry, Mar-21, Volume: 75	Synthesis, biological evaluation and molecular modeling study of novel tacrine-carbazole hybrids as potential multifunctional agents for the treatment of Alzheimer's disease.
AID1537271	Selectivity index, ratio of IC50 for human BuChE to IC50 for human AChE	2019	Journal of natural products, 02-22, Volume: 82, Issue:2	Isoquinoline Alkaloids from Berberis vulgaris as Potential Lead Compounds for the Treatment of Alzheimer's Disease.
AID1636642	Inhibition of electric eel AChE preincubated for 6 mins followed by addition of acetylthiocholine iodide by Ellman's method	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Synthesis and evaluation of novel 1,2,3-triazole-based acetylcholinesterase inhibitors with neuroprotective activity.
AID707700	Inhibition of human recombinant GST-tagged DYRK1A expressed in Escherichia coli using GRSRSRSRSRSR as substrate and [gamma33P]ATP at 10 uM after 30 mins by scintillation counting	2012	Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21	Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B.
AID1331323	Inhibition of electric eel AChE at 2 uM by spectrophotometric analysis based Ellman's assay	2017	Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2	Synthesis and application of β-carbolines as novel multi-functional anti-Alzheimer's disease agents.
AID1578093	Antitrypanosomal activity against Trypanosoma cruzi	2019	Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20	Antiprotozoal alkaloid principles of the plant family Amaryllidaceae.
AID1339190	Inhibition of horse serum BuChE using butyrylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition by Ellman's method	2017	Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4	Synthesis, anticholinesterase activity and molecular modeling study of novel carbamate-substituted thymol/carvacrol derivatives.
AID1328971	Neuroprotective activity against oligomycine/rotenone-induced oxidative stress-mediated cell death in human SH-SY5Y cells assessed as increase in cell viability after 24 hrs by XTT assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Avarol derivatives as competitive AChE inhibitors, non hepatotoxic and neuroprotective agents for Alzheimer's disease.
AID1498462	Inhibition of horse serum BChE at 6.25 ug using butyrylthiocholine chloride as substrate preincubated for 15 mins followed by substrate addition measured every 5 mins for 15 mins by spectrophotometric method relative to control	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	A cascade synthesis, in vitro cholinesterases inhibitory activity and docking studies of novel Tacrine-pyranopyrazole derivatives.
AID298279	Inhibition of human recombinant butyrylcholinesterase	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease.
AID437955	Antibacterial activity against Bacillus subtilis at 1 mg/mL after 18 hrs by disc diffusion assay	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis, spectral characterization and biological evaluation of phosphorylated derivatives of galanthamine.
AID1267381	Inhibition of horse serum butyrylcholinesterase using butyrylthiocholine iodide as substrate preincubated for 5 mins followed by substrate addition measured after 5 mins by Ellman's method	2016	European journal of medicinal chemistry, Jan-01, Volume: 107	Synthesis, pharmacological assessment, molecular modeling and in silico studies of fused tricyclic coumarin derivatives as a new family of multifunctional anti-Alzheimer agents.
AID1267382	Selectivity ratio of IC50 for horse serum BuChE to IC50 for electric eel AChE	2016	European journal of medicinal chemistry, Jan-01, Volume: 107	Synthesis, pharmacological assessment, molecular modeling and in silico studies of fused tricyclic coumarin derivatives as a new family of multifunctional anti-Alzheimer agents.
AID437945	Antibacterial activity against Staphylococcus aureus after 18 hrs	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis, spectral characterization and biological evaluation of phosphorylated derivatives of galanthamine.
AID526489	Inhibition of electric eel AChE by Ellman's method	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Indole alkaloids from Ervatamia hainanensis with potent acetylcholinesterase inhibition activities.
AID378482	Inhibition of electric eel AChE by Ellman's assay	2006	Journal of natural products, Sep, Volume: 69, Issue:9	Taspine: bioactivity-guided isolation and molecular ligand-target insight of a potent acetylcholinesterase inhibitor from Magnolia x soulangiana.
AID752001	Inhibition of electric eel AChE using acetylthiocholine iodide as substrate incubated for 6 mins prior to substrate addition measured after 60 to 180 secs by Ellman's method	2013	Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9	Design, synthesis and evaluation of flavonoid derivatives as potential multifunctional acetylcholinesterase inhibitors against Alzheimer's disease.
AID482854	Inhibition of equine serum BuChE by Ellman's method	2010	Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14	Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives.
AID437948	Antibacterial activity against Escherichia coli after 18 hrs	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis, spectral characterization and biological evaluation of phosphorylated derivatives of galanthamine.
AID298281	Inhibition of self-induced amyloid beta (1-40) aggregation at 10 uM by thioflavin T based fluorometric assay	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease.
AID1472441	Inhibition of BChE (unknown origin)	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.
AID1389181	Inhibition of equine serum BuChE using S-butyrylthiocholine chloride as substrate preincubated for 15 mins followed by substrate addition and measured for 45 mins by Ellmans microplate assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	In silico studies, synthesis and pharmacological evaluation to explore multi-targeted approach for imidazole analogues as potential cholinesterase inhibitors with neuroprotective role for Alzheimer's disease.
AID1271109	Inhibition of electric eel AChE using acetylthiocholine iodide as substrate at by Ellman spectrophotometric method	2016	European journal of medicinal chemistry, Jan-01, Volume: 107	Synthesis and evaluation of bis-thiazole derivatives as new anticancer agents.
AID1347788	Disaggregation of amyloid beta (25 to 35 residues) (unknown origin) preformed fibrils at 50 ug/ml after 96 hrs to 9 days by ThT-based fluorescence spectroscopic method
AID1678842	Antioxidant activity in STZ-induced mouse model of Alzheimer's disease assessed as reduction in TBARS level in brain at 0.5 mg/kg, ip treated from 3 to 12 days starting from 3 days post initial STZ stimulation and measured on day 17 by spectrophotometric	2020	RSC medicinal chemistry, Feb-01, Volume: 11, Issue:2	Structure-activity relationships of sulfonamides derived from carvacrol and their potential for the treatment of Alzheimer's disease.
AID1545271	Inhibition of human acetylcholinesterase	2019	Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6	Anti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer's disease (1998-2018).
AID1063990	Selectivity ratio of IC50 for equine serum butyrylcholinesterase to IC50 for Electrophorus electricus acetylcholinesterase	2014	Bioorganic & medicinal chemistry, Jan-15, Volume: 22, Issue:2	Cholinesterase inhibitory activity versus aromatic core multiplicity: a facile green synthesis and molecular docking study of novel piperidone embedded thiazolopyrimidines.
AID635415	Inhibition of equine serum BuChE using butyrylthiocholine chloride as substrate preincubated for 15 mins by Ellman's method	2011	Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23	Benzenediol-berberine hybrids: multifunctional agents for Alzheimer's disease.
AID437949	Antioxidant activity in Wistar rat brain assessed as superoxide dismutase content	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis, spectral characterization and biological evaluation of phosphorylated derivatives of galanthamine.
AID1076769	Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of amyloid beta 1 to 42-induced toxicity by measuring cell viability at 10 uM pretreated for 24 hrs followed by amyloid beta 1 to 42 challenge measured after 24	2014	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6	Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
AID1507310	Inhibition of human AChE	2017	European journal of medicinal chemistry, Aug-18, Volume: 136	Discorhabdin alkaloids from Antarctic Latrunculia spp. sponges as a new class of cholinesterase inhibitors.
AID670563	Inhibition of human AChE using acetylthiocholine iodide as substrate after 5 mins by DTNB method	2012	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14	Development and evaluation of multifunctional agents for potential treatment of Alzheimer's disease: application to a pyrimidine-2,4-diamine template.
AID311339	Inhibition of AChE by Ellman method	2007	Journal of natural products, Sep, Volume: 70, Issue:9	Benzylphenethylamine alkaloids from Hosta plantaginea with inhibitory activity against tobacco mosaic virus and acetylcholinesterase.
AID707054	Inhibition of AChE in Wistar rat brain homogenates using acetylthiocholine iodide and DTNB as substrate after 10 mins by Ellman method	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease.
AID281639	Increase in extracellular acetylcholine at 2 uM in urethane anesthetized Sprague-Dawley rat nucleus accumbens	2004	Journal of medicinal chemistry, Dec-02, Volume: 47, Issue:25	Acetylcholinesterase inhibitory activity of scopolin and scopoletin discovered by virtual screening of natural products.
AID688351	Cytotoxicity against human BJ cells after 72 hrs by Calcein AM assay	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	Apoptosis-inducing effects of distichamine and narciprimine, rare alkaloids of the plant family Amaryllidaceae.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1076768	Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of glutamate-induced toxicity by measuring cell viability at 10 nM pretreated for 24 hrs followed by glutamate challenge measured after 24 hrs by MTT assay rela	2014	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6	Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
AID1593771	Selectivity index, ratio of IC50 for equine serum BChE to IC50 for electric eel AChE	2019	Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12	Dispiropyrrolidinyl-piperidone embedded indeno[1,2-b]quinoxaline heterocyclic hybrids: Synthesis, cholinesterase inhibitory activity and their molecular docking simulation.
AID1854488	Inhibition of electric eel AChE using acetylthiocholine iodide as substrate pre-incubated for 5 mins followed by substrate addition at 4.5 uM and measured after 6 mins by Ellman's method relative to control	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	New naphtho/thienobenzo-triazoles with interconnected anti-inflammatory and cholinesterase inhibitory activity.
AID1736860	Inhibition of human plasma BuChE using butyrylthiocholine as substrate measured after 5 mins by Ellman's method	2020	European journal of medicinal chemistry, Apr-01, Volume: 191	Design, synthesis and biological evaluation of 2,3-dihydro-5,6-dimethoxy-1H-inden-1-one and piperazinium salt hybrid derivatives as hAChE and hBuChE enzyme inhibitors.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1129234	Inhibition of equine serum BChE using S-butyrylthiocholine chloride as substrate preincubated for 15 mins by spectrophotometer analysis	2014	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7	Synthesis and discovery of highly functionalized mono- and bis-spiro-pyrrolidines as potent cholinesterase enzyme inhibitors.
AID765550	Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins by Ellman's microplate assay	2013	European journal of medicinal chemistry, Sep, Volume: 67	An expedient, ionic liquid mediated multi-component synthesis of novel piperidone grafted cholinesterase enzymes inhibitors and their molecular modeling study.
AID1872732	Inhibition of AChE (unknown origin) incubated for 30 mins by Ellman's method	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Resveratrol-based compounds and neurodegeneration: Recent insight in multitarget therapy.
AID1066951	Memory enhancing effect in ICR mouse assessed as reversal of scopolamine-induced amnesia by measuring step-through latencies at 1 mg/kg, po administered 1 hr prior to acquisition trial measured after 24 hrs by passive avoidance test relative to control	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Synthesis of aminoalkyl-substituted coumarin derivatives as acetylcholinesterase inhibitors.
AID1356515	Inhibition of AChE (unknown origin) using acetylthiocholine iodide as substrate pretreated for 15 mins followed by substrate addition and measured by DTNB reagent based assay	2018	Journal of natural products, 08-24, Volume: 81, Issue:8	A Bioactive Resveratrol Trimer from the Stem Bark of the Sri Lankan Endemic Plant Vateria copallifera.
AID666573	Inhibition of electric eel acetylcholine esterase using acetylcholine chloride as substrate incubated for 15 mins prior to substrate addition measured every 1 min by Ellman's assay	2012	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13	Design, synthesis, and evaluation of indanone derivatives as acetylcholinesterase inhibitors and metal-chelating agents.
AID1179994	Inhibition of BuChE (unknown origin)	2014	Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15	Coumarin hybrids as novel therapeutic agents.
AID670564	Inhibition of equine BuChE using butyrylthiocholine iodide as substrate after 5 mins by DTNB method	2012	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14	Development and evaluation of multifunctional agents for potential treatment of Alzheimer's disease: application to a pyrimidine-2,4-diamine template.
AID1328983	Neuroprotective activity against NMDA-induced excitotoxicity in Sprague-Dawley rat primary cortical neurons assessed as increase in cell viability after 3 hrs by MTT assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Avarol derivatives as competitive AChE inhibitors, non hepatotoxic and neuroprotective agents for Alzheimer's disease.
AID670569	Inhibition of self-induced amyloid beta (1 to 40) aggregation at 100 uM after 24 hrs by thioflavin T-based fluorescence analysis	2012	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14	Development and evaluation of multifunctional agents for potential treatment of Alzheimer's disease: application to a pyrimidine-2,4-diamine template.
AID1780622	Inhibition of electric eel AChE using acetylcholine iodide as a substrate measured for 125 secs by DNTB reagent based Ellman's method	2021	ACS medicinal chemistry letters, Nov-11, Volume: 12, Issue:11	Ugi Reaction Synthesis of Oxindole-Lactam Hybrids as Selective Butyrylcholinesterase Inhibitors.
AID1142530	Inhibition of yeast alpha-glucosidase type 3 using p-nitrophenyl-alpha-D-glucopyranoside as substrate preincubated with substrate for 5 mins prior to enzyme challenge for 30 mins by absorbance analysis	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	Dual inhibition of the α-glucosidase and butyrylcholinesterase studied by molecular field topology analysis.
AID1315225	Inhibition of electric eel AChE using ATCI as substrate preincubated for 30 mins followed by substrate addition measured after 5 mins by DTNB-based spectrophotometric analysis	2016	Journal of natural products, 05-27, Volume: 79, Issue:5	Alkaloids from Hippeastrum argentinum and Their Cholinesterase-Inhibitory Activities: An in Vitro and in Silico Study.
AID600978	Inhibition of human erythrocytes AChE	2011	European journal of medicinal chemistry, Jun, Volume: 46, Issue:6	Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease.
AID263610	Inhibition of AChE activity	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Isoquinoline derivatives as potential acetylcholinesterase inhibitors.
AID365698	Inhibition of AchE	2008	Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16	Solid-phase synthesis and biological evaluation of a parallel library of 2,3-dihydro-1,5-benzothiazepines.
AID1678841	Antialzheimer activity in streptozotocin-induced mouse model of memory impairment assessed as median time of avoidance latency descent at 0.5 mg/kg, ip treated from 3 to 12 days starting from 3 days post initial STZ stimulation and measured on day 16 by a	2020	RSC medicinal chemistry, Feb-01, Volume: 11, Issue:2	Structure-activity relationships of sulfonamides derived from carvacrol and their potential for the treatment of Alzheimer's disease.
AID1331322	Inhibition of BuChE (unknown origin) at 10 uM by spectrophotometric analysis based Ellman's assay	2017	Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2	Synthesis and application of β-carbolines as novel multi-functional anti-Alzheimer's disease agents.
AID437942	Antioxidant activity in Wistar rat brain assessed as reduction in glutathione content	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis, spectral characterization and biological evaluation of phosphorylated derivatives of galanthamine.
AID404434	Inhibition of Torpedo californica AChE	2008	Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11	Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors.
AID1678837	Anxiolytic-like activity in STZ-induced mouse model of Alzheimer's disease assessed as open arm time permanency at 0.5 mg/kg, ip treated from 3 to 12 days starting from 3 days post initial STZ stimulation and measured on day 14 by elevated plus maze test	2020	RSC medicinal chemistry, Feb-01, Volume: 11, Issue:2	Structure-activity relationships of sulfonamides derived from carvacrol and their potential for the treatment of Alzheimer's disease.
AID1075991	Inhibition of BuChE in human serum using butyrylthiocholine iodide as substrate measured every 30s for 5 mins by Ellman's spectrophotometric method	2014	European journal of medicinal chemistry, Mar-21, Volume: 75	Synthesis, biological evaluation and molecular modeling study of novel tacrine-carbazole hybrids as potential multifunctional agents for the treatment of Alzheimer's disease.
AID1070089	Inhibition of equine serum BChE using S-butyrylthiocholine chloride as substrate preincubated for 15 mins followed by substrate addition by Ellman's method	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Ionic liquid mediated synthesis of mono- and bis-spirooxindole-hexahydropyrrolidines as cholinesterase inhibitors and their molecular docking studies.
AID480455	Inhibition of dexamethasone-induced human NR1-1a/NR2B receptor-mediated excitotoxicity in (S)-glutamate/glycine-stimulated mouse L13-E6 cells assessed as LDH release after 30 mins	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.
AID776490	Selectivity index, ratio of IC50 for equine serum BuChE to IC50 for electric eel AChE	2013	European journal of medicinal chemistry, Nov, Volume: 69	Multifunctional tacrine-flavonoid hybrids with cholinergic, β-amyloid-reducing, and metal chelating properties for the treatment of Alzheimer's disease.
AID1075979	Selectivity index, ratio of IC50 for human serum BuChE to IC50 for electric eel acetylcholinesterase type VI-S	2014	European journal of medicinal chemistry, Mar-21, Volume: 75	Synthesis, biological evaluation and molecular modeling study of novel tacrine-carbazole hybrids as potential multifunctional agents for the treatment of Alzheimer's disease.
AID1443980	Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch	2010	Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID1498444	Selectivity ratio of IC50 for horse serum BChE to IC50 for electric eel AChE	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	A cascade synthesis, in vitro cholinesterases inhibitory activity and docking studies of novel Tacrine-pyranopyrazole derivatives.
AID730448	Inhibition of Electrophorus electricus AChE using acetylthiocholine as substrate after 10 mins by Ellman's method	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	Synthesis and in vitro evaluation of new derivatives of 2-substituted-6-fluorobenzo[d]thiazoles as cholinesterase inhibitors.
AID1237656	Inhibition of human acetylcholinesterase using ATCI/DTNB as substrate preincubated for 30 mins followed by substrate addition measured for 60 mins by Ellman method	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	In vitro evaluation and in silico screening of synthetic acetylcholinesterase inhibitors bearing functionalized piperidine pharmacophores.
AID707698	Inhibition of mouse recombinant GST-tagged CLK1 expressed in Escherichia coli using GRSRSRSRSRSR as substrate and [gamma33P]ATP at 10 uM after 30 mins by scintillation counting	2012	Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21	Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B.
AID437952	Antioxidant activity in Wistar rat brain assessed as glutathione content	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis, spectral characterization and biological evaluation of phosphorylated derivatives of galanthamine.
AID462833	Inhibition of bovine AChE by Elman's method	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Acetylcholinesterase inhibitors from the toadstool Cortinarius infractus.
AID1779363	Inhibition of human erythrocyte AChE using acetylthiocholine iodide as substrate incubated for 25 mins by DTNB reagent based Ellman's method	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	"Clicking" fragment leads to novel dual-binding cholinesterase inhibitors.
AID1899571	Inhibition of electric eel AChE at 10 uM using acetylthiocholine iodide as substrate preincubated with enzyme for 20 mins followed by substrate addition and measured after 45 mins by Ellman's method	2022	European journal of medicinal chemistry, Jan-15, Volume: 228	Imidazolylacetophenone oxime-based multifunctional neuroprotective agents: Discovery and structure-activity relationships.
AID1564162	Inhibition of electric eel AChE assessed as dissociation constant for enzyme-inhibitor complex using acetylthiocholine iodide as substrate measured for 125 secs by Ellman's method	2019	European journal of medicinal chemistry, Nov-01, Volume: 181	Tacrine-O-protected phenolics heterodimers as multitarget-directed ligands against Alzheimer's disease: Selective subnanomolar BuChE inhibitors.
AID486996	Selectivity ratio of IC50 for equine serum BuChE to IC50 for electric eel AChE	2010	Bioorganic & medicinal chemistry, Jun-15, Volume: 18, Issue:12	Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase.
AID1498447	Inhibition of electric eel AChE at 3.125 ug using acetylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition measured every 5 mins for 15 mins by spectrophotometric method relative to control	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	A cascade synthesis, in vitro cholinesterases inhibitory activity and docking studies of novel Tacrine-pyranopyrazole derivatives.
AID1780623	Inhibition of equine serum BuChE using S-butyrylthiocholine iodide as a substrate measured for 125 secs by DNTB reagent based Ellman's method	2021	ACS medicinal chemistry letters, Nov-11, Volume: 12, Issue:11	Ugi Reaction Synthesis of Oxindole-Lactam Hybrids as Selective Butyrylcholinesterase Inhibitors.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID1167623	Inhibition of equine serum BChE using S-butyrylthiocholine chloride as substrate incubated for 6 mins by spectrophotometric method	2014	Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21	Design, synthesis and evaluation of novel tacrine-(β-carboline) hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID1865084	Inhibition of human recombinant AChe using acetylthiocholine iodide as substrate incubated for 10 mins by DTNB reagent based Ellman's method
AID480450	Selectivity ratio of IC50 for equine serum BChE to IC50 for electric eel AChE	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.
AID1063989	Selectivity ratio of IC50 for Electrophorus electricus acetylcholinesterase to IC50 for equine serum butyrylcholinesterase	2014	Bioorganic & medicinal chemistry, Jan-15, Volume: 22, Issue:2	Cholinesterase inhibitory activity versus aromatic core multiplicity: a facile green synthesis and molecular docking study of novel piperidone embedded thiazolopyrimidines.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID383200	Selectivity ratio of IC50 for electric eel AChE to IC50 for equine serum BuChE	2008	Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8	Design, synthesis and pharmacological evaluation of hybrid molecules out of quinazolinimines and lipoic acid lead to highly potent and selective butyrylcholinesterase inhibitors with antioxidant properties.
AID456907	Selectivity for electric eel AChE over horse serum BChE	2010	Bioorganic & medicinal chemistry, Feb, Volume: 18, Issue:3	Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors.
AID1557015	Inhibition of Electrophorus electricus AChE using acetylthiocholine iodide as substrate by Ellman's method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Novel N-benzylpiperidine carboxamide derivatives as potential cholinesterase inhibitors for the treatment of Alzheimer's disease.
AID1567163	Inhibition of human recombinant BuChE using butyrylthiocholine iodide as substrate preincubated for 20 mins followed by substrate addition by Ellman's spectrophotometric method	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery of novel benzofuran-based compounds with neuroprotective and immunomodulatory properties for Alzheimer's disease treatment.
AID1389180	Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition and measured for 45 mins by Ellmans microplate assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	In silico studies, synthesis and pharmacological evaluation to explore multi-targeted approach for imidazole analogues as potential cholinesterase inhibitors with neuroprotective role for Alzheimer's disease.
AID262756	Selectivity for AChE over BChE	2006	Journal of medicinal chemistry, Apr-06, Volume: 49, Issue:7	Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine.
AID1498459	Inhibition of horse serum BChE at 0.781 ug using butyrylthiocholine chloride as substrate preincubated for 15 mins followed by substrate addition measured every 5 mins for 15 mins by spectrophotometric method relative to control	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	A cascade synthesis, in vitro cholinesterases inhibitory activity and docking studies of novel Tacrine-pyranopyrazole derivatives.
AID276347	Selectivity for AChE over BChE	2006	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 16, Issue:22	6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors.
AID694073	Inhibition of human recombinant AChE using acetylthiocholine as substrate	2012	Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22	Design, synthesis, and bioevaluation of benzamides: novel acetylcholinesterase inhibitors with multi-functions on butylcholinesterase, Aβ aggregation, and β-secretase.
AID1175427	Inhibition of ICR mouse brain AChE using acetylthiocholine iodide as substrate preincubated for 10 mins before substrate addition by modified Ellman's method	2015	Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1	Synthesis of aminoalkyl-substituted aurone derivatives as acetylcholinesterase inhibitors.
AID752000	Inhibition of equine serum BuChE using S-butyrylthiocholine iodide as substrate incubated for 6 mins prior to substrate addition measured after 60 to 180 secs by Ellman's method	2013	Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9	Design, synthesis and evaluation of flavonoid derivatives as potential multifunctional acetylcholinesterase inhibitors against Alzheimer's disease.
AID383158	Inhibition of acetylcholinesterase at 10 uM by Ellman's method	2008	Journal of natural products, May, Volume: 71, Issue:5	Xanthones from Gentianella amarella ssp. acuta with acetylcholinesterase and monoamine oxidase inhibitory activities.
AID1066955	Inhibition of ICR mouse brain AChE using acetylthiocholine iodide as substrate incubated 10 mins prior to substrate addition measured after 10 mins by Ellman's method	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Synthesis of aminoalkyl-substituted coumarin derivatives as acetylcholinesterase inhibitors.
AID294502	Inhibition of BuChE in horse serum	2007	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 17, Issue:8	Methyl 2-(2-(4-formylphenoxy)acetamido)-2-substituted acetate derivatives: a new class of acetylcholinesterase inhibitors.
AID456906	Inhibition of horse serum BChE by Ellman's method	2010	Bioorganic & medicinal chemistry, Feb, Volume: 18, Issue:3	Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors.
AID593739	Inhibition of equine serum Butyrylcholinesterase	2011	Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7	Synthesis, biological evaluation and molecular modeling of novel triazole-containing berberine derivatives as acetylcholinesterase and β-amyloid aggregation inhibitors.
AID707048	Neuroprotective activity in human SH-SY5Y cells assessed as protection against NMDA-induced cell death after 6 hrs by MTS assay	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease.
AID1597702	Inhibition of equine serum BChE using butyrylthiocholine as substrate preincubated for 20 mins followed by substrate addition and measured upto 5 mins by Ellman's method	2019	European journal of medicinal chemistry, Sep-01, Volume: 177	Investigating 1,2,3,4,5,6-hexahydroazepino[4,3-b]indole as scaffold of butyrylcholinesterase-selective inhibitors with additional neuroprotective activities for Alzheimer's disease.
AID307545	Inhibition of electric eel AChE	2007	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13	Derivatives of oxoisoaporphine alkaloids: a novel class of selective acetylcholinesterase inhibitors.
AID1426027	Inhibition of electric eel AChE using acetylthiocholine iodide as substrate measured every minute for fifteen minutes by Ellman's method	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Amaryllidaceae alkaloids with new framework types from Zephyranthes candida as potent acetylcholinesterase inhibitors.
AID114804	Compound was evaluated for the cholinergic activity in vivo in mice by administering the compound intraperitoneally and observation of the tremors was made after 30 min	1994	Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5	Novel [2-(4-piperidinyl)ethyl](thio)ureas: synthesis and antiacetylcholinesterase activity.
AID482855	Inhibition of AChE in human erythrocytes by Ellman's method	2010	Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14	Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives.
AID262755	Anticholinesterase activity against human plasma BChE	2006	Journal of medicinal chemistry, Apr-06, Volume: 49, Issue:7	Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1077143	Antialzheimer activity in Wistar rat scopolamine-induced cognition impairment model assessed as decrease in amount of errors plus baits not found during exploration at 1 umol/100 g body weight, ip treated for 5 mins prior to scopolamine-challenge measured	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	Design, synthesis and biological evaluation of D-ring opened galantamine analogs as multifunctional anti-Alzheimer agents.
AID765547	Selectivity ratio of IC50 for electric eel AChE to IC50 for horse serum BChE	2013	European journal of medicinal chemistry, Sep, Volume: 67	An expedient, ionic liquid mediated multi-component synthesis of novel piperidone grafted cholinesterase enzymes inhibitors and their molecular modeling study.
AID593738	Inhibition of electric eel Acetylcholinesterase	2011	Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7	Synthesis, biological evaluation and molecular modeling of novel triazole-containing berberine derivatives as acetylcholinesterase and β-amyloid aggregation inhibitors.
AID754043	Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 6 mins prior to substrate addition measured at 60 to 180 seconds by Ellman's method	2013	European journal of medicinal chemistry, Jun, Volume: 64	Design, synthesis and evaluation of novel tacrine-coumarin hybrids as multifunctional cholinesterase inhibitors against Alzheimer's disease.
AID1317853	Inhibition of equine serum BuChE preincubated for 5 mins followed by addition of butyrylthiocholine iodide as substrate measured after 2 mins by Ellman's method	2016	European journal of medicinal chemistry, Aug-25, Volume: 119	Synthesis and screening of triazolopyrimidine scaffold as multi-functional agents for Alzheimer's disease therapies.
AID345205	Inhibition of human recombinant AChE by Ellman's assay	2008	Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22	Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 4. Further investigation on the inner spacer.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID260080	Inhibitory activity against BuChE from horse serum	2006	Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3	Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum.
AID1736859	Inhibition of human erythrocyte AChE using acetylthiocholine as substrate measured after 5 mins by Ellman's method	2020	European journal of medicinal chemistry, Apr-01, Volume: 191	Design, synthesis and biological evaluation of 2,3-dihydro-5,6-dimethoxy-1H-inden-1-one and piperazinium salt hybrid derivatives as hAChE and hBuChE enzyme inhibitors.
AID1347784	Disaggregation of amyloid beta (25 to 35 residues) (unknown origin) preformed fibrils at 50 ug/ml after 96 hrs to 9 days by FTIR spectroscopy
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID294503	Selectivity for Torpedo californica AChE over horse BuChE	2007	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 17, Issue:8	Methyl 2-(2-(4-formylphenoxy)acetamido)-2-substituted acetate derivatives: a new class of acetylcholinesterase inhibitors.
AID1230202	Inhibition of electric eel AChE using acetylthiocholine as substrate assessed as concentration of 5-thio-2-nitrobenzoic acid ion formed by spectrophotometric/Ellman's method	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	In Vitro Inhibitory Effects of 8-O-Demethylmaritidine and Undulatine on Acetylcholinesterase and Their Predicted Penetration across the Blood-Brain Barrier.
AID1594569	Inhibition of equine serum BChE using butyrylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition by Ellman's method	2019	Bioorganic & medicinal chemistry letters, 06-01, Volume: 29, Issue:11	Design, synthesis, evaluation and molecular modeling study of 4-N-phenylaminoquinolines for Alzheimer disease treatment.
AID1807564	Selectivity index, ratio of IC50 for human BuChe to IC50 for human AChE	2021	Bioorganic & medicinal chemistry letters, 11-01, Volume: 51	Derivatives of montanine-type alkaloids and their implication for the treatment of Alzheimer's disease: Synthesis, biological activity and in silico study.
AID343772	Inhibition of Torpedo californica AchE activity by Ellman's assay	2008	Bioorganic & medicinal chemistry, Jul-01, Volume: 16, Issue:13	Petrosamine, a potent anticholinesterase pyridoacridine alkaloid from a Thai marine sponge Petrosia n. sp.
AID456905	Inhibition of electric eel AChE by modified Ellman method	2010	Bioorganic & medicinal chemistry, Feb, Volume: 18, Issue:3	Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors.
AID116900	Compound was evaluated for the cholinergic activity by the induction of amnesia at high toxic doses and lethal dose was determined	1994	Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5	Novel [2-(4-piperidinyl)ethyl](thio)ureas: synthesis and antiacetylcholinesterase activity.
AID381366	Inhibition of AChE by microplate assay	2000	Journal of natural products, Jun, Volume: 63, Issue:6	The application of HPLC with on-line coupled UV/MS-biochemical detection for isolation of an acetylcholinesterase inhibitor from narcissus 'Sir Winston Churchill'.
AID1443225	Selectivity index, ratio of IC50 for butyrylcholinesterase (unknown origin) to IC50 for acetylcholinesterase (unknown origin)	2017	Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7	Green synthesis of novel spiro-indenoquinoxaline derivatives and their cholinesterases inhibition activity.
AID1427875	Inhibition of electric eel AChE using acetylthiocholine iodide as substrate by Ellman's method	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Targeting Alzheimer's disease by investigating previously unexplored chemical space surrounding the cholinesterase inhibitor donepezil.
AID765549	Inhibition of horse serum BChE using S-butyrylthiocholine chloride as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins by Ellman's microplate assay	2013	European journal of medicinal chemistry, Sep, Volume: 67	An expedient, ionic liquid mediated multi-component synthesis of novel piperidone grafted cholinesterase enzymes inhibitors and their molecular modeling study.
AID1273007	Inhibition of equine BChE using BTC as substrate preincubated for 5 mins followed by substrate addition measured after 2 mins by Ellman's assay	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Ferulic acid-carbazole hybrid compounds: Combination of cholinesterase inhibition, antioxidant and neuroprotection as multifunctional anti-Alzheimer agents.
AID1186580	Selectivity ratio of Ki for human BChE to Ki for human AChE	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Syntheses of coumarin-tacrine hybrids as dual-site acetylcholinesterase inhibitors and their activity against butylcholinesterase, Aβ aggregation, and β-secretase.
AID1498454	Inhibition of electric eel AChE at 0.049 ug using acetylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition measured every 5 mins for 15 mins by spectrophotometric method relative to control	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	A cascade synthesis, in vitro cholinesterases inhibitory activity and docking studies of novel Tacrine-pyranopyrazole derivatives.
AID1537270	Inhibition of human BuChE using butyrylthiocholine iodide as substrate measured for 1 min by Ellman's method	2019	Journal of natural products, 02-22, Volume: 82, Issue:2	Isoquinoline Alkaloids from Berberis vulgaris as Potential Lead Compounds for the Treatment of Alzheimer's Disease.
AID746379	Inhibition of AChE (unknown origin) by Ellman method	2013	Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9	Design, synthesis and biological activity of multifunctional α,β-unsaturated carbonyl scaffolds for Alzheimer's disease.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1076767	Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of glutamate-induced toxicity by measuring cell viability at 100 nM pretreated for 24 hrs followed by glutamate challenge measured after 24 hrs by MTT assay rel	2014	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6	Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
AID1491305	Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition measured for 30 mins by Ellman's method	2017	European journal of medicinal chemistry, Sep-08, Volume: 137	Isosteroidal alkaloids as potent dual-binding site inhibitors of both acetylcholinesterase and butyrylcholinesterase from the bulbs of Fritillaria walujewii.
AID1176927	Inhibition of AChE (unknown origin) assessed as reduction in acetylthiocholine iodide hydrolysis at 2 uM after 15 mins by Ellman method	2015	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3	Sulfonamides as multifunctional agents for Alzheimer's disease.
AID600981	Inhibition of human plasma BChE	2011	European journal of medicinal chemistry, Jun, Volume: 46, Issue:6	Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease.
AID1335319	Inhibition of horse serum butyrylcholinesterase by Ellman's method	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	New piperidine-hydrazone derivatives: Synthesis, biological evaluations and molecular docking studies as AChE and BChE inhibitors.
AID31036	In vitro inhibition of human recombinant AChE.	2002	Bioorganic & medicinal chemistry letters, Sep-16, Volume: 12, Issue:18	Quaternary salts of E2020 analogues as acetylcholinesterase inhibitors for the reversal of neuromuscular block.
AID345208	Inhibition of self-induced amyloid beta (1-40) aggregation at 10 uM by thioflavin T formation assay	2008	Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22	Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 4. Further investigation on the inner spacer.
AID1524944	Inhibition of BChE (unknown origin) at 20 ug/mL using butyrylthiocholine iodide as substrate by spectrophotometry based Ellman's method	2019	Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10	Bioactivity-guided identification of flavonoids with cholinesterase and β-amyloid peptide aggregation inhibitory effects from the seeds of Millettia pachycarpa.
AID437953	Antibacterial activity against Klebsiella pneumoniae at 1 mg/mL after 18 hrs by disc diffusion assay	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis, spectral characterization and biological evaluation of phosphorylated derivatives of galanthamine.
AID1739255	Selectivity index, ratio of IC50 for BuChE (unknown origin) to IC50 for AChE (unknown origin)	2020	European journal of medicinal chemistry, Aug-15, Volume: 200	Simple analogues of natural product chelerythrine: Discovery of a novel anticholinesterase 2-phenylisoquinolin-2-ium scaffold with excellent potency against acetylcholinesterase.
AID1491307	Selectivity index, ratio of IC50 for equine serum BChE to IC50 for electric eel AChE	2017	European journal of medicinal chemistry, Sep-08, Volume: 137	Isosteroidal alkaloids as potent dual-binding site inhibitors of both acetylcholinesterase and butyrylcholinesterase from the bulbs of Fritillaria walujewii.
AID749372	Inhibition of equine serum BuChE using S-butyrylthiocholine chloride as substrate incubated for 15 mins prior to substrate addition measured after 30 mins by Ellman's method	2013	Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11	Microwave assisted synthesis, cholinesterase enzymes inhibitory activities and molecular docking studies of new pyridopyrimidine derivatives.
AID656680	Inhibition of electric eel AChE using acetylcholine iodide as substrate measured every 5 sec for 2 mins by Ellman's method	2012	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8	Prospective acetylcholinesterase inhibitory activity of indole and its analogs.
AID1593769	Inhibition of equine serum BChE using butyrylthiocholine chloride as substrate preincubated for 15 mins followed by substrate addition and measured after 30 mins by Ellman's method	2019	Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12	Dispiropyrrolidinyl-piperidone embedded indeno[1,2-b]quinoxaline heterocyclic hybrids: Synthesis, cholinesterase inhibitory activity and their molecular docking simulation.
AID1466564	Inhibition of equine serum BuChE using acetylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition by spectrophotometric analysis
AID1400272	Inhibition of equine serum BuChE using butyrylthiocholine iodide as substrate preincubated for 10 mins followed by substrate addition measured for 5 mins by Ellman's method	2018	Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17	Design, synthesis, and biological evaluation of selective and potent Carbazole-based butyrylcholinesterase inhibitors.
AID1317854	Selectivity ratio, ratio of IC50 for equine serum BuChE to electric eel AChE	2016	European journal of medicinal chemistry, Aug-25, Volume: 119	Synthesis and screening of triazolopyrimidine scaffold as multi-functional agents for Alzheimer's disease therapies.
AID298280	Inhibition of human AChE-induced amyloid beta (1-40) aggregation at 100 uM	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease.
AID421515	Inhibition of equine serum BuChE by Ellman's method	2009	European journal of medicinal chemistry, Jun, Volume: 44, Issue:6	Synthesis, biological evaluation and molecular modeling of oxoisoaporphine and oxoaporphine derivatives as new dual inhibitors of acetylcholinesterase/butyrylcholinesterase.
AID568572	Inhibition of human erythrocytes acetylcholinesterase after 15 mins	2011	Journal of natural products, Jan-28, Volume: 74, Issue:1	Biotransformation of turmerones by Aspergillus niger.
AID603787	Inhibition of electric eel AChE by colorimetric Ellman's assay	2011	European journal of medicinal chemistry, Jul, Volume: 46, Issue:7	Mycobacterium tuberculosis and cholinesterase inhibitors from Voacanga globosa.
AID1077144	Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 5 mins followed by substrate addition measured after 5 mins by Ellman's method	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	Design, synthesis and biological evaluation of D-ring opened galantamine analogs as multifunctional anti-Alzheimer agents.
AID30544	In vitro inhibitory activity against acetylcholinesterase (AChE) in Electrophorus electricus	2003	Bioorganic & medicinal chemistry letters, Jul-21, Volume: 13, Issue:14	Synthesis and structure-activity relationships of open D-Ring galanthamine analogues.
AID1678836	Inhibition of AChE (unknown origin) using acetylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition and measured after 30 mins by Ellman's method	2020	RSC medicinal chemistry, Feb-01, Volume: 11, Issue:2	Structure-activity relationships of sulfonamides derived from carvacrol and their potential for the treatment of Alzheimer's disease.
AID670568	Inhibition of human AChE-induced amyloid beta (1 to 40) aggregation at 100 uM after 24 hrs by thioflavin T-based fluorescence analysis	2012	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14	Development and evaluation of multifunctional agents for potential treatment of Alzheimer's disease: application to a pyrimidine-2,4-diamine template.
AID44285	Ex vivo inhibition of human plasma Butyrylcholinesterase.	2002	Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17	Anticholinesterase activity of compounds related to geneserine tautomers. N-Oxides and 1,2-oxazines.
AID1739253	Inhibition of AChE (unknown origin) preincubated for 30 mins followed by substrate addition acetylthiocholineiodide measured after 40 mins by Ellman's method	2020	European journal of medicinal chemistry, Aug-15, Volume: 200	Simple analogues of natural product chelerythrine: Discovery of a novel anticholinesterase 2-phenylisoquinolin-2-ium scaffold with excellent potency against acetylcholinesterase.
AID345207	Inhibition of human recombinant AChE-induced amyloid beta (1-40) aggregation at 100 uM by thioflavin T formation assay	2008	Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22	Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 4. Further investigation on the inner spacer.
AID1328951	Inhibition of Electrophorus electricus AChE using acetylthiocholine iodide as substrate incubated for 15 mins followed by substrate addition by Ellman's method	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Avarol derivatives as competitive AChE inhibitors, non hepatotoxic and neuroprotective agents for Alzheimer's disease.
AID333566	Inhibition of rat brain acetylcholinesterase by colorimetric method	2004	Journal of natural products, Nov, Volume: 67, Issue:11	Indole glucoalkaloids from Chimarrhis turbinata and their evaluation as antioxidant agents and acetylcholinesterase inhibitors.
AID416453	Inhibition of AChE from rat cortex homogenate by Ellmans method	2009	European journal of medicinal chemistry, Feb, Volume: 44, Issue:2	Design, synthesis and evaluation of galanthamine derivatives as acetylcholinesterase inhibitors.
AID1556704	Inhibition of BuChE in human serum using S-butyrylthiocholine iodide as substrate at 100 uM preincubated with enzyme for 10 mins followed by substrate addition measured for 15 mins by Ellman's method relative to control	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Carboxamides vs. methanimines: Crystal structures, binding interactions, photophysical studies, and biological evaluation of (indazole-5-yl)methanimines as monoamine oxidase B and acetylcholinesterase inhibitors.
AID1524943	Inhibition of AChE (unknown origin) at 20 ug/mL using acetylthiocholine iodide as substrate by spectrophotometry based Ellman's method	2019	Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10	Bioactivity-guided identification of flavonoids with cholinesterase and β-amyloid peptide aggregation inhibitory effects from the seeds of Millettia pachycarpa.
AID1328972	Neuroprotective activity against okadaic acid-induced tau phosphorylation-mediated cell death in human SH-SY5Y cells assessed as increase in cell viability after 24 hrs by XTT assay	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	Avarol derivatives as competitive AChE inhibitors, non hepatotoxic and neuroprotective agents for Alzheimer's disease.
AID1556711	Inhibition of BuChE in human serum using S-butyrylthiocholine iodide as substrate preincubated with enzyme for 10 mins followed by substrate addition measured for 15 mins by Ellman's method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Carboxamides vs. methanimines: Crystal structures, binding interactions, photophysical studies, and biological evaluation of (indazole-5-yl)methanimines as monoamine oxidase B and acetylcholinesterase inhibitors.
AID707699	Inhibition of human recombinant GST-tagged DYRK2 expressed in Escherichia coli using GRSRSRSRSRSR as substrate and [gamma33P]ATP at 10 uM after 30 mins by scintillation counting	2012	Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21	Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B.
AID1872733	Inhibition of BChE (unknown origin) incubated for 30 mins by Ellman's method	2022	European journal of medicinal chemistry, Apr-05, Volume: 233	Resveratrol-based compounds and neurodegeneration: Recent insight in multitarget therapy.
AID1076765	Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of glutamate-induced toxicity by measuring cell viability at 10 uM pretreated for 24 hrs followed by glutamate challenge measured after 24 hrs by MTT assay rela	2014	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6	Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
AID1186578	Inhibition of human AChE assessed as acetylthiocholine hydrolysis	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Syntheses of coumarin-tacrine hybrids as dual-site acetylcholinesterase inhibitors and their activity against butylcholinesterase, Aβ aggregation, and β-secretase.
AID1498460	Inhibition of horse serum BChE at 1.563 ug using butyrylthiocholine chloride as substrate preincubated for 15 mins followed by substrate addition measured every 5 mins for 15 mins by spectrophotometric method relative to control	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	A cascade synthesis, in vitro cholinesterases inhibitory activity and docking studies of novel Tacrine-pyranopyrazole derivatives.
AID1466565	Selectivity ratio of IC50 for equine serum BuChE to IC50 for electric eel AChE
AID765548	Selectivity ratio of IC50 for horse serum BChE to IC50 for electric eel AChE	2013	European journal of medicinal chemistry, Sep, Volume: 67	An expedient, ionic liquid mediated multi-component synthesis of novel piperidone grafted cholinesterase enzymes inhibitors and their molecular modeling study.
AID1524941	Inhibition of AChE (unknown origin) at 100 ug/mL using acetylthiocholine iodide as substrate by spectrophotometry based Ellman's method	2019	Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10	Bioactivity-guided identification of flavonoids with cholinesterase and β-amyloid peptide aggregation inhibitory effects from the seeds of Millettia pachycarpa.
AID566361	Inhibition of AChE by Ellman's method	2010	Journal of natural products, Nov-29, Volume: 73, Issue:11	Triterpenoidal alkaloids from Buxus natalensis and their acetylcholinesterase inhibitory activity.
AID336177	Inhibition of acetylcholinesterase-mediated hydrolysis of acetylcholine at 0.16 mg/mL relative to galanthamine	2002	Journal of natural products, Oct, Volume: 65, Issue:10	Bioactive constituents from Iryanthera megistophylla.
AID26362	Ionization constant (pKa)	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID416454	Inhibition of BChE from rat serum by Ellmans method	2009	European journal of medicinal chemistry, Feb, Volume: 44, Issue:2	Design, synthesis and evaluation of galanthamine derivatives as acetylcholinesterase inhibitors.
AID688344	Cytotoxicity against human CEM cells after 72 hrs by Calcein AM assay	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	Apoptosis-inducing effects of distichamine and narciprimine, rare alkaloids of the plant family Amaryllidaceae.
AID1570262	Inhibition of AChE (unknown origin)	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	Triazole derivatives as inhibitors of Alzheimer's disease: Current developments and structure-activity relationships.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID422295	Inhibition of AChE by spectrophotometry	2009	Journal of natural products, Mar-27, Volume: 72, Issue:3	Antioxidant and anticholinesterase activity evaluation of ent-kaurane diterpenoids from Sideritis arguta.
AID566384	Inhibition of horse serum BChE after 2 mins by Ellman's reaction	2010	Journal of natural products, Nov-29, Volume: 73, Issue:11	Citrusosides A-D and furanocoumarins with cholinesterase inhibitory activity from the fruit peels of Citrus hystrix.
AID1498463	Inhibition of horse serum BChE at 12.5 ug using butyrylthiocholine chloride as substrate preincubated for 15 mins followed by substrate addition measured every 5 mins for 15 mins by spectrophotometric method relative to control	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	A cascade synthesis, in vitro cholinesterases inhibitory activity and docking studies of novel Tacrine-pyranopyrazole derivatives.
AID437954	Antibacterial activity against Staphylococcus aureus at 1 mg/mL after 18 hrs by disc diffusion assay	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis, spectral characterization and biological evaluation of phosphorylated derivatives of galanthamine.
AID365699	Inhibition of BchE	2008	Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16	Solid-phase synthesis and biological evaluation of a parallel library of 2,3-dihydro-1,5-benzothiazepines.
AID47967	Effective dose required for the reversal of vecuronium-induced neuromuscular block in-vivo in Chloaralose anaesthetised cats; NT denotes not tested	2002	Bioorganic & medicinal chemistry letters, Sep-16, Volume: 12, Issue:18	Quaternary salts of E2020 analogues as acetylcholinesterase inhibitors for the reversal of neuromuscular block.
AID407780	Inhibition of human AChE	2008	Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11	Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors.
AID422296	Inhibition of BChE by spectrophotometry	2009	Journal of natural products, Mar-27, Volume: 72, Issue:3	Antioxidant and anticholinesterase activity evaluation of ent-kaurane diterpenoids from Sideritis arguta.
AID1594568	Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition by Ellman's method	2019	Bioorganic & medicinal chemistry letters, 06-01, Volume: 29, Issue:11	Design, synthesis, evaluation and molecular modeling study of 4-N-phenylaminoquinolines for Alzheimer disease treatment.
AID1076764	Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of glutamate-induced toxicity by measuring cell viability at 100 uM pretreated for 24 hrs followed by glutamate challenge measured after 24 hrs by MTT assay rel	2014	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6	Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
AID1339189	Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition by Ellman's method	2017	Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4	Synthesis, anticholinesterase activity and molecular modeling study of novel carbamate-substituted thymol/carvacrol derivatives.
AID1498457	Inhibition of electric eel AChE at 0.391 ug using acetylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition measured every 5 mins for 15 mins by spectrophotometric method relative to control	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	A cascade synthesis, in vitro cholinesterases inhibitory activity and docking studies of novel Tacrine-pyranopyrazole derivatives.
AID1129233	Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 15 mins by spectrophotometer analysis	2014	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7	Synthesis and discovery of highly functionalized mono- and bis-spiro-pyrrolidines as potent cholinesterase enzyme inhibitors.
AID32109	Inhibitory dose for anticholinesterase activity by ex vivo determination in rat forebrain after intraperitoneal administration	1994	Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5	Novel [2-(4-piperidinyl)ethyl](thio)ureas: synthesis and antiacetylcholinesterase activity.
AID1400273	Selectivity index, ratio of IC50 for electric eel AChE to IC50 for equine serum BuChE	2018	Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17	Design, synthesis, and biological evaluation of selective and potent Carbazole-based butyrylcholinesterase inhibitors.
AID754041	Selectivity index, ratio of IC50 for equine serum BChE to IC50 for electric eel AChE	2013	European journal of medicinal chemistry, Jun, Volume: 64	Design, synthesis and evaluation of novel tacrine-coumarin hybrids as multifunctional cholinesterase inhibitors against Alzheimer's disease.
AID241692	Inhibitory concentration against human erythrocyte Acetylcholinesterase	2005	Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4	Novel anticholinesterases based on the molecular skeletons of furobenzofuran and methanobenzodioxepine.
AID315115	Inhibition of electric eel acetylcholinesterase	2008	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 18, Issue:7	N-Alkylated galanthamine derivatives: Potent acetylcholinesterase inhibitors from Leucojum aestivum.
AID1332254	Inhibition of acetylcholinesterase (unknown origin) assessed as reduction in formation of 5-thio-2-nitrobenzoate from acetylthiocholine iodide preincubated for 15 mins followed by substrate addition measured after 30 mins by Ellman's method	2017	Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2	Design and synthesis of new piperidone grafted acetylcholinesterase inhibitors.
AID1317852	Inhibition of electric eel AChE preincubated for 5 mins followed by addition of acetylthiocholine iodide as substrate measured after 2 mins by Ellman's method	2016	European journal of medicinal chemistry, Aug-25, Volume: 119	Synthesis and screening of triazolopyrimidine scaffold as multi-functional agents for Alzheimer's disease therapies.
AID175558	Effect after an intraperitoneal dose of 1.0 mg/kg on amnesia induced in passive avoidance test in rats by Scopolamine	1994	Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5	Novel [2-(4-piperidinyl)ethyl](thio)ureas: synthesis and antiacetylcholinesterase activity.
AID480453	Inhibition of dexamethasone-induced human NR1-1a/NR2A receptor-mediated excitotoxicity in (S)-glutamate/glycine-stimulated mouse L12-G10 cells assessed as LDH release after 30 mins	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.
AID688348	Cytotoxicity against human MCF7 cells after 72 hrs by Calcein AM assay	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	Apoptosis-inducing effects of distichamine and narciprimine, rare alkaloids of the plant family Amaryllidaceae.
AID421516	Selectivity ratio of IC50 for equine serum BuChE to IC50 for electric eel AChE	2009	European journal of medicinal chemistry, Jun, Volume: 44, Issue:6	Synthesis, biological evaluation and molecular modeling of oxoisoaporphine and oxoaporphine derivatives as new dual inhibitors of acetylcholinesterase/butyrylcholinesterase.
AID1231568	Inhibition of acetylcholinesterase (unknown origin) assessed as AChI hydrolysis using AChI and DTNB as substrate by Ellman's method	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Discovery of potent carbonic anhydrase and acetylcholine esterase inhibitors: novel sulfamoylcarbamates and sulfamides derived from acetophenones.
AID1861405	Inhibition of Equine serum BuChE using S-butyrylthiocholine iodide as a substrate and measured for 125 sec by DTNB based Ellman's method	2022	Bioorganic & medicinal chemistry, 08-15, Volume: 68	Evaluation of chromane derivatives: Promising privileged scaffolds for lead discovery within Alzheimer's disease.
AID729525	Selectivity index, ratio of IC50 for equine serum BuChE to IC50 for AChE (unknown origin)	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	Synthesis and discovery of novel piperidone-grafted mono- and bis-spirooxindole-hexahydropyrrolizines as potent cholinesterase inhibitors.
AID1739254	Inhibition of BuChE (unknown origin) preincubated for 30 mins followed by substrate addition acetylthiocholineiodide measured after 40 mins by Ellman's method	2020	European journal of medicinal chemistry, Aug-15, Volume: 200	Simple analogues of natural product chelerythrine: Discovery of a novel anticholinesterase 2-phenylisoquinolin-2-ium scaffold with excellent potency against acetylcholinesterase.
AID1567162	Inhibition of human recombinant BuChE at 25 uM using butyrylthiocholine iodide as substrate preincubated for 20 mins followed by substrate addition by Ellman's spectrophotometric method relative to control	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Discovery of novel benzofuran-based compounds with neuroprotective and immunomodulatory properties for Alzheimer's disease treatment.
AID294501	Inhibition of AChE	2007	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 17, Issue:8	Methyl 2-(2-(4-formylphenoxy)acetamido)-2-substituted acetate derivatives: a new class of acetylcholinesterase inhibitors.
AID302143	Inhibition of Electrophorus electricus AChE by Ellman's method	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	New potent acetylcholinesterase inhibitors in the tetracyclic triterpene series.
AID421514	Inhibition of electric eel AChE by Ellman's method	2009	European journal of medicinal chemistry, Jun, Volume: 44, Issue:6	Synthesis, biological evaluation and molecular modeling of oxoisoaporphine and oxoaporphine derivatives as new dual inhibitors of acetylcholinesterase/butyrylcholinesterase.
AID635414	Inhibition of electric eel AChE using acetylcholine chloride as substrate preincubated for 15 mins by Ellman's method	2011	Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23	Benzenediol-berberine hybrids: multifunctional agents for Alzheimer's disease.
AID1070087	Selectivity ratio of IC50 for equine serum BChE to IC50 for AChE (unknown origin)	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Ionic liquid mediated synthesis of mono- and bis-spirooxindole-hexahydropyrrolidines as cholinesterase inhibitors and their molecular docking studies.
AID1861404	Inhibition of electric eel AChE using acetylcholine iodide as a substrate and measured for 125 sec by DTNB based Ellman's method	2022	Bioorganic & medicinal chemistry, 08-15, Volume: 68	Evaluation of chromane derivatives: Promising privileged scaffolds for lead discovery within Alzheimer's disease.
AID298278	Inhibition of human recombinant acetylcholinesterase	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease.
AID437960	Antibacterial activity against Escherichia coli at 2 mg/mL after 18 hrs by disc diffusion assay	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis, spectral characterization and biological evaluation of phosphorylated derivatives of galanthamine.
AID1657598	Effective permeability of the compound at pH 7.4 at 100 uM measured after 3 to 6 hrs by PAMPA assay	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Aromatic Esters of the Crinane Amaryllidaceae Alkaloid Ambelline as Selective Inhibitors of Butyrylcholinesterase.
AID1070088	Selectivity index, ratio of IC50 for AChE (unknown origin) to IC50 for equine serum BChE	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Ionic liquid mediated synthesis of mono- and bis-spirooxindole-hexahydropyrrolidines as cholinesterase inhibitors and their molecular docking studies.
AID437959	Antibacterial activity against Bacillus subtilis at 2 mg/mL after 18 hrs by disc diffusion assay	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis, spectral characterization and biological evaluation of phosphorylated derivatives of galanthamine.
AID749373	Inhibition of electric eel AChE using acetylcholine iodide as substrate incubated for 15 mins prior to substrate addition measured after 30 mins by Ellman's method	2013	Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11	Microwave assisted synthesis, cholinesterase enzymes inhibitory activities and molecular docking studies of new pyridopyrimidine derivatives.
AID694074	Inhibition of human recombinant BChE using acetylthiocholine as substrate	2012	Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22	Design, synthesis, and bioevaluation of benzamides: novel acetylcholinesterase inhibitors with multi-functions on butylcholinesterase, Aβ aggregation, and β-secretase.
AID31964	In vitro inhibitory effect on rat Acetylcholinesterase	1995	Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15	Flexible 1-[(2-aminoethoxy)alkyl]-3-ar(o)yl(thio)ureas as novel acetylcholinesterase inhibitors. Synthesis and biochemical evaluation.
AID446351	Inhibition of human recombinant AChE	2010	Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2	Probing Torpedo californica acetylcholinesterase catalytic gorge with two novel bis-functional galanthamine derivatives.
AID30543	Compound was assessed for in vitro inhibition of Acetylcholinesterase isolated from Electrophorus electricus	2000	Bioorganic & medicinal chemistry letters, Apr-03, Volume: 10, Issue:7	Potent acetylcholinesterase inhibitors: design, synthesis and structure-activity relationships of alkylene linked bis-galanthamine and galanthamine-galanthaminium salts.
AID1631831	Selectivity ratio of IC50 for human plasma BuChE to IC50 for human erythrocyte AChE	2016	Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16	Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1356517	Inhibition of BChE (unknown origin) using butyrylthiocholine iodide as substrate pretreated for 15 mins followed by substrate addition and measured by DTNB reagent based assay relative to control	2018	Journal of natural products, 08-24, Volume: 81, Issue:8	A Bioactive Resveratrol Trimer from the Stem Bark of the Sri Lankan Endemic Plant Vateria copallifera.
AID1073062	Inhibition of Electric eel AChE assessed as amount of thiocholine released using acetylthiocholine iodide as substrate after 6 mins by Ellman's method	2014	Journal of natural products, Mar-28, Volume: 77, Issue:3	Chemical composition of the bark of Tetrapterys mucronata and identification of acetylcholinesterase inhibitory constituents.
AID1556710	Inhibition of AChE in human erythrocytes using acetylthiocholine iodide as substrate preincubated with enzyme for 10 mins followed by substrate addition measured for 15 mins by Ellman's method	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Carboxamides vs. methanimines: Crystal structures, binding interactions, photophysical studies, and biological evaluation of (indazole-5-yl)methanimines as monoamine oxidase B and acetylcholinesterase inhibitors.
AID1886771	Cognitive enhancing effect in amyloid beta (1 to 42)-induced ICR mouse model assessed as reduction in latency at 2.5 mg/kg, icv measured on day 14 by Morris Water maze method
AID1657597	Selectivity index, ratio of IC50 for inhibition of human AChE using acetylthiocholine iodide as substrate to inhibition of human BuChE using butyrylthiocholine iodide as substrate	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Aromatic Esters of the Crinane Amaryllidaceae Alkaloid Ambelline as Selective Inhibitors of Butyrylcholinesterase.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1865085	Inhibition of human recombinant BuChe using butyrylthiocholine iodide as substrate incubated for 10 mins by DTNB reagent based Ellman's method
AID1076775	Neuroprotective activity in Sprague-Dawley rat primary cortical neurons assessed as inhibition of amyloid beta 1 to 42-induced toxicity by measuring cell viability at 100 uM pretreated for 24 hrs followed by amyloid beta 1 to 42 challenge measured after 2	2014	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6	Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
AID1537274	Inhibition of POP (unknown origin) using (Z)-Gly-Pro-p-nitroanilide as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by spectrophotometric method	2019	Journal of natural products, 02-22, Volume: 82, Issue:2	Isoquinoline Alkaloids from Berberis vulgaris as Potential Lead Compounds for the Treatment of Alzheimer's Disease.
AID1366160	Antibacterial activity against Staphylococcus aureus incubated overnight by two-fold serial dilution method	2017	Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22	Antibacterial constituents of the plant family Amaryllidaceae.
AID1498456	Inhibition of electric eel AChE at 0.195 ug using acetylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition measured every 5 mins for 15 mins by spectrophotometric method relative to control	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	A cascade synthesis, in vitro cholinesterases inhibitory activity and docking studies of novel Tacrine-pyranopyrazole derivatives.
AID1634699	Inhibition of electric eel AChE using acetylthiocholine iodide as substrate measured every 13 secs by Ellman's method	2016	Journal of natural products, Apr-22, Volume: 79, Issue:4	Galanthamine, Plicamine, and Secoplicamine Alkaloids from Zephyranthes candida and Their Anti-acetylcholinesterase and Anti-inflammatory Activities.
AID284418	Inhibition of eel AChE	2007	Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2	Preparation of secolycorines against acetylcholinesterase.
AID241560	Inhibitory concentration against human plasma Butyrylcholinesterase	2005	Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4	Novel anticholinesterases based on the molecular skeletons of furobenzofuran and methanobenzodioxepine.
AID746380	Inhibition of AChE (unknown origin) at 2 uM by Ellman method	2013	Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9	Design, synthesis and biological activity of multifunctional α,β-unsaturated carbonyl scaffolds for Alzheimer's disease.
AID1537276	Inhibition of GSK3B (unknown origin) at 10 uM relative to control	2019	Journal of natural products, 02-22, Volume: 82, Issue:2	Isoquinoline Alkaloids from Berberis vulgaris as Potential Lead Compounds for the Treatment of Alzheimer's Disease.
AID407781	Inhibition of human BuChE	2008	Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11	Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors.
AID234643	Selectivity at AChE and BChE	2002	Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17	Anticholinesterase activity of compounds related to geneserine tautomers. N-Oxides and 1,2-oxazines.
AID1186579	Inhibition of human BChE assessed as acetylthiocholine hydrolysis	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Syntheses of coumarin-tacrine hybrids as dual-site acetylcholinesterase inhibitors and their activity against butylcholinesterase, Aβ aggregation, and β-secretase.
AID1063992	Inhibition of Electrophorus electricus acetylcholinesterase using acetylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition measured for 30 mins by Ellman's method	2014	Bioorganic & medicinal chemistry, Jan-15, Volume: 22, Issue:2	Cholinesterase inhibitory activity versus aromatic core multiplicity: a facile green synthesis and molecular docking study of novel piperidone embedded thiazolopyrimidines.
AID271050	Selectivity for horse serum BChE over electric eel AChE	2006	Journal of medicinal chemistry, Sep-07, Volume: 49, Issue:18	Homobivalent quinazolinimines as novel nanomolar inhibitors of cholinesterases with dirigible selectivity toward butyrylcholinesterase.
AID1682145	Inhibition of acetylcholinesterase (unknown origin)	2020	Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24	Pyridine alkaloids with activity in the central nervous system.
AID1140465	Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated with enzyme for 6 mins followed by substrate addition by Ellman's method	2014	Bioorganic & medicinal chemistry letters, May-15, Volume: 24, Issue:10	Design, synthesis and biological evaluation of benzylisoquinoline derivatives as multifunctional agents against Alzheimer's disease.
AID482723	Inhibition of AChE assessed as minimum drug level causing white zone of enzyme inhibition by TLC bioautography	2010	Journal of natural products, May-28, Volume: 73, Issue:5	Semisynthesis and acetylcholinesterase inhibitory activity of stemofoline alkaloids and analogues.
AID1273004	Inhibition of electric eel AChE using ATC as substrate preincubated for 5 mins followed by substrate addition measured after 2 mins by Ellman's assay	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Ferulic acid-carbazole hybrid compounds: Combination of cholinesterase inhibition, antioxidant and neuroprotection as multifunctional anti-Alzheimer agents.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1811	Experimentally measured binding affinity data derived from PDB	2001	Proteins, Feb-01, Volume: 42, Issue:2	Three-dimensional structure of a complex of galanthamine (Nivalin) with acetylcholinesterase from Torpedo californica: implications for the design of new anti-Alzheimer drugs.
AID977608	Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB	2001	Proteins, Feb-01, Volume: 42, Issue:2	Three-dimensional structure of a complex of galanthamine (Nivalin) with acetylcholinesterase from Torpedo californica: implications for the design of new anti-Alzheimer drugs.
AID1802055	In vitro AChE and BChE Assay from Article 10.1016/j.bioorg.2016.10.002: \\Rational design and synthesis of dihydropyrimidine based dual binding site acetylcholinesterase inhibitors.\\	2016	Bioorganic chemistry, 12, Volume: 69	Rational design and synthesis of dihydropyrimidine based dual binding site acetylcholinesterase inhibitors.
AID1799735	Cholinesterase Inhibition Assay from Article 10.1080/14756360802236393: \\Butyrylcholinesterase inhibitory activity of testosterone and some of its metabolites.\\	2009	Journal of enzyme inhibition and medicinal chemistry, Apr, Volume: 24, Issue:2	Butyrylcholinesterase inhibitory activity of testosterone and some of its metabolites.
AID1802058	Cholinesterase Inhibition Assay from Article 10.1111/cbdd.12773: \\Novel N-allyl/propargyl tetrahydroquinolines: Synthesis via Three-component Cationic Imino Diels-Alder Reaction, Binding Prediction, and Evaluation as Cholinesterase Inhibitors.\\	2016	Chemical biology & drug design, 10, Volume: 88, Issue:4	Novel N-allyl/propargyl tetrahydroquinolines: Synthesis via Three-component Cationic Imino Diels-Alder Reaction, Binding Prediction, and Evaluation as Cholinesterase Inhibitors.
AID1802597	Cholinesterase Inhibition Assay from Article 10.1016/j.bioorg.2017.02.010: \\Synthesis of readily available fluorophenylalanine derivatives and investigation of their biological activity.\\	2017	Bioorganic chemistry, 04, Volume: 71	Synthesis of readily available fluorophenylalanine derivatives and investigation of their biological activity.
AID1799683	Enzyme Inhibition Assay from Article 10.1080/14756360600889708: \\New natural cholinesterase inhibiting and calcium channel blocking quinoline alkaloids.\\	2006	Journal of enzyme inhibition and medicinal chemistry, Dec, Volume: 21, Issue:6	New natural cholinesterase inhibiting and calcium channel blocking quinoline alkaloids.
AID1802939	Acetylcholinesterase Inhibition Assay from Article 10.3109/14756360903213481: \\Nostotrebin 6, a bis(cyclopentenedione) with cholinesterase inhibitory activity isolated from Nostoc sp. str. Lukesovu00E1 27/97.\\	2010	Journal of enzyme inhibition and medicinal chemistry, Jun, Volume: 25, Issue:3	Nostotrebin 6, a bis(cyclopentenedione) with cholinesterase inhibitory activity isolated from Nostoc sp. str. Lukesová 27/97.
AID1797821	In vitro BuChE Inhibition Assay from Article 10.1021/jm070536w: \\New potent acetylcholinesterase inhibitors in the tetracyclic triterpene series.\\	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	New potent acetylcholinesterase inhibitors in the tetracyclic triterpene series.
AID1796450	Enzyme Inhibition Assay from Article 10.1021/ja0466154: \\The complex of a bivalent derivative of galanthamine with torpedo acetylcholinesterase displays drastic deformation of the active-site gorge: implications for structure-based drug design.\\	2004	Journal of the American Chemical Society, Dec-01, Volume: 126, Issue:47	The complex of a bivalent derivative of galanthamine with torpedo acetylcholinesterase displays drastic deformation of the active-site gorge: implications for structure-based drug design.
AID1796451	Enzyme Inhibition Assay from Article 10.1016/s0968-0896(98)00133-3: \\Potent acetylcholinesterase inhibitors: design, synthesis, and structure-activity relationships of bis-interacting ligands in the galanthamine series.\\	1998	Bioorganic & medicinal chemistry, Oct, Volume: 6, Issue:10	Potent acetylcholinesterase inhibitors: design, synthesis, and structure-activity relationships of bis-interacting ligands in the galanthamine series.
AID1800998	Ellman's Method from Article 10.1016/j.bioorg.2014.11.005: \\Salicylanilide diethyl phosphates as cholinesterases inhibitors.\\	2015	Bioorganic chemistry, Feb, Volume: 58	Salicylanilide diethyl phosphates as cholinesterases inhibitors.
AID1801810	AChE Inhibitory Assay from Article 10.1111/cbdd.12732: \\Synthesis, Biological Evaluation, and Molecular Docking of 8-imino-2-oxo-2H,8H-pyrano[2,3-f]chromene Analogs: New Dual AChE Inhibitors as Potential Drugs for the Treatment of Alzheimer's Disease.	2016	Chemical biology & drug design, 07, Volume: 88, Issue:1	Synthesis, Biological Evaluation, and Molecular Docking of 8-imino-2-oxo-2H,8H-pyrano[2,3-f]chromene Analogs: New Dual AChE Inhibitors as Potential Drugs for the Treatment of Alzheimer's Disease.
AID1802080	Cholinesterase Inhibition Assay from Article 10.1111/cbdd.12800: \\Structure-activity relationship studies of benzyl-, phenethyl-, and pyridyl-substituted tetrahydroacridin-9-amines as multitargeting agents to treat Alzheimer's disease.\\	2016	Chemical biology & drug design, 11, Volume: 88, Issue:5	Structure-activity relationship studies of benzyl-, phenethyl-, and pyridyl-substituted tetrahydroacridin-9-amines as multitargeting agents to treat Alzheimer's disease.
AID1796482	Cholinesterase Inhibition Assay from Article 10.1021/jm050578p: \\Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine.\\	2006	Journal of medicinal chemistry, Apr-06, Volume: 49, Issue:7	Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine.
AID1796572	Cholinesterase Inhibition Assay from Article 10.1021/jm010491d: \\Anticholinesterase activity of compounds related to geneserine tautomers. N-Oxides and 1,2-oxazines.\\	2002	Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17	Anticholinesterase activity of compounds related to geneserine tautomers. N-Oxides and 1,2-oxazines.
AID1802583	AChE/BChE Inhibition Assay from Article 10.1016/j.bioorg.2017.01.004: \\Synthesis, biological evaluation and docking studies of 2,3-dihydroquinazolin-4(1H)-one derivatives as inhibitors of cholinesterases.\\	2017	Bioorganic chemistry, 02, Volume: 70	Synthesis, biological evaluation and docking studies of 2,3-dihydroquinazolin-4(1H)-one derivatives as inhibitors of cholinesterases.
AID1801040	Anticholinesterase Activity Assays from Article 10.1016/j.bioorg.2015.02.002: \\Synthesis, antioxidant and anticholinesterase activities of novel coumarylthiazole derivatives.\\	2015	Bioorganic chemistry, Apr, Volume: 59	Synthesis, antioxidant and anticholinesterase activities of novel coumarylthiazole derivatives.
AID1801888	EqBuChE Inhibition Assay from Article 10.1016/j.bioorg.2016.05.004: \\New cholinesterase inhibitors for Alzheimer's disease: Structure Activity Studies (SARs) and molecular docking of isoquinolone and azepanone derivatives.\\	2016	Bioorganic chemistry, 08, Volume: 67	New cholinesterase inhibitors for Alzheimer's disease: Structure Activity Studies (SARs) and molecular docking of isoquinolone and azepanone derivatives.
AID1797820	In Vitro AChE Inhibition Assay from Article 10.1021/jm070536w: \\New potent acetylcholinesterase inhibitors in the tetracyclic triterpene series.\\	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	New potent acetylcholinesterase inhibitors in the tetracyclic triterpene series.
AID1801887	EeAChE Inhibition Assay from Article 10.1016/j.bioorg.2016.05.004: \\New cholinesterase inhibitors for Alzheimer's disease: Structure Activity Studies (SARs) and molecular docking of isoquinolone and azepanone derivatives.\\	2016	Bioorganic chemistry, 08, Volume: 67	New cholinesterase inhibitors for Alzheimer's disease: Structure Activity Studies (SARs) and molecular docking of isoquinolone and azepanone derivatives.
AID1802975	Enzyme Inhibition Assay from Article 10.3109/14756361003671078: \\Nantenine as an acetylcholinesterase inhibitor: SAR, enzyme kinetics and molecular modeling investigations.\\	2011	Journal of enzyme inhibition and medicinal chemistry, Feb, Volume: 26, Issue:1	Nantenine as an acetylcholinesterase inhibitor: SAR, enzyme kinetics and molecular modeling investigations.
AID1811	Experimentally measured binding affinity data derived from PDB	1999	FEBS letters, Dec-17, Volume: 463, Issue:3	Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution.
AID977608	Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB	1999	FEBS letters, Dec-17, Volume: 463, Issue:3	Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution.
AID1345946	Human acetylcholinesterase (Cartwright blood group) (Hydrolases)	2002	Bioorganic & medicinal chemistry letters, Sep-16, Volume: 12, Issue:18	Quaternary salts of E2020 analogues as acetylcholinesterase inhibitors for the reversal of neuromuscular block.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	248 (14.49)	18.7374
1990's	49 (2.86)	18.2507
2000's	625 (36.53)	29.6817
2010's	624 (36.47)	24.3611
2020's	165 (9.64)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Trials	209 (11.15%)	5.53%
Reviews	0 (0.00%)	6.00%
Reviews	266 (14.19%)	6.00%
Case Studies	0 (0.00%)	4.05%
Case Studies	47 (2.51%)	4.05%
Observational	0 (0.00%)	0.25%
Observational	10 (0.53%)	0.25%
Other	7 (100.00%)	84.16%
Other	1,342 (71.61%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (95)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Dr.Reddy's Laboratories, Ltd. and Janssen Pharmaceutical Products, l.P. (Reminyl®)4 mg Galantamine HBr Tablets in Healthy Adult Male Volunteers Under Fed Conditions [NCT01372306]	Phase 1	24 participants (Actual)	Interventional	2004-10-31	Completed
Evaluation of Three Potential CNS Pretreatments for Soman Exposure - Huperzine A, Donepezil, and Galantamine - on Human Performance [NCT01194336]		84 participants (Actual)	Observational	2012-02-29	Completed
Randomized, 2-Way Crossover, Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fasting Conditions [NCT01190748]	Phase 1	24 participants (Actual)	Interventional	2004-11-30	Completed
Galantamine Treatment for Nonfluent Aphasia in Stroke Patients [NCT01129479]		8 participants (Actual)	Interventional	2004-10-31	Completed
An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms [NCT00161044]		20 participants	Interventional	2004-09-30	Completed
Oxytocin or Galantamine vs. Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia [NCT01012167]	Phase 2	86 participants (Actual)	Interventional	2010-02-28	Completed
A Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease in Long Term Care Setting [NCT02035982]	Phase 3	40 participants (Actual)	Interventional	2010-07-31	Completed
Enhancing Parasympathetic Activity to Improve Endothelial Dysfunction, Vascular Oxidative Stress in African Americans [NCT04769206]	Phase 1/Phase 2	88 participants (Anticipated)	Interventional	2021-12-20	Recruiting
Symptomatic Treatment of Vascular Cognitive Impairment [NCT02098824]	Phase 2/Phase 3	30 participants (Anticipated)	Interventional	2014-02-28	Recruiting
Effects of Cholinergic Stimulation on Visceral Fat, Oxidative Stress and Inflammatory Markers in Patients With Metabolic Syndrome: a Randomized Clinical Trial [NCT02283242]	Phase 4	60 participants (Actual)	Interventional	2014-03-31	Completed
Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Dr. Reddy's Laboratories, Ltd. and Janssen Pharmaceutical Products, l.P. (Reminyl®)4 mg Galantamine HBr Tablets in Healthy Adult Male Volunteers Under Fasting Conditions [NCT01372280]	Phase 1	28 participants (Actual)	Interventional	2004-10-31	Completed
Randomized, 2-Way Crossover, Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fed Conditions [NCT01190761]	Phase 1	24 participants (Actual)	Interventional	2004-12-31	Completed
Galantamine Effects on Nicotine Responses in Smokers [NCT01417429]	Phase 1	12 participants (Actual)	Interventional	2010-03-31	Completed
Effects of Galantamine and Donépézil on the Amount and the Quality oh the Sleep in Patients Suffering From Alzheimer Disease. [NCT00750529]	Phase 1	15 participants (Actual)	Interventional	2008-11-30	Completed
The Efficacy and Safety of Galantamine for Dysfunction in Bipolar Disorder [NCT00741598]	Phase 4	72 participants (Actual)	Interventional	2008-09-30	Completed
A Randomized, Double-Blind, Placebo-controlled Trial of Long-term (2-year) Treatment of Galantamine in Mild to Moderately-Severe Alzheimer's Disease [NCT00679627]	Phase 3	2,051 participants (Actual)	Interventional	2008-06-30	Terminated(stopped due to Due to a pre-specified imbalance of deaths between treatment groups, the DSMB recommended early termination of the trial)
Interventions to Test the Alpha7 Nicotinic Receptor Model in Schizophrenia [NCT00509067]	Phase 2	43 participants (Actual)	Interventional	2007-11-30	Completed
Galantamine Effects on Cognitive Function in Marijuana Users [NCT00969696]	Phase 1	29 participants (Actual)	Interventional	2009-08-31	Completed
A Bioequivalent Study to Compare Galantamine Oral Solution With Marketed Galantamine Capsule After Single Oral Administration of 10 mg. [NCT00645554]	Phase 1	2 participants (Actual)	Interventional		Completed
Non-interventional Study on Long-term Application of Galantamine and Nootropics in Patients With Alzheimer's Disease [NCT01009476]		1,134 participants (Actual)	Observational	2006-03-31	Completed
The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning [NCT00566735]	Phase 3	39 participants (Actual)	Interventional	2004-07-31	Completed
Characteristics of Treatment Responders to Galantamine Administration in the Patients With Alzheimer's Disease [NCT01029132]		66 participants (Actual)	Interventional	2007-04-30	Completed
A Prospective, Open-labeled, Multicenter Study of Galantamine on the Attention and Frontal Function of the Patients With Dementia of Alzheimer Type [NCT00216515]	Phase 4	102 participants (Actual)	Interventional	2004-03-31	Completed
Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse With Methadone Maintained Individuals [NCT00809835]	Phase 2	120 participants (Actual)	Interventional	2007-12-31	Completed
The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life [NCT00814658]	Phase 4	22 participants (Actual)	Interventional	2008-06-30	Completed
Phase IV Study for the Assessment of Modulating Effect of Galantamine (Reminyl PRC) on Circadian Rhythm in Patients With Moderate Alzheimer's Disease [NCT01181921]	Phase 4	1 participants (Actual)	Interventional	2011-05-31	Terminated(stopped due to The recruitment rate was very low (one screening failure and one early withdrawal patient))
A Randomized, Double Blind, Active Control, Flexible Dose, Multicenter Study to Evaluate Galantamine HBr in the Treatment of Alzheimer's Disease:Safety and Effectiveness of an Immediate-release Table Formulation. [NCT00645190]	Phase 3	215 participants (Actual)	Interventional	2004-03-31	Completed
Evaluation of Efficacy and Safety of Galantamine in Subjects With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil [NCT01478633]	Phase 4	102 participants (Actual)	Interventional	2011-09-30	Completed
Galantamine Augmentation of Escitalopram for Treatment of Depression Associated Cognitive Impairment in Outpatients - A Randomized Single Blind Clinical Trial [NCT00423969]	Phase 4	20 participants	Interventional	2003-11-30	Terminated
Galantamine Effects on Cognitive Function in Abstinent Cocaine Users [NCT00606801]		34 participants (Actual)	Interventional	2007-06-30	Completed
Vagal Stimulation in POTS - The Autonomic Inflammatory Reflex (Pilot 3) [NCT03124355]	Phase 1	11 participants (Actual)	Interventional	2017-09-30	Active, not recruiting
"Competence Network - Dementia (BMBF) Pharmacological and Psychosocial Treatment (Modul E.2) Part II: The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease" [NCT01921972]	Phase 4	232 participants (Actual)	Interventional	2004-11-30	Completed
Placebo Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy Under a Slow-Titration Regimen [NCT00000172]	Phase 3	0 participants	Interventional		Completed
Diffusion Tensor Weighted MRI in Alzheimer's Disease: Prediction and Mapping of Symptomatic and Disease Modifying Treatment Effects of Galantamine (Reminyl®) [NCT00523666]	Phase 4	20 participants (Anticipated)	Interventional	2006-09-30	Recruiting
A Study of the Effect of Concomitant Administration of Multiple Doses of BMS-708163 on the Pharmacokinetics of Galantamine in Healthy Subjects [NCT01039194]	Phase 1	18 participants (Actual)	Interventional	2010-01-31	Completed
A Phase 4 Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder [NCT00195845]	Phase 4	30 participants (Anticipated)	Interventional	2003-04-30	Completed
Comparison of Therapeutic Strategies With Cholinesterase Inhibitors: Stop or Still (SOS) Trial [NCT03454646]	Phase 4	1,205 participants (Anticipated)	Interventional	2024-06-01	Not yet recruiting
Pilot Examination of Galantamine in the Management of Tic Disorders [NCT00226824]	Phase 4	1 participants (Actual)	Interventional	2005-09-30	Terminated(stopped due to Unable to recruit subjects into the trial.)
An Open Label 24-Week, Flexible Dose Trial to Assess the Safety and Efficacy of Galantamine in Patients With Dementia With Lewy Bodies [NCT00230997]	Phase 3	50 participants	Interventional	2002-12-31	Completed
A Double-blind, Randomized Pilot Study to Evaluate the Effects of Galantamine and Donepezil on Sleep and Attention and Gastrointestinal (GI) Tolerance in Patients With Mild to Moderate Alzheimer's Disease (AD) [NCT00035204]	Phase 4	63 participants (Actual)	Interventional		Completed
Lewy Body Spectrum Disorders: Investigating Neuropsychiatric Benefit and Adverse Effects in Response to Cholinesterase Inhibitors Using Genetics and Brain SPECT [NCT01944436]		57 participants (Actual)	Observational	2006-09-30	Completed
Effects of Galantamine on Cognition [NCT01100775]	Phase 2	12 participants (Actual)	Interventional	2010-05-31	Completed
Galantamine in the Preventive Treatment of Chronic Post-Traumatic Headache [NCT00219869]	Phase 4	30 participants	Interventional	2005-07-31	Recruiting
Galantamine Versus Placebo in Childhood Autism [NCT00252603]	Phase 3	20 participants	Interventional	2004-04-30	Completed
Efficacy, Tolerability and Safety of Galantamine in the Treatment of Alzheimer's Disease [NCT00253188]	Phase 3	653 participants (Actual)	Interventional	1997-02-28	Completed
Galantamine in the Treatment of Alzheimer's Disease: Flexible Dose Range Trial [NCT00253227]	Phase 3	387 participants (Actual)	Interventional	1997-07-31	Completed
Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: A Cardiac Safety Study. [NCT00309725]	Phase 3	139 participants (Actual)	Interventional		Completed
Placebo-controlled Confirmatory Study of Galantamine (R113675) for Alzheimer's Type Dementia [NCT00814801]	Phase 3	580 participants (Actual)	Interventional	2007-02-28	Completed
Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD) [NCT00637442]		30 participants (Anticipated)	Interventional	2008-02-29	Active, not recruiting
Phase IV Study of General Clinical Research Center Of the Jinan Mental Hospital(TAIWAN) [NCT00626613]	Phase 4	0 participants	Interventional		Active, not recruiting
A Randomized 26-Week, Double-Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular Dementia [NCT00035191]	Phase 3	254 participants (Actual)	Interventional	2001-10-31	Completed
Randomized Controlled Trial of Galantamine, Methylphenidate, and Placebo for the Treatment of Cognitive Symptoms in Patients With Traumatic Brain Injury (TBI) and/or Posttraumatic Stress Disorder (PTSD) [NCT01416948]	Phase 2	32 participants (Actual)	Interventional	2011-08-31	Terminated(stopped due to The funding agency, DoD, determined that the study could not meet its enrollment numbers by the end of the grant.)
A Double-Blind Comparison of Galantamine HBr and Placebo in Adults With Attention Deficit Hyperactivity Disorder [NCT00181675]	Phase 4	40 participants	Interventional	2002-12-31	Completed
A European Multi-Center Study to Determine the Safety and Efficacy of Galanthamine Hydrobromide 40mg/Day (32 mg /Day GAL Base, Tid Dose Regimen) in Patients Diagnosed With Alzheimer-Type Dementia [NCT00338117]	Phase 3	554 participants (Actual)	Interventional	1995-08-31	Completed
Targeting the Cholinergic Pathway in HIV-associated Inflammation and Cognitive Dysfunction [NCT03384784]	Phase 2	114 participants (Actual)	Interventional	2017-10-30	Completed
An Open Pilot Study to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Pick's Disease/Frontotemporal Dementia /Pick Complex [NCT00416169]	Phase 2	41 participants (Actual)	Interventional	2003-05-31	Completed
A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Clinically Probable Alzheimer's Disease [NCT00236431]	Phase 3	1,063 participants (Actual)	Interventional	2001-05-31	Completed
Efficacy, Tolerability and Safety of Galantamine in the Treatment of Alzheimer's Disease [NCT00253201]	Phase 3	636 participants (Actual)	Interventional		Completed
Galantamine for Cognitive Deficits in Schizophrenia [NCT00463879]	Phase 2/Phase 3	21 participants (Actual)	Interventional	2005-09-30	Completed
The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease [NCT01054976]	Phase 4	99 participants (Actual)	Interventional	2006-10-31	Completed
Investigator Initiated Study: Galantamine CR Potential Enhancement of Attentional and Executive Function in Non-Demented Patients With Parkinson's Disease [NCT00211588]		90 participants (Anticipated)	Interventional	2004-06-30	Active, not recruiting
Long Term Treatment With Galantamine In Dementia [NCT00216502]	Phase 3	254 participants (Actual)	Interventional	2001-08-31	Completed
A Study of Galantamine HBr as an Adjunctive Treatment to Atypical Antipsychotic Medications in Outpatients With Schizophrenia and Associated Cognitive Deficits. [NCT00077727]	Phase 3	107 participants (Actual)	Interventional	2003-03-31	Completed
Galantamine ER Open Label Rapid Dose Escalation Trial in Alzheimer's Disease [NCT00082602]	Phase 3	83 participants (Actual)	Interventional	2004-05-31	Completed
Treatment of Tardive Dyskinesia With Galantamine [NCT00164242]	Phase 4	36 participants	Interventional	2002-01-31	Completed
[NCT00181636]		25 participants	Interventional		Completed
Pilot Study of Galantamine and CBT4CBT to Reduce Post-taper Relapse for MAT [NCT03547622]	Early Phase 1	6 participants (Actual)	Interventional	2018-05-01	Completed
A Randomized Double Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Clinically Probable Alzheimer's Disease. [NCT00236574]	Phase 3	974 participants (Actual)	Interventional	2001-05-31	Completed
An Open-Label Trial of Adjunctive Galantamine Maintenance Therapy to Treat Functional Impairments in Chronic Outpatients With Schizophrenia [NCT00232349]	Phase 4	21 participants (Actual)	Interventional	2005-02-28	Terminated(stopped due to Study terminated due to no apparent benefit.)
The Safety and Efficacy of Galantamine in the Treatment of Vascular and Mixed Dementia [NCT00261573]	Phase 3	593 participants (Actual)	Interventional	1998-12-31	Completed
An Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Galantamine HBr in the Treatment of Mild Cognitive Impairment [NCT00240695]	Phase 3	724 participants (Actual)	Interventional	2003-05-31	Completed
Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation [NCT00253214]	Phase 3	973 participants (Actual)	Interventional	2001-03-31	Completed
An Observational Study of Clinical Outcomes and Safety Profile of Galantamine in the Treatment of Patients With Alzheimer's Disease Over an 18-month Period [NCT00299676]		61 participants (Actual)	Observational	2005-05-31	Completed
Effect of Nicotine Agonist Galantamine Added to High Potency Medications for Cognitive Function in Patients With Schizophrenia and Schizoaffective Disorder [NCT00320736]	Phase 4	20 participants	Interventional	2004-01-31	Completed
Long Term Safety and Efficacy of Galantamine in Alzheimer's Disease (Extension INT-8) [NCT00304629]	Phase 3	241 participants (Actual)	Interventional	2000-03-31	Completed
Open Observational Study of Galantamine Hydrobromide Administration for the Treatment of Patients With Mild to Moderate Dementia of the Alzheimer Type [NCT00297362]		344 participants (Actual)	Observational	2004-06-30	Completed
Placebo-Controlled, Double-Blind Study of Galantamine (R113675) in the Treatment of Alzheimer's Disease. [NCT00301574]	Phase 3	398 participants (Actual)	Interventional	2001-04-30	Completed
Evaluation de l'efficacité de la Galantamine Versus Placebo associée à Une Revalidation Neuropsychologique Chez Des Patients présentant un Trouble Cognitif après un Premier Infarctus cérébral : étude en Neuroimagerie Fonctionnelle [NCT01508494]	Phase 2	47 participants (Actual)	Interventional	2011-06-29	Completed
Treatment of Severe Alzheimer's Disease in a Residential Home, Nursing Home, or Geriatric Residential Setting: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Randomised, Doubleblind, Placebo-Controlled Study. [NCT00216593]	Phase 3	415 participants (Actual)	Interventional	2003-12-31	Completed
Comparative Effectiveness Research Trial of Alzheimer's Disease Drugs [NCT01362686]		200 participants (Actual)	Interventional	2011-04-30	Terminated(stopped due to Low study accrual caused the study to be ended early.)
Functional Neuroimaging (fMRI) Biomarker of Allosteric Nicotinic Receptor Modulation in Mild Alzheimer's Disease Patients: A Razadyne vs. Aricept Dose Escalation Trial [NCT00369603]	Phase 4	4 participants (Actual)	Interventional	2006-10-31	Terminated(stopped due to Reduced access to AchEI medication-naive mild AD patients.)
Cholinergic Enhancement as a Treatment for Nicotine Addiction [NCT01880099]		60 participants (Actual)	Interventional	2013-12-31	Completed
A Pilot Parallel Double-Blind, Randomized Trial of Galantamine for Subarachnoid Hemorrhage [NCT02872857]	Phase 1/Phase 2	60 participants (Actual)	Interventional	2016-09-30	Completed
Repurposing Cholinesterase Inhibitors for Smoking Cessation. [NCT01669538]	Phase 2	98 participants (Actual)	Interventional	2012-08-31	Completed
Racial Differences in Vagal Control of Glucose Homeostasis, Chronic Study [NCT03014323]	Phase 1	0 participants (Actual)	Interventional	2017-01-31	Withdrawn(stopped due to No fundings)
Adjunctive Galantamine for Treatment of Cognitive Impairments in Patients With Schizophrenia [NCT00176423]	Phase 4	117 participants (Actual)	Interventional	2002-05-31	Completed
Donepezil/ Galantamine in the Treatment of Post-stroke Cognitively Impaired Rehabilitating Elderly [NCT00227994]	Phase 4	40 participants (Actual)	Interventional	2003-04-30	Completed
Racial Differences in Vagal Control of Glucose Homeostasis [NCT02365285]	Phase 1/Phase 2	23 participants (Actual)	Interventional	2015-03-31	Completed
The Use of Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine [NCT02420327]		43 participants (Actual)	Interventional	2014-09-30	Completed
Cognitive Enhancement as a Target for Cocaine Pharmacotherapy [NCT01531153]		93 participants (Actual)	Interventional	2011-09-30	Completed
Pharmacovigilance in Gerontopsychiatric Patients [NCT02374567]	Phase 3	407 participants (Actual)	Interventional	2015-01-31	Terminated
The Effect of the Acetylcholinesterase Inhibitor, Galantamine, on Short-term Abstinence [NCT01548638]	Phase 2	13 participants (Actual)	Interventional	2012-02-29	Completed
A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of RO4602522 Added to Background Alzheimer's Disease Therapy in Patients With Moderate Severity Alzheimer's Disease [NCT01677754]	Phase 2	542 participants (Actual)	Interventional	2012-10-24	Completed
A Proof-of Concept Trial of Galantamine and Memantine for Cognitive Impairments in Schizophrenia: Is the Combination Effective? [NCT02234752]	Phase 2	3 participants (Actual)	Interventional	2014-09-30	Terminated(stopped due to Funding no longer available and PI no longer working at the institution)
An Observational, Multi-Center Study to Demonstrate That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease [NCT01734395]		1,882 participants (Actual)	Observational	2007-03-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00176423 (4) [back to overview]	Overall Cognitive Improvement Z-score
NCT00176423 (4) [back to overview]	ECG Changes From Baseline to 12 Weeks.
NCT00176423 (4) [back to overview]	Abnormal Involuntary Movement Scale (AIMS)
NCT00176423 (4) [back to overview]	Simpson Angus Scale (SAS) Total Score
NCT00227994 (2) [back to overview]	Physical Function (Measured by the FIM-motor)
NCT00227994 (2) [back to overview]	Medication Tolerability
NCT00509067 (3) [back to overview]	Clinical Global Impression
NCT00509067 (3) [back to overview]	MATRICS Verbal Learning and Memory
NCT00509067 (3) [back to overview]	Negative Symptoms Measured on Positive and Negative Syndrome Scale (PANSS)
NCT00566735 (3) [back to overview]	Cognitive Functioning
NCT00566735 (3) [back to overview]	Baseline Depressive Symptoms
NCT00566735 (3) [back to overview]	Number of Side Effects
NCT00606801 (15) [back to overview]	Performance on the Sustained Attention to Response Task (SART)- Mean Reaction Time for Correct Press on Go Trial
NCT00606801 (15) [back to overview]	Performance on the Sustained Attention to Response Task (SART)- Number of Errors on Go Trials
NCT00606801 (15) [back to overview]	Performance on the Modified Stroop Task (Cocaine-Stroop)- Stroop Effect
NCT00606801 (15) [back to overview]	Paired Associate Learning (PAL) - Mean Errors
NCT00606801 (15) [back to overview]	Paired Associate Learning (PAL) - Stages Complete
NCT00606801 (15) [back to overview]	Pattern Recognition Memory (PRM) - Number Correct Answers
NCT00606801 (15) [back to overview]	Performance on the Cambridge Neuropsychological Test Automated Battery (CANTAB) - RVIP A' (Sensitivity to Target Sequences)
NCT00606801 (15) [back to overview]	Pattern Recognition Memory (PRM) - Response Time for Correct Answers
NCT00606801 (15) [back to overview]	Performance on the Cambridge Neuropsychological Test Automated Battery (CANTAB) - RVIP B' (Strength to Detect to Target Sequences)
NCT00606801 (15) [back to overview]	Performance on the Cambridge Neuropsychological Test Automated Battery (CANTAB) - RVIP Reaction Time
NCT00606801 (15) [back to overview]	Performance on the Cambridge Neuropsychological Test Automated Battery (CANTAB) - RVIP Total Correct Rejections
NCT00606801 (15) [back to overview]	Performance on the Cambridge Neuropsychological Test Automated Battery (CANTAB) - RVIP Total Hits
NCT00606801 (15) [back to overview]	Performance on the Modified Stroop Task (Cocaine-Stroop)- Carry-over Effect
NCT00606801 (15) [back to overview]	Performance on the Modified Stroop Task (Cocaine-Stroop)- Reaction Time
NCT00606801 (15) [back to overview]	Performance on the Sustained Attention to Response Task (SART) - Number of Errors on NoGo Trials
NCT00679627 (9) [back to overview]	Change From Baseline in Caregiver Time Spent With the Patient Measured Using the Assessment of Subject Accommodation Status and Caregiver Burden (APAS-CarB)
NCT00679627 (9) [back to overview]	Change From Baseline in Disability Assessment in Dementia (DAD) Scores
NCT00679627 (9) [back to overview]	Change From Baseline in the Mini-Mental State Examination (MMSE) Score
NCT00679627 (9) [back to overview]	Change From Baseline in the Mini-Mental State Examination (MMSE) Score
NCT00679627 (9) [back to overview]	The Number of Deaths Reported in Participants
NCT00679627 (9) [back to overview]	Change From Baseline in Institutional Status
NCT00679627 (9) [back to overview]	Change From Baseline in Patient Accommodation Measured Using the Assessment of Subject Accommodation Status and Caregiver Burden (APAS-CarB)
NCT00679627 (9) [back to overview]	Change From Baseline in the Mini-Mental State Examination (MMSE) Subscales (Orientation, Registration, Attention and Calculation, Recall, and Language)
NCT00679627 (9) [back to overview]	Change From Baseline in the Disability Assessment in Dementia (DAD) Subscales (Initiation, Planning and Organization, Effective Performance, Basic, Instrumental, and Leisure)
NCT00741598 (5) [back to overview]	Quality of Life Satisfaction Questionnaire (Q-LES-Q)
NCT00741598 (5) [back to overview]	Scores on the California Verbal Learning Test (CVLT-II) at Screening and Week 16
NCT00741598 (5) [back to overview]	The Conners' Continuous Performance Test (CPT) at Baseline, Weeks 4, 8, 12, and 16
NCT00741598 (5) [back to overview]	The Range of Impaired Functioning Tool (LIFE-RIFT)
NCT00741598 (5) [back to overview]	Scores on the Wisconsin Card Sorting Test (WCST) at Screening and Week 16
NCT00809835 (3) [back to overview]	Cocaine Use
NCT00809835 (3) [back to overview]	Cognitive Function
NCT00809835 (3) [back to overview]	Cocaine Abstinence
NCT00814658 (10) [back to overview]	Reaction Time for Face Recognition Test at Baseline, Week 8, and Week 24
NCT00814658 (10) [back to overview]	Reaction Time for Two-choice Reaction Time Test at Baseline, Week 8, and Week 24
NCT00814658 (10) [back to overview]	Reaction Time for Simple Reaction Time Test at Baseline, Week 8, and Week 24
NCT00814658 (10) [back to overview]	The Clinical Global Impression (CGI) at Week 4, Week 8, Week 16, and Week 24
NCT00814658 (10) [back to overview]	The Neuropsychiatric Inventory (NPI) at Baseline, Week 8, and Week 24
NCT00814658 (10) [back to overview]	The Quality of Life Assessment for Caregivers of Patients With Alzheimer's Disease (QoL- AD) Total Scores at Baseline, Week 8, Week 24
NCT00814658 (10) [back to overview]	The Quality of Life Assessment for Patients With Alzheimer's Disease (QoL- AD) Total Scores at Baseline, Week 8, Week 24
NCT00814658 (10) [back to overview]	The Quality of Life Assessment for Patients With Alzheimer's Disease (QoL- AD) Total Scores, Based on the Caregiver's Opinion, at Baseline, Week 8, Week 24
NCT00814658 (10) [back to overview]	The Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) at Baseline, Week 8, and Week 24
NCT00814658 (10) [back to overview]	Reaction Time for Word Recognition and Learning Test at Baseline, Week 8, and Week 24
NCT00814801 (5) [back to overview]	Change From Baseline in the Alzheimer's Disease Assessment Scale - Japan Cognitive Subscale (ADAS-J Cog)
NCT00814801 (5) [back to overview]	Change From Baseline in the Behavioral Pathology in Alzheimer's Disease Rating Scale (Behave-AD)
NCT00814801 (5) [back to overview]	Change From Baseline in the Disability Assessment for Dementia (DAD)
NCT00814801 (5) [back to overview]	Distribution of Clinician's Interview-Based Impression of Change Plus - Japan (CIBIC Plus-J)
NCT00814801 (5) [back to overview]	Change From Baseline in the Mental Function Impairment Scale (MENFIS)
NCT01012167 (83) [back to overview]	Arizona Sexual Experience Questionnaire (ASEX) Male
NCT01012167 (83) [back to overview]	Barnes Akathisia Scale (BAS) - Global Score
NCT01012167 (83) [back to overview]	Blood Oxytocin Levels
NCT01012167 (83) [back to overview]	Brief Psychiatric Rating Scale (BPRS) - Psychosis Score
NCT01012167 (83) [back to overview]	Brief Psychiatric Rating Scale (BPRS) - Total Score
NCT01012167 (83) [back to overview]	Calgary Depression Scale (CDS) - Total Score
NCT01012167 (83) [back to overview]	Electrocardiogram (EKG)
NCT01012167 (83) [back to overview]	Laboratory Measures - A/G Ratio
NCT01012167 (83) [back to overview]	Laboratory Measures - Albumin
NCT01012167 (83) [back to overview]	Laboratory Measures - Alkaline Phosphatase
NCT01012167 (83) [back to overview]	Laboratory Measures - ALT/SGPT
NCT01012167 (83) [back to overview]	Laboratory Measures - AST/SGOT
NCT01012167 (83) [back to overview]	Laboratory Measures - Bilirubin
NCT01012167 (83) [back to overview]	Laboratory Measures - BUN
NCT01012167 (83) [back to overview]	Laboratory Measures - Calcium
NCT01012167 (83) [back to overview]	Laboratory Measures - Chloride
NCT01012167 (83) [back to overview]	Laboratory Measures - Cholesterol
NCT01012167 (83) [back to overview]	Laboratory Measures - CO2
NCT01012167 (83) [back to overview]	Laboratory Measures - Globulin
NCT01012167 (83) [back to overview]	Laboratory Measures - Glucose
NCT01012167 (83) [back to overview]	Laboratory Measures - HDL
NCT01012167 (83) [back to overview]	Laboratory Measures - LDL
NCT01012167 (83) [back to overview]	Laboratory Measures - Potassium
NCT01012167 (83) [back to overview]	Laboratory Measures - Protein
NCT01012167 (83) [back to overview]	Laboratory Measures - Sodium
NCT01012167 (83) [back to overview]	Laboratory Measures - Triglycerides
NCT01012167 (83) [back to overview]	Laboratory Measures - VLDL
NCT01012167 (83) [back to overview]	Mean Z-Scores for Composite Cognitive Primary Outcome* by Treatment Group and Week
NCT01012167 (83) [back to overview]	Neurocognitive Assessment Battery (MCCB) - Attention Vigilance
NCT01012167 (83) [back to overview]	Neurocognitive Assessment Battery (MCCB) - Composite Score
NCT01012167 (83) [back to overview]	Neurocognitive Assessment Battery (MCCB) - Processing Speed
NCT01012167 (83) [back to overview]	Neurocognitive Assessment Battery (MCCB) - Reasoning/Problem Solving
NCT01012167 (83) [back to overview]	Neurocognitive Assessment Battery (MCCB) - Social Cognition
NCT01012167 (83) [back to overview]	Neurocognitive Assessment Battery (MCCB) - Verbal Learning
NCT01012167 (83) [back to overview]	Neurocognitive Assessment Battery (MCCB) - Visual Learning
NCT01012167 (83) [back to overview]	Neurocognitive Assessment Battery (MCCB) - Working Memory
NCT01012167 (83) [back to overview]	Positive and Negative Affect Schedule (PANAS) - Negative
NCT01012167 (83) [back to overview]	Positive and Negative Affect Schedule (PANAS) - Positive
NCT01012167 (83) [back to overview]	Reactions to Partner
NCT01012167 (83) [back to overview]	Scale for the Assessment of Negative Symptoms (SANS) - Alogia
NCT01012167 (83) [back to overview]	Scale for the Assessment of Negative Symptoms (SANS) - Anhedonia
NCT01012167 (83) [back to overview]	Scale for the Assessment of Negative Symptoms (SANS) - Avolition
NCT01012167 (83) [back to overview]	Scale for the Assessment of Negative Symptoms (SANS) - Blunted Affect
NCT01012167 (83) [back to overview]	Scale for the Assessment of Negative Symptoms (SANS) Total Score
NCT01012167 (83) [back to overview]	Simpson-Angus Scale (SAS)
NCT01012167 (83) [back to overview]	Vital Signs - Diastolic Blood Pressure
NCT01012167 (83) [back to overview]	Vital Signs - Pulse
NCT01012167 (83) [back to overview]	Vital Signs - Systolic Blood Pressure
NCT01012167 (83) [back to overview]	Willingness to Interact
NCT01012167 (83) [back to overview]	Vital Signs - Weight
NCT01012167 (83) [back to overview]	Side Effect Checklist (SEC) - Abdominal Pain
NCT01012167 (83) [back to overview]	Side Effect Checklist (SEC) - Anorexia
NCT01012167 (83) [back to overview]	Side Effect Checklist (SEC) - Bruising Easily
NCT01012167 (83) [back to overview]	Side Effect Checklist (SEC) - Constipation
NCT01012167 (83) [back to overview]	Side Effect Checklist (SEC) - Diarrhea
NCT01012167 (83) [back to overview]	Side Effect Checklist (SEC) - Dizziness
NCT01012167 (83) [back to overview]	Side Effect Checklist (SEC) - Dry Eye
NCT01012167 (83) [back to overview]	Side Effect Checklist (SEC) - Dry Mouth
NCT01012167 (83) [back to overview]	Side Effect Checklist (SEC) - Enuresis
NCT01012167 (83) [back to overview]	Side Effect Checklist (SEC) - Excessive Tearing of the Eye
NCT01012167 (83) [back to overview]	Side Effect Checklist (SEC) - Fever
NCT01012167 (83) [back to overview]	Side Effect Checklist (SEC) - Headache
NCT01012167 (83) [back to overview]	Side Effect Checklist (SEC) - Hyperhydrosis
NCT01012167 (83) [back to overview]	Side Effect Checklist (SEC) - Hypersalivation
NCT01012167 (83) [back to overview]	Side Effect Checklist (SEC) - Insomnia
NCT01012167 (83) [back to overview]	Side Effect Checklist (SEC) - Malaise
NCT01012167 (83) [back to overview]	Side Effect Checklist (SEC) - Mucosal Ulceration
NCT01012167 (83) [back to overview]	Side Effect Checklist (SEC) - Nasal Irritation
NCT01012167 (83) [back to overview]	Side Effect Checklist (SEC) - Nausea
NCT01012167 (83) [back to overview]	Side Effect Checklist (SEC) - Rash
NCT01012167 (83) [back to overview]	Side Effect Checklist (SEC) - Restlessness
NCT01012167 (83) [back to overview]	Side Effect Checklist (SEC) - Sedation
NCT01012167 (83) [back to overview]	Side Effect Checklist (SEC) - Sore Throat
NCT01012167 (83) [back to overview]	Side Effect Checklist (SEC) - Stiffness
NCT01012167 (83) [back to overview]	Side Effect Checklist (SEC) - Tinnitus
NCT01012167 (83) [back to overview]	Side Effect Checklist (SEC) - Tremor
NCT01012167 (83) [back to overview]	Side Effect Checklist (SEC) - Urticaria
NCT01012167 (83) [back to overview]	Side Effect Checklist (SEC) - Uterine Contractions
NCT01012167 (83) [back to overview]	Side Effect Checklist (SEC) - Vomiting
NCT01012167 (83) [back to overview]	Side Effect Checklist (SEC) - Weight Loss
NCT01012167 (83) [back to overview]	Side Effect Checklist (SEC) - Wheezing
NCT01012167 (83) [back to overview]	Abnormal Involuntary Movement Scale (AIMS)
NCT01012167 (83) [back to overview]	Arizona Sexual Experience Questionnaire (ASEX) Female
NCT01054976 (5) [back to overview]	Change From Baseline in Choice Reaction Time
NCT01054976 (5) [back to overview]	Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)
NCT01054976 (5) [back to overview]	Change From Baseline in Korean Version of Disability Assessment for Demential Scale (DAD-K)
NCT01054976 (5) [back to overview]	Change From Baseline in Seoul-Instrumental Activities of Daily Livings (S-IADL)
NCT01054976 (5) [back to overview]	Change From Baseline in Simple Reaction Time
NCT01100775 (9) [back to overview]	Trust Game (Dollar Amount Earned)
NCT01100775 (9) [back to overview]	Facial Affect Recognition Score (Number of Responses)
NCT01100775 (9) [back to overview]	The Brief Smell Identification Test (B-SIT) Score (Number of Correct Responses)
NCT01100775 (9) [back to overview]	RVIP Target Hit and False Alarm (Number of Responses)
NCT01100775 (9) [back to overview]	Hopkins Verbal Learning Test (HVLT) Score
NCT01100775 (9) [back to overview]	RVIP Reaction Times (ms)
NCT01100775 (9) [back to overview]	Reading the Mind in the Eyes Score (Number of Correct Responses)
NCT01100775 (9) [back to overview]	Brief Assessment of Cognition for Schizophrenia (BACS) Score
NCT01100775 (9) [back to overview]	Social Affiliation Measured by Social Affiliative Role Play (Rating Scale Score)
NCT01362686 (3) [back to overview]	Discontinuation Rates
NCT01362686 (3) [back to overview]	Healthy Aging Brain Care (HABC)-Monitor
NCT01362686 (3) [back to overview]	Neuropsychiatric Inventory (NPI)
NCT01531153 (17) [back to overview]	Heart Rate
NCT01531153 (17) [back to overview]	Stroop- RT Correct Neutral
NCT01531153 (17) [back to overview]	Digit Span- LDSF
NCT01531153 (17) [back to overview]	Digit Span- LDSB
NCT01531153 (17) [back to overview]	Digit Span- DSF
NCT01531153 (17) [back to overview]	Digit Span- DSB
NCT01531153 (17) [back to overview]	CANTAB SST- SD Correct
NCT01531153 (17) [back to overview]	CANTAB SST- SSRT
NCT01531153 (17) [back to overview]	CANTAB SST- Median Correct
NCT01531153 (17) [back to overview]	CANTAB RVIP Measure: RVP FALSE ALARM
NCT01531153 (17) [back to overview]	CANTAB RVIP Measure: RVP B
NCT01531153 (17) [back to overview]	CANTAB RVIP Measure: RVP A
NCT01531153 (17) [back to overview]	Blood Pressure- Systolic
NCT01531153 (17) [back to overview]	Blood Pressure- Diastolic
NCT01531153 (17) [back to overview]	Urine Toxicology
NCT01531153 (17) [back to overview]	Stroop- Effect Drug Neutral Mean Correct
NCT01531153 (17) [back to overview]	Stroop- RT Correct Drug
NCT01548638 (7) [back to overview]	Number of Days of Abstinence During a 7-day Quit Attempt
NCT01548638 (7) [back to overview]	Cognitive Performance: Working Memory Accuracy
NCT01548638 (7) [back to overview]	Cognitive Performance: Working Memory Reaction Time
NCT01548638 (7) [back to overview]	Side Effects of Galantamine
NCT01548638 (7) [back to overview]	Subjective Symptoms (Negative Affect)
NCT01548638 (7) [back to overview]	Subjective Symptoms (Nicotine Withdrawal)
NCT01548638 (7) [back to overview]	Subjective Symptoms (Smoking Urges)
NCT01669538 (4) [back to overview]	Subjective Symptoms
NCT01669538 (4) [back to overview]	Common Side Effects of Galantamine Check List
NCT01669538 (4) [back to overview]	Cognitive Performance
NCT01669538 (4) [back to overview]	Total Number of Smoke-free Days (Biochemically Verified) During a 7-day Quit Attempt.
NCT01734395 (3) [back to overview]	Change From Screening at Week 16 in Mini Mental State Exam Scores (MMSE)
NCT01734395 (3) [back to overview]	Change From Baseline at Week 16 in Attention Questionnaire Scores (AQS)
NCT01734395 (3) [back to overview]	Change From Baseline at Week 16 in Burden Interview (BI) Scores
NCT01880099 (1) [back to overview]	Smoking Choice Procedure
NCT02234752 (8) [back to overview]	KYN/TRP
NCT02234752 (8) [back to overview]	KYNA/KYN
NCT02234752 (8) [back to overview]	Kynurenic Acid (KYNA)
NCT02234752 (8) [back to overview]	Kynurenine (KYN)
NCT02234752 (8) [back to overview]	PIC/KYN
NCT02234752 (8) [back to overview]	Picolinic Acid (PIC)
NCT02234752 (8) [back to overview]	Free Tryptophan (TRP)
NCT02234752 (8) [back to overview]	Change in Level of Cognition
NCT02365285 (2) [back to overview]	Change in Oxidative Stress: Baseline to 4 Hours
NCT02365285 (2) [back to overview]	Change in Oxidative Stress: Baseline to 2 Hours
NCT02420327 (7) [back to overview]	Change Detection Task Reaction Time
NCT02420327 (7) [back to overview]	Change Detection Task Accuracy
NCT02420327 (7) [back to overview]	Spatial Attentional Resource Allocation Task (SARAT) Non-predictive Trial Reaction Time
NCT02420327 (7) [back to overview]	Spatial Attentional Resource Allocation Task Predictive Trials Reaction Time
NCT02420327 (7) [back to overview]	Rapid Visual Information Processing Task Reaction Time
NCT02420327 (7) [back to overview]	Rapid Visual Information Processing Task Hit Rate
NCT02420327 (7) [back to overview]	Profile of Mood Scale - Total Mood Disturbance
NCT02872857 (5) [back to overview]	Montreal Cognitive Assessment (MoCA)
NCT02872857 (5) [back to overview]	Mortality
NCT02872857 (5) [back to overview]	Montreal Cognitive Assessment (MoCA)
NCT02872857 (5) [back to overview]	EuroQOL Score as Assessed by a Visual Analogue Scale (VAS)
NCT02872857 (5) [back to overview]	Tolerability as Assessed by the Number of Participants Who Stop Study Medication Due to Adverse Event Possibly Associated With Study Drug
NCT03547622 (3) [back to overview]	Substance Use Calendar
NCT03547622 (3) [back to overview]	Clinical Opioid Withdrawal Scale (COWS)
NCT03547622 (3) [back to overview]	Change in Methadone/Buprenorphine Dose to 0 mg for Successful Completion of Taper

Overall Cognitive Improvement Z-score

Participants were administered an eight-test neuropsychological test battery at baseline and end-of-study. The battery included the following tests: working memory: WAIS-III Letter-Number Sequencing and Brief Assessment of Cognition in Schizophrenia Number Sequencing; verbal memory: California Verbal Learning Test (CVLT); visual memory: Brief Visuospatial Memory Test (BVMT); motor speed: Grooved Pegboard; processing speed: WAIS-III Digit Symbol and WAIS-III Symbol Search; and the Gordon Diagnostic System CPT. Alternate forms of the CVLT and BVMT were used for the two test occasions. For each neuropsychological test, participant scores were converted to z-scores: z = (score - baseline mean)/baseline SD. For the primary outcome measure, an overall composite z-score was computed from the average of the individual test z-scores. A positive z-score would reflect better performance compared to baseline; a negative z-score would reflect worse performance compared to baseline. (NCT00176423)
Timeframe: 12 weeks

Intervention	z-score (Mean)
	Week 0	Week 12
Galantamine	0.03	0.15
Placebo	-0.03	0.61

Intervention	msec (Mean)
	PR interval	QRS interval	QTc interval
Galantamine	25.7	11.4	3.03
Placebo	3.0	-1.6	3.03

Intervention	units on a scale (Mean)
	Baseline	Week 4	Week 8	Week 12	Week 16
Galantamine and CDP-choline Group	4.32	4	3.67	3.87	3.8
Placebo Group	4.38	3.92	4.04	4	3.68

Intervention	milliseconds (Mean)
	Baseline	Day 5	Day 10
Galantamine	375.3	382.6	357.8
Placebo	399.7	405.4	411.1

Intervention	Days (Mean)
	Provided caregiving during past week - Baseline	Provided caregiving during past week - Month 12	Provided caregiving during past week - Month 24
Galantamine	5.77	6.07	6.20
Placebo	5.91	6.06	6.13

Intervention	Percentage of participants (Number)
	Home with friend or relative - Baseline	Home with friend or relative - Month 12	Home with friend or relative - Month 24
Galantamine	62.8	61.8	60.1
Placebo	62.1	61.4	55.3

Intervention	Scores on scale (Mean)
	Orientation	Registration	Attention and Calculation	Recall	Language
Galantamine	-0.76	-0.16	-0.16	0.10	-0.68
Placebo	-0.96	-0.20	-0.46	0.00	-0.93

Intervention	Scores on scale (Mean)
	Initiation	Planning and Organization	Effective Performance	Basic	Instrumental	Leisure
Galantamine	-9.60	-9.96	-10.82	-9.84	-10.72	-10.46
Placebo	-13.53	-13.14	-13.82	-14.24	-13.52	-13.02

Intervention	units on a scale (Mean)
	Q-LES-Q Total, Baseline	Q-LES-Q Total, Week 4	Q-LES-Q Total, Week 8	Q-LES-Q Total, Week 12	Q-LES-Q Total, Week 16
Galantamine-ER	62.3	66.03	62.62	66.96	64.75
Placebo	63.03	64.75	65.28	66.52	61.31

Intervention	number of total words remembered (Mean)
	CVLT Total Trials 1-5, Baseline	CVLT Total Trials 1-5, Week 16
Galantamine-ER	50.15	58.88
Placebo	47.21	52.90

Intervention	total number of errors (Mean)
	CPT Total omission + commission errors, Baseline	CPT Total omission + commission errors, Week 4	CPT Total omission + commission errors, Week 8	CPT Total omission + commission errors, Week 12	CPT Total omission + commission errors, Week 16
Galantamine-ER	22.16	21.87	15.61	9.91	14.23
Placebo	19.40	19.24	16.39	16.41	15.18

Intervention	units on a scale (Mean)
	Baseline	Week 4	Week 8	Week 12	Week 16
Galantamine/CDP Choline	17.63	17.06	13.93	14.93	13.93
Placebos for Galantamine/CDP Choline	18.29	17.08	17.26	17.32	16.05

Intervention	Score on the DMI (Mean)
	Pre-ECT	Post-ECT
Galantamine	88.75	88.17
Placebo	80.33	68.50

Intervention	units on a scale (Mean)
	LIFE-RIFT total score, Baseline	LIFE-RIFT total score, Week 4	LIFE-RIFT total score, Week 8	LIFE-RIFT total score, Week 12	LIFE-RIFT total score, Week 16
Galantamine-ER	10.39	9.66	9.07	8.24	8.88
Placebo	9.41	9.03	8.53	8.03	8.20

Intervention	number of card choices made (Mean)
	Total Correct Baseline	Total Errors Baseline	Total Correct Week 16	Total Errors Week 16
Galantamine-ER	45.87	29.70	51.94	27.75
Placebo	44.11	29.79	44.28	29.61

Intervention	Days (Mean)
	Baseline	12 Weeks
Galantamine	14.81	6.32
Galantamine and CBT	18.82	8.60
Placebo and CBT	15.68	7.65
Placebo Only	14.85	10.25

Intervention	scores on a scale (Mean)
Galantamine and CBT	-.12
Galantamine	.11
Placebo and CBT	-.06
Placebo Only	.03

Intervention	percentage of negative urines (Mean)
Galantamine and CBT	22.45
Galantamine	31.13
Placebo and CBT	20.49
Placebo Only	14.78

Intervention	milliseconds (Mean)
Galantamine + Nimodipine (Baseline)	3124.00
Galantamine + Placebo (Baseline)	2684.45
Galantamine + Nimodipine (Week 8)	2262.50
Galantamine + Placebo (Week 8)	2734.25
Galantamine + Nimodipine (Week 24)	2357.80
Galantamine + Placebo (Week 24)	3099.38

Intervention	milliseconds (Mean)
Galantamine + Nimodipine (Baseline)	1919.72
Galantamine + Placebo (Baseline)	1096.75
Galantamine + Nimodipine (Week 8)	852.70
Galantamine + Placebo (Week 8)	1187.78
Galantamine + Nimodipine (Week 24)	727.60
Galantamine + Placebo (Week 24)	1116.25

Intervention	milliseconds (Mean)
Galantamine + Nimodipine (Baseline)	1024.06
Galantamine + Placebo (Baseline)	729.18
Galantamine + Nimodipine (Week 8)	466.60
Galantamine + Placebo (Week 8)	671.33
Galantamine + Nimodipine (Week 24)	467.60
Galantamine + Placebo (Week 24)	584.44

Intervention	participants (Number)
	Very much improved	Much improved	Minimally improved	No change	Minimally worse	Much worse	Very much worse
Galantamine + Nimodipine (Week 16)	0	1	2	1	1	0	0
Galantamine + Nimodipine (Week 24)	0	1	3	1	0	0	0
Galantamine + Nimodipine (Week 4)	0	1	1	4	1	0	0
Galantamine + Nimodipine (Week 8)	0	0	2	2	1	0	0
Galantamine + Placebo (Week 16)	0	0	3	5	0	0	0
Galantamine + Placebo (Week 24)	0	2	4	1	1	0	0
Galantamine + Placebo (Week 4)	0	1	5	4	0	0	0
Galantamine + Placebo (Week 8)	0	1	6	2	0	0	0

Intervention	scores on a scale (Mean)
Galantamine + Nimodipine (Baseline)	24.0
Galantamine + Placebo (Baseline)	26.92
Galantamine + Nimodipine (Week 8)	20.20
Galantamine + Placebo (Week 8)	22.11
Galantamine + Nimodipine (Week 24)	15.00
Galantamine + Placebo (Week 24)	19.75

galantamine

Description

Related Flora

Cross-References

Synonyms (166)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (5)

Drug Classes (5)

Pathways (1)

Protein Targets (29)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (164)

Molecular Functions (73)

Ceullar Components (44)

Bioassays (585)

Research

Studies (1,711)

Market Indicators

Research Demand Index: 95.79

Study Types

Clinical Trials (95)

Trial Overview

Trial Outcomes

Overall Cognitive Improvement Z-score

ECG Changes From Baseline to 12 Weeks.

Abnormal Involuntary Movement Scale (AIMS)

Simpson Angus Scale (SAS) Total Score

Physical Function (Measured by the FIM-motor)

Medication Tolerability

Clinical Global Impression

MATRICS Verbal Learning and Memory

Negative Symptoms Measured on Positive and Negative Syndrome Scale (PANSS)

Cognitive Functioning

Baseline Depressive Symptoms

Number of Side Effects

Performance on the Sustained Attention to Response Task (SART)- Mean Reaction Time for Correct Press on Go Trial

Performance on the Sustained Attention to Response Task (SART)- Number of Errors on Go Trials

Performance on the Modified Stroop Task (Cocaine-Stroop)- Stroop Effect

Paired Associate Learning (PAL) - Mean Errors

Paired Associate Learning (PAL) - Stages Complete

Pattern Recognition Memory (PRM) - Number Correct Answers

Performance on the Cambridge Neuropsychological Test Automated Battery (CANTAB) - RVIP A' (Sensitivity to Target Sequences)

Pattern Recognition Memory (PRM) - Response Time for Correct Answers

Performance on the Cambridge Neuropsychological Test Automated Battery (CANTAB) - RVIP B' (Strength to Detect to Target Sequences)

Performance on the Cambridge Neuropsychological Test Automated Battery (CANTAB) - RVIP Reaction Time

Performance on the Cambridge Neuropsychological Test Automated Battery (CANTAB) - RVIP Total Correct Rejections

Performance on the Cambridge Neuropsychological Test Automated Battery (CANTAB) - RVIP Total Hits

Performance on the Modified Stroop Task (Cocaine-Stroop)- Carry-over Effect

Performance on the Modified Stroop Task (Cocaine-Stroop)- Reaction Time

Performance on the Sustained Attention to Response Task (SART) - Number of Errors on NoGo Trials

Change From Baseline in Caregiver Time Spent With the Patient Measured Using the Assessment of Subject Accommodation Status and Caregiver Burden (APAS-CarB)

Change From Baseline in Disability Assessment in Dementia (DAD) Scores

Change From Baseline in the Mini-Mental State Examination (MMSE) Score

Change From Baseline in the Mini-Mental State Examination (MMSE) Score

The Number of Deaths Reported in Participants

Change From Baseline in Institutional Status

Change From Baseline in Patient Accommodation Measured Using the Assessment of Subject Accommodation Status and Caregiver Burden (APAS-CarB)

Change From Baseline in the Mini-Mental State Examination (MMSE) Subscales (Orientation, Registration, Attention and Calculation, Recall, and Language)

Change From Baseline in the Disability Assessment in Dementia (DAD) Subscales (Initiation, Planning and Organization, Effective Performance, Basic, Instrumental, and Leisure)

Quality of Life Satisfaction Questionnaire (Q-LES-Q)

Scores on the California Verbal Learning Test (CVLT-II) at Screening and Week 16

The Conners' Continuous Performance Test (CPT) at Baseline, Weeks 4, 8, 12, and 16

The Range of Impaired Functioning Tool (LIFE-RIFT)

Scores on the Wisconsin Card Sorting Test (WCST) at Screening and Week 16

Cocaine Use

Cognitive Function

Cocaine Abstinence

Reaction Time for Face Recognition Test at Baseline, Week 8, and Week 24

Reaction Time for Two-choice Reaction Time Test at Baseline, Week 8, and Week 24

Reaction Time for Simple Reaction Time Test at Baseline, Week 8, and Week 24

The Clinical Global Impression (CGI) at Week 4, Week 8, Week 16, and Week 24

The Neuropsychiatric Inventory (NPI) at Baseline, Week 8, and Week 24

Intervention	scores on a scale (Mean)
Galantamine + Nimodipine (Baseline)	34.00
Galantamine + Placebo (Baseline)	36.50
Galantamine + Nimodipine (Week 8)	32.00
Galantamine + Placebo (Week 8)	33.56
Galantamine + Nimodipine (Week 24)	36.60
Galantamine + Placebo (Week 24)	34.88

Intervention	scores on a scale (Mean)
Galantamine + Nimodipine (Baseline)	28.33
Galantamine + Placebo (Baseline)	29.33
Galantamine + Nimodipine (Week 8)	27.80
Galantamine + Placebo (Week 8)	29.78
Galantamine + Nimodipine (Week 24)	29.80
Galantamine + Placebo (Week 24)	29.13

Intervention	scores on a scale (Mean)
Galantamine + Nimodipine (Baseline)	30.40
Galantamine + Placebo (Baseline)	28.20
Galantamine + Nimodipine (Week 8)	25.10
Galantamine + Placebo (Week 8)	31.03
Galantamine + Nimodipine (Week 24)	25.02
Galantamine + Placebo (Week 24)	27.70

Intervention	milliseconds (Mean)
Galantamine + Nimodipine (Baseline)	2022.17
Galantamine + Placebo (Baseline)	2978.77
Galantamine + Nimodipine (Week 8)	1966.40
Galantamine + Placebo (Week 8)	2379.83
Galantamine + Nimodipine (Week 24)	1722.00
Galantamine + Placebo (Week 24)	3038.81

Intervention	Scores on a scale (Mean)
Placebo Group	0.90
Galantamine Group 1	-0.58
Galantamine Group 2	-1.66

Intervention	Scores on a scale (Mean)
Placebo Group	0.0
Galantamine Group 1	-0.2
Galantamine Group 2	-0.3

Intervention	Scores on a scale (Mean)
Placebo Group	-2.8
Galantamine Group 1	-1.0
Galantamine Group 2	-2.2

Intervention	patients (Number)
	Markedly improved	Moderately improved	Minimally improved	No change	Minimally worse	Moderately worse	Markedly worse
Galantamine Group 1	0	12	39	60	64	16	0
Galantamine Group 2	1	4	32	73	61	20	1
Placebo Group	0	7	36	64	62	22	0

Intervention	units on a scale (Mean)
	Treatment Week 0	Treatment Week 6	Change
1: Oxytocin/Placebo-galantamine	16.5	17.1	1.5
2: Galantamine/Placebo-oxytocin	18.1	20.2	1.6
3: Placebo-galantamine /Placebo-oxytocin	20.8	21.7	0.8

Intervention	percentage of participants (Number)
	No worsening (0)	Worsening of 1
1: Oxytocin/Placebo-galantamine	93.33	6.67
2: Galantamine/Placebo-oxytocin	100	0
3: Placebo-galantamine /Placebo-oxytocin	94.12	5.88